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Summary
Radiotherapy plays an important role in modern treatment for cancer, such as cervical
and prostate radiation treatment. One of the major issue in radiotherapy is that the target
should be aligned to the planned target volume prior to each treatment fraction, for which
different kilovoltage (kV) and megavoltage (MV) image guided radiotherapy (IGRT)
methods are developed. However, these ionization systems provide poor visualization
of soft tissue, and therefore the bone matching is frequently applied as a daily tumor
alignment method in cervical radiotherapy. In this project, the Clarity 3D ultrasound
system, non-invasive, non-ionizing, and good in visualization soft tissue, was used to
apply uterine matching for determining the uterine shifts relative to the bone structure.
The main purpose was to investigate the reliability of the Clarity system as a possible
IGRT method. We found that the conventional probe (C-probe) has limitations, while
applying transabdominal US (TAUS) scan, when it came to capturing the entire uterus
owing to the difficulty in probe handling. Contrarily, the novel autoscan-probe (A-probe)
was shown to be capable of capturing the entire uterus in almost all of the scans. The
operators found the A-probe to be more user-friendly, and image acquisition was also
performed more smoothly. In conclusion the A-probe is a more reliable IGRT tool, and it
might replace the kV- and the MV IGRT systems.
In prostate radiotherapy, the movement of the prostate during radiation delivery
(intrafractional prostate motion) remains challenging. To determine the intrafractional
prostate motion, various imaging techniques have been introduced, such as kV, and MV
imaging, CineMRI, implanted markers and transponders. Most of the systems are based
on acquiring pre- and posttreatment images, which has limitations in addressing real-time
prostate motion, and includes inter-observer variations while matching image to image.
In this project, the recently developed transperineal ultrasound 4D autoscan probe is
used to investigate the real-time prostate monitoring. The purpose of this study was to
investigate the feasibility of the 4D autoscan in tracking the prostate for a duration of 2 to
2.5 minutes.
We found that most of the intrafractional prostate motion is less than 2 mm, which was in
concordance with previously reported data. Thus, during a RapidArc/VMAT plan delivery
with a beam-on time of approximately 2.5 minutes, the intrafractional prostate motion is
negligible. But, since the prostate motion increases with monitoring time, the prostate
vii
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displacement during 3D conformal and IMRT plans must be taken into consideration.
Additionally, we conducted a prostate probe pressure study, in which TAUS scan was
simulated, using a C-probe, while the prostate was continuously monitored using the
TPUS autoscan. We found that the TAUS induced pressure displacement of the prostate,
in most cases, was clinically irrelevant. Since this conclusion was in opposition to most
of the previously published results, which reported displacements of up to 7 mm, we
discovered that 4D real-time monitoring is the most reliable method for determining the
pressure displacement compared to US/US or US/CT matching methods, in which the
considerable inter-observer variability, due to variations in applied probe pressure and
image/image match, limits the accuracy of the readings.
Resumé
(Summary in Danish)
Stråleterapi spiller en vigtig rolle i kræftbehandling. I moderne stråleterapi, kan der
opnås en høj dosis i tumor. Det er derfor vigtigt, at man kender den eksakte placering af
kræftknuden og de omkringliggende risikoorganer i forbindelse med behandlingen. For at
kunne identificere tumorens beliggenhed præcist og for at reducere medbestrålingen af
raskt normalvæv, bruges daglig billedvejledt strålebehandling, ”Image Guided Radiation
Therapy” (IGRT). IGRT kan fx være et sæt ortogonale kilovolt (kV) eller megavolt (MV),
2D kontrolbilleder. Men disse billed-metoder har begrænset visualisering af bløddelsvæv,
såsom livmoder, blære eller rektum. Således udføres ofte dagligt match på knogle-
strukturer i stedet for direkte match på tumorvæv. Der er derfor et ønske at tilføje ultralyd
som et nyt IGRT system, hvilket nu er muligt med Clarity systemet. Clarity systemet,
som hverken er invasivt eller ioniserende, er et relativt billigt billedverifikations system,
som er velegnet til bl.a. visualisering af bløddelsvæv i det kvindelige bækken. Der er
dog forskellige udfordringer med brugen af ultralyd-systemet, såsom transducer-tryk,
billedtolkning og inter-operatør variabilitet.
Hovedformålet med dette projekt er at undersøge muligheden for at bruge Clarity som
IGRT-metode for at identificere den daglige positionelle variation af livmoderen.
Vi fandt, at den konventionelle probe (C-proben) har begrænsninger således at det er svært
at skanne hele livmoderen ved anvendelse af transabdominal ultralydsskanning (TAUS), på
grund af vanskeligheder med probe håndteringen. Autoscan-transduceren (A-probe) viste
sig imidlertid at være i stand til at skanne hele livmoderen i næsten alle skanningsforsøg.
Operatørerne fandt at A-proben var mere brugervenlig, og at billedoptagelse også udføres
mere smidigt, med brug af mindre transducer-tryk. Afslutningsvis: A-proben er et mere
pålideligt IGRT værktøj end C-proben, og den kan formentligt erstatte kV- og MV IGRT
systemer.
Ved prostata strålebehandling er bevægelighed af prostata under bestråling (intrafrak-
tionelle prosata bevægelse) stadig en udfordring. For at bestemme den intrafraktionelle
bevægelse har forskellige IGRT systemer været indført, såsom røntgenbilleder (kV og
MV), CineMRI, ”in-room” CT og implanterede markører og ”transponders”. De fleste af
disse systemer er baseret på før- og efter behandling billedtagning, som har begrænsninger
i at identificere prostatabevægelse i ”real time”. En anden ulempe er inter-observatør
variationer ved billed-match.
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For nyligt udviklede Clarity et produkt (transperineal ultralyd 4D autoscan probe (TPUS))
til at kunne overvåge prostata under bestråling. Prostataforskydning har vist sig at øges
med strålingsvarigheden, hvilket betyder at størrelsen af forskydningen afhænger af behan-
dlingstiden. På Herlev hospital, får alle prostata patienter RapidArc behandling, hvilket
indebærer en bestrålingstid på ca. 2,5 minutter sammenlignet med op til 10 minutter ved
anvendelse af en konventionel ”konform” plan eller en IMRT behandling. Formålet med
dette studie er at undersøge gennemførligheden af Clarity 4D autoscan til at følge prostata
i 2 til 2,5 minut.
Vi fandt, at de fleste intrafraktionelle prostatabevægelser er mindre end 2 mm, hvilket var
i god overensstemmelse med tidligere rapporterede data. Dette betyder at, ved brug af
RapidArc er den intrafraktionelle prostata bevægelse ofte ubetydelig. Hvis man behandler
med konventionel stråleterapi eller IMRT , bør der tages hensyn til prostataforskydningen.
Desuden gennemførte vi et transducer-tryk-studie, hvor TAUS skanning blev simuleret
ved hjælp af en C-probe, mens prostata kontinuert blev overvåget ved hjælp af TPUS
autoscan.
Vi fandt, at froskydningen af prostate som følge af C-probens tryk i de fleste tilfælde er
klinisk ubetydelig. Dette resultat var i modsætning til de tidligere offentliggjorte resultater,
hvor der er rapporteret forskydninger på op til 7 mm. Vi konkluderede at 4D autoscan
overvågning er en pålidelig metode til at bestemme forskydning som følge af probe-tryk.
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CHAPTER1
Introduction
1.1 Radiotherapy
Radiotherapy mainly uses high-energy photon or electron beams to kill tumor cells, by
damaging the DNA chain, disabling the cells from reproducing themselves. Cancer cells
are usually more sensitive to radiation since they divide more quickly than normal cells.
The intention behind the application of radiation is either curative, curing the disease by
eradicating the cancer cells, or palliative, relieving symptoms, such as pain or seizures,
when the cancer has developed or spread (metastases). Radiotherapy, often in combination
with either surgery or chemotherapy, or both, is an effective treatment method to eradicate
the cancer cells. For instance, treatment of prostate and cervical cancer patients requires
often external radiation, using linear accelerator machines (LINAC) (Fig. 1.1) and/or
internal (Brachy) radioactive sources, to achieve an optimal outcome.
Since the cancer sites are usually surrounded by healthy tissues and normal organs
(Organs at risk (OARs)), it is of the utmost importance that the OARs are protected
from the prescribed radiation dose while the tumor is adequately covered, in order to
minimize radiation complications, such as gastrointestinal toxicity in cervical radiotherapy
(Salama et al. 2006). Since a course of treatment for cervical radiation can include 25
fractions, while for prostate cancer patients the sessions include up to 39 fractions, daily
target positional variations (interfractional displacement) due to organ motion, tumor
regressions, and setup variations, may occur. This positional uncertainty, for example for
uterine position, can be as large as some centimeters (Chan et al. 2008). To minimize
this uncertainty, daily target alignment is a necessity, and for this reason different daily
pre-treatment verification imaging (Image Guided Radiation Therapy (IGRT)) modalities
have been introduced into radiotherapy (Beadle et al. 2009; Chan et al. 2008; Kupelian
et al. 2008; Langen and Jones 2001; Scarbrough et al. 2006), which makes it possible to
correct misalignment, thereby improving the precision of the radiation treatment (Mackie
et al. 2003).
Another challenge in radiotherapy is that during treatment delivery target displacement
might occur (intrafractional displacement)(Ghilezan et al. 2005; Huang et al. 2002), which
may lead to underdosage of the target (Kitamura 2002; H. Li et al. 2008). For instance,
large prostate positional shifts have been observed, due to bladder filling variations, rectal
volume changes, and respiratory motions (Dawson 2000; Herk 1995; Padhani 1999). To
address the intrafractional uncertainty, different imaging modalities have been developed.
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Figure 1.1: Linear accelerator (LINAC); Using high energy photon and electron beams
(illustrated in yellow color) to irradiate the planned target, but verification imaging (illustrated
in green color) prior to treatment delivery is necessary to correct for daily positional variations.
1.2 Image Guided Radiation Therapy (IGRT) of cervical cancer pa-
tients
In adaptive conformal radiotherapy with tight margins and steep dose gradients, such
as intensity-modulated radiotherapy (IMRT), and volumetric modulated arc therapy
(VMAT)/RapidArc, it is essential that the position of the clinical target volume (CTV)
is precisely defined prior to each treatment fraction throughout the entire course of
treatment. Recent technical innovations have enabled the direct integration of various
image verification methods into clinical practice in radiotherapy. This allows uncertainty
with patient and tumor positioning to be addressed and corrected. Different kilovoltage
(kV) and megavoltage (MV) planar radiographic imaging (electronic portal imaging
device (EPID)), and kV volumetric cone beam CT (CBCT) imaging are standard IGRT
methods. However, these ionizing radiation systems have poor soft tissue visualization of
the uterus of gynecological (GYN) cancer patients (Fig. 1.2). As a result, bone matching
is frequently applied as a daily tumor alignment method in cervical cancer treatment.
However, the weakness of employing bone-match is that it cannot take the relative uterine
shift to the bone structure into consideration. Additionally, tumor regression might occur,
with up to 80 % volume-reduction by the end of the treatment course (Beadle et al. 2009;
Lim et al. 2008; Nam et al. 2007), which adversely impacts the precision of the target
coverage and increment of the dose to the healthy tissues.
For GYN cancer patients, large margins are applied around the delineated gross tumor
volume (GTV), to ensure target radiation dose coverage. The large margin is due to the
complexity of the pelvis with its tumor and normal organ motion as well as deformational
dynamics, which adversely impacts on the irradiated healthy tissues (Chan et al. 2008).
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Figure 1.2: CT and CBCT images; CT-reference image, where soft tissue structures of
uterus and bladder are easily recognizable, but in the acquired CBCT verification image the
organs are barely identifiable.
Another method involves using implanted fiducial markers, readily identifiable in kV
and MV verification imaging, as a surrogate (Heide et al. 2007; Litzenberg et al. 2002).
Implanting fiducial markers in GYN radiotherapy has been found to be a substantial
challenge (Kaatee et al. 2002; Lee et al. 2007; X. Li et al. 2007), because implanted
fiducial markers can fall out, or be displaced due to tumor shrinkage and organ deformation.
Another disadvantage of implanted fiducial markers is that they necessitate an invasive
procedure, with an inherent risk of infection and discomfort to the patient, as well as
a risk of fiducial migration, with consequent risk of misalignment during the course of
treatment. On the other hand, MR imaging provides outstanding visualization of the
uterus and cervix, enabling distinguishing them from other organs (Bunt et al. 2008).
The application of MRI as IGRT requires MRI/LINAC accessibility, which is costly and
rarely used clinically (Kerkhof et al. 2008; Lagendijk et al. 2008). Therefore, various
3D ultrasound (US) systems have been developed, such as the Clarity R© Soft Tissue
Visualization system (Clarity R© Model 310C00, Elekta, Stockholm, Sweden) and the
NOMOS B-mode Acquisition and Targeting (BAT) ultrasound system (Boda-Heggemann
et al. 2008; Feigenberg et al. 2007). Both of these systems are based on 3D transabdominal
US (3D-TAUS) scanning (Fig. 1.3). The Clarity system, for instance, is non invasive, non
ionizing and cheap medical imaging technology. However, different uncertainty factors
such as probe handling, image quality, and inter-operator variability are involved in the
use of a US system.
1.3 Prostate monitoring
The movements of internal organs are one of the most challenging and unpredictable
factors in delivering the prescribed radiation dose to the target in prostate cancer radio-
therapy (Graham, Gee, and S.Hilton 2003; Meijer et al. 2003). This is mostly due to
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Figure 1.3: The Clarity 3D ultrasound imaging system; Based on (A) transabdominal
uterine IGRT, and (B) transpernieal prostate monitoring.
variations in the volume and shape of rectum and bladder between consecutive fractions
(interfractional) and during the delivery of radiation (intrafractional). Thus, interfractional
movements emphasize the significance of accurate prostate localization prior to the deliv-
ery of radiation, and intrafractional prostate motion, on the other hand, refers to internal
prostate displacement occurring during the actual delivery of treatment.
To determine the intrafractional prostate motion, various imaging techniques have
been investigated in different studies, such as X-ray imaging, kilovoltage (kV) CBCT and
megavoltage (MV) imaging, CineMRI, in-room CT, implanted markers and transponders,
and ultrasound (Chan et al. 2008; Ghilezan et al. 2005; Mayyas et al. 2013; Tong et al.
2015). Most of the studies are based on acquiring pre- and post-treatment images (Adam-
son and Wu 2009; Kron et al. 2010). Furthermore, various techniques are developed to
enable real-time online prostate localization and monitoring, such as: tracking implanted
electromagnetic transponders (Calypso Medical Technologies, Seattle, WA), and tracking
fiducial markers or implanted radioactive seeds (in Brachytherapy) using real-time X-ray
imaging.
Recently, transperineal ultrasound (TPUS) auatoscan (Clarity R©, Elekta, Stockholm, Swe-
den) (Fig. 1.3 B) has been developed to allow real-time prostate tracking (Lachaine and
Falco 2013).
The relevance of addressing prostate motion during treatment delivery is dependent on
the treatment time. With faster treatment techniques, such as VMAT or RapidArc R©
Radiotherapy Technology, as used at our institution, the magnitude of intrafractional
prostate motion are reduced (J. Li et al. 2013; Mutanga et al. 2012).
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1.4 Motivation and Objective
The overall objective of this project is to investigate the feasibility of the ultrasound
systems to identify daily uterine positional variations, and to address the prostate motion
during treatment delivery.
1.4.1 Clarity 3D ultrasound system as cervical IGRT system
The main purpose of the current study is to implement and evaluate the potential benefit of
the new 3D ultrasound system during daily radiation treatment fractions of gynecological
cancer patients.
The objective of the thesis is to confirm or deny its working hypothesis, that the Clarity
3D-TAUS, as a soft tissue uterine IGRT system, is a reliable method.
1.4.2 Clarity 4D ultrasound system as prostate tracking system
The aim is to investigate the feasibility of the clarity 4D ultrasound system for real-time
prostate tracking during radiation delivery.
We hypothesize that prostate motion can be tracked with the 4D ultrasound probe, hence
recording the magnitude and direction of prostate displacement in real time. As a result,
the clinical consequences of this motion can be determined during VMAT/RapidArc
radiation delivery.
1.5 Publications in the Thesis
This thesis is based on the 6 papers listed below, covering two main subjects: Interfrac-
tional uterine displacement, and intrafractional prostate motion. In the printed version of
the thesis, the publications are included as separate appendix collection. The publication
letters (A to F) refer to the appendix containing the corresponding paper.
Interfractional uterine displacement
Two conference papers and two journal papers cover implementing the 3D-US imaging of
the cervix, focusing on phantom, volunteer, and patient studies.
Paper A
M. Baker, J. A. Jensen, and C. F. Behrens
“Inter-operator Variability in Defining Uterine Position Using Three-dimensional Ultra-
sound Imaging”.
Published in: Proceedings of IEEE Ultrason. Symp., pp. 848-851 (2013).
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Paper B
M. Baker, J. A. Jensen, and C. F. Behrens
“Determining inter-fractional motion of the uterus using 3D ultrasound imaging during
radiotherapy for cervical cancer”.
Published in: Proceedings of SPIE, the Medical Imaging 2014: Ultrasonic Imaging and
Tomography.,Vol. 9040 90400Y-1, (2014).
Paper C
M. Baker, T. Juhler-Nøttrup, and C. F. Behrens
“Impact of ultrasound probe pressure on uterine positional displacement in gynecologic
cancer patients”.
Published in: Future Medicine Women’s Health., Vol. , pp. 583-590, (2014).
Paper E
M. Baker, D. T. Cooper, and C. F. Behrens
“Evaluation of uterine ultrasound imaging in cervical radiotherapy; a comparison of
autoscan and conventional probe”.
Submitted (2015).
Intrafractional prostate motion
Two journal papers cover inrafractional prostate motion, using 4D TPUS system, and
the prostate induced displacement during TAUS simulation, using 4D TPUS autoscan for
real-time prostate monitoring.
Paper D
M. Baker, and C. F. Behrens
“Prostate displacement during transabdominal ultrasound image-guided radiotherapy
assessed by real-time four-dimensional transperineal monitoring”.
Published in: Acta Oncologica (2015).
Paper F
M. Baker, and C. F. Behrens
“Determining intrafractional prostate motion using four dimensional ultrasound system”.
Submitted (2015).
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1.6 Thesis Outline
In this work, the Clarity 3D-TAUS and 4D-TPUS systems are used as a platform to
determine the daily displacements of the uterus, as well as intrafractional prostate motion.
Chapter 2 describes the Clarity ultrasound system, and provides details of the system’s
characteristics.
Chapter 3 covers interfractional uterine displacement during cervical radiotherapy.
After a brief literature review, the principle behind using ultrasound as a new IGRT method
is described. Initially, the implementation of the conventional 3D-TAUS probe is explained
and the advantages and disadvantages of this probe are highlighted. Furthermore, the
challenges in terms of image acquisition and image interpretation are discussed. Moreover,
the potential utility of the system relative to other IGRT systems is debated. In addition, the
obstacles to implementing the conventional probe in cervical radiotherapy are explained,
based on phantom, volunteer and patient studies.
The chapter also covers the novel 3D-TAUS autoscan probe. The advantage of this probe
over conventional ones is reported based on a volunteer study. Moreover, the capacity of
this probe as cervical IGRT imaging modality is clarified according to feedback from the
operators during a clinical study.
In Chapter 4, the focus is shifted towards the intrafractional prostate motion using
4D TPUS autoscan system. Firstly, a literature review shows previously used prostate
tracking systems. Secondly, the magnitude of the intrafraction prostate motion, based
on a clinical study, is determined for a monitoring duration of 2-2.5 minutes, a typical
beam-on time required to deliver a VMAT/RapidArc fraction.
The chapter encompasses also the challenges in using conventional 3D TAUS probe, in
the term of impact of probe pressure in prostate displacement. The magnitude of the
induced prostate displacement is addressed based on a clinical paper.
The thesis is concluded in Chapter 5, where suggestions for future research are also
provided.
The aim with the chapters is to highlight basic information of the Clarity system
and key results from the project. Additional details can be found in the original paper
manuscripts, which are provided in the appendix section.
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CHAPTER2
The Clarity 3D-TAUS and
4D-TPUS systems
The division of radiotherapy at Herlev hospital is a large site, where over 3 000 cancer
patients receiving radiation treatment annually, using nine LINACs and a superficial
kilovoltage apparatus. The site is provided with two CT units and one MR imaging
device. Over 100 RTTs and radiographers are among the clinical staff directly involved
in the treatment of the patients. For the cervical IGRT, daily EPID-imaging are acquired
to align the patient based on bone-matching. For prostate IGRT daily fiducial markers’
matching is performed, using daily EPID verification imaging. The treatment of prostate
and cervical cancer patients is based on RapidArc plans. The Clarity ultrasound system
was installed in 2012, and Herlev is a pioneer in implementing the ultrasound imaging as
cervical IGRT.
The clarity system consists of two US units - one located in the CT-room, and one in
the treatment room. These units are connected through a workstation/server located at an
independent location on site. Each US unit is equipped with a convex array probe for 3D
TAUS scanning of the cervix, and an autoscan probe for 4D prostate monitoring. After
our feedback regarding the limitation of the 3D TAUS probe, the Clarity provided us with
a novel 3D TAUS autoscan probe (Fig. 2.1).
Figure 2.1: The Clarity ultrasound probes; (A) the 3D TAUS probe for cervical scanning,
(B) the 3D TAUS autoscan probe for cervical scanning, and (C) the 4D TPUS probe for
prostate monitoring.
Each unit consists of a ceiling-mounted infrared (IR) camera that can track the US-
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Figure 2.2: The Clarity ultrasound components; (A) Ultrasound unit in the CT-simulation
room, (B) The Clarity guide in the treatment room (LINAC-room), (C) The ultrasound
alignment phantom for probe-, and room-calibration, and (D) The Clarity workstation, in
which all acquired images are stored.
probe by monitoring the IR-reflectors/emitters are permanently mounted on each probe.
This is central for determining the geographical position of the reconstructed anatomical
structures. To enable superimposing the acquired CT images over the 3DUS-image-sets,
the 3D-US system is calibrated to the same coordinate system as the CT and treatment
rooms, respectively (Fig. 2.2). The calibration procedure is accomplished by means of a
delivered alignment phantom. Quality assurance checks confirm system calibration each
day of use.
2.1 Physics of Ultrasonic Wave
Ultrasound imaging is basically about sending acoustic waves into the body and mea-
suring the reflective of waves at the interfaces between tissue. Comparing to the x-rays,
that penetrates through the body to the detector, and is dependent on the tissue through
which the beams passes, the ultrasound behaves very differently. Many of the objects and
artifacts seen in ultrasound images are due to the physical properties of the ultrasonic
beams, such as reflection, refraction and attenuation (Fig. 2.3 A) (Weyman 1994). As
a beam of ultrasound passes through a media, it can be reflected, called for echo, at
the boundary between two materials with different acoustic impedance (impedance is a
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Figure 2.3: The ultrasound acoustic waves; (A) Ultrasonic beams reflects, refracts, and
attenuates when it travels through tissues in different speed (C); (B) The strength of the echo
(reflected waves) is dependent on the tissues’ impedance (modified from http://coreten.ca/wp-
content/uploads/2012/01/BX-Tissue-Graphic.png).
product of the material’s density and propagation speed) (Middleton, Kurtz, and Hertzberg
2004). The speed of sound is [m/s] approximately 343, 1 480, 4 080, for air, tissue and
bone, respectively. The strength of the reflected echo is dependent on the difference of the
impedance. When the acoustic impedance is very large, as in bone, the ultrasound will be
totally reflected, and tissues beyond them cannot be imaged (Fig. 2.3 B). This is where
the technique of the operator becomes important, since the operator should avoid such
structures or regions.
Just as there are infrared, visible, and ultraviolet ranges in the electromagnetic spectrum,
so there are infrasound (< 20 Hz), audible (20 Hz to 20 kHz), and ultrasound (> 20 kHz).
The frequency of an ultrasound wave, which determines by the transducer, consists of the
number of cycles or pressure changes that occur in one second. The frequency used in
diagnostic imaging is in the range of 1 - 5 MHz.
2.2 The 3D-TAUS scan of the cervical cancer patients
2.2.1 The conventional 3D-TAUS probe (C-probe) and the 3D-TAUS
autoscan probe (A-probe)
The 3D TAUS probe consists of a transducer array of 128 elements, using a central
frequency of 3.4 MHz. The probe is provided with IR reflectors fixed so that they can
be detected by the ceiling-mounted IR camera. The camera cannot detect the reflectors
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Figure 2.4: The 3D TAUS scan of the uterus; (A) The autoscan probe (A-probe) acquires
images in the sagittal paln, (B) The conventional probe (C-probe) acquires images in the
transversal plane.
if the probe, for instance, is rotated 90 degrees, thus restricting image acquisition to the
transversal plane. Initially, the probe is tilted backwards to localize the vaginal region,
followed by sweeping to the vertical position. Approximately half of the uterine volume
can be captured by the sweep, thus a cranial slide technique is required to cover the rest
of the uterus (Fig. 2.4 B).
The A-US probe comprises the similar type of transducer, but with a central frequency
of 5 MHz. Initially, and prior to acquiring the scan, the desired uterine structure is
identified in the sagittal plane. The semiautomatic transabdominal scan is achieved
by localizing the central slice of the uterus and then allowing the motorized head to
automatically sweep over the uterine volume (Fig. 2.4 A).
2.2.2 Image acquisition and structure contouring
2.2.2.1 CT simulation room
At CT simulation, all patients are CT scanned in a supine position, according to a standard
cervix protocol. The acquired CT-data sets are used for treatment planning (Eclipse,
Varian Medical System). After the CT scan, all the GYN patients undergo a standard
MR-scan. Eventually, the CT-MR fusion is carried out by the radiographers using the
Eclipse planning system. The fusion is based on bone-matches.
The uterine target and OARs are delineated in the CT-MR fusion data sets. Initially,
the specialized GYN oncologist outlines the CTV after the CT-MR fusion is performed.
The planning target volume (PTV) is then obtained by an additional margin to CTV in
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Figure 2.5: CT-US fusion process; Fusion of acquired US-scan to CT-image dataset, in
which the positioning reference volume (PRV) of the uterus is contoured, is performed in US
workstation.
anterior-posterior (A/P), and left-right (L/R), and inferior-superior (I/S) directions. The
treatment is administered in a total of 25 fractions, at 2Gy/fraction. A CT image and
digitally reconstructed radiographs (DRRs) are created of the anterior and left lateral
treatment fields in order to provide planned bone position for daily IGRT.
In this project, immediately after the CT scan, the patient is prepared for the trans-
abdominal US-scan. The US-scans are performed using the C-probe by one of the six
experienced radiation therapists (RTTs). (Note that the A-probe was implemented after we
confirmed that the C-probe has limitations as cervical IGRT). Each RTT has participated
in an extensive two week training provided by the Clarity’s manufacturer, and participated
in several practice sessions before commencement of the study. Furthermore, the patients
were instructed to follow a moderate bladder filling protocol, which involved not urinating
after leaving their home on their way to their daily radiation treatment. The bladder-rectal
protocol is important for daily reproducibility of the uterine position. A moderately full
bladder also provides better propagation of US waves and hence enhances image quality
by sharpening the outlines of the bladder and uterus interface. Further, the acquired CT
datasets, delineated structures, and the planning treatment fields can be exported from
Eclipse to the US workstation. Hence, co-registering and superimposition of US and
CT can be performed, in which the positioning reference volume (PRV) of the uterus
is contoured (Fig. 2.5). Thus the PRV defines uterine position at the time of planning.
Moreover, the PRV is later used as an initial reference for the consecutive US-guide-scans
acquired in the treatment room.
2.2.2.2 Treatment room
Initially, the patient is aligned to the room lasers by means of skin marks (setup tattoos
from CT-scan alignment). For each patient, daily IGRT is performed by acquiring
verification IGRT images, either using the EPID-image, or weekly CBCT-imaging, in
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Figure 2.6: Bone match process; Alignment of bony structure landmarks from verfication
CBCT image to the DRR-images from planned CT, in both sagittal and transversal planes.
order to adjust for bone misalignment, i.e. interfractional setup uncertainties. The images
are used to align bony structure landmarks to DRR-images from planned CT (Fig. 2.6).
Consequently, any possible daily bone positional displacement is addressed and corrected
for through applying a set of orthogonal shifts to the therapy treatment couch prior to
radiation delivery. After the uterine positional correction, the radiation treatment is
delivered.
Immediately after the delivery of each radiotherapy fraction, a US scan is acquired.
Instantly, the outlined uterus is superimposed on the initial reference PRV from the CT
room. The intramodal comparison reveals couch shifts in three dimensions that can be
recorded and compared to the actual clinical couch shift performed prior to the treatment
delivery. Hence, the deviation of interfractional uterine displacement, based on bony
alignment and US, can be statistically represented and evaluated. And thus, the possible
shift between the US-guide uterus (red) and the US-reference (PRV) (green) can be
observed as in (Fig. 2.7).
2.3 The 4D-TPUS tracking system of the prostate cancer patients
The Clarity 4D-TPUS unit system is identical to the 3D-TAUS system, except for using a
4D autoscan probe for transperineal monitoring of the prostate.
2.3.1 The 4D TPUS autoscan probe
The autoscan-US probe consists of a one dimensional (1D) sector array of 128 elements,
and a radius of curvature of 40 mm, using a frequency bandwidth from 3.2 to 5.8 MHz
(center frequency of 5 MHz) and a penetration depth of 17 cm. The transducer is
motorized, offering automatic scanning over the region of interest.
The probe is provided with IR reflectors fixed so that they can be detected by the ceiling-
mounted IR camera. Initially, the probe is affixed to a TPUS base, placed over the coach
under the patient’s knees, and pushed gently to the patient for transperineal scanning
(Fig. 2.8). The motorized head is capable of real-time online scanning of the prostate.
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Figure 2.7: Uterine match process; Alignment of uterus from the US-guide (red) to the
US-reference (green).
2.3.2 CT-simulation and autoscan imaging
In this study, after the CT scan acquisition, the patient was prepared for the US scan
using vendor provided knee cushions (immobilization devices) resting over the autoscan
base, implying a different setup in comparison to the CT position. The aim of this study
was to determine intrafractional prostate motion during a certain period of time (2.0 -
2.5 minutes), corresponding to the beam-on time required to deliver a RapidArc fraction.
Therefore differences in setup were not considered to have a significant impact on the
acquired results. First the operator mounts the autoscan probe on the base and gently
attaches the probe head to the patient until the prostate, bladder, and rectum are visually
identified on the US console. The patient was instructed to remain motionless during
image acquisition and US monitoring.
Figure 2.8: Transperineal prostate 4D monitoring: the autoscan is attached to the base,
before being gently pushed to the patient, whose legs are resting on the vendor provided
cushions.
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Figure 2.9: CT-US fusion process; Using the Clarity workstation, the positioning reference
volume (PRV) of the prostate is contoured after performing CT-US fusion.
After repositioning of the patient, a TPUS image was acquired by radiographers.
Furthermore, the acquired CT datasets, delineated structures and planning treatment
fields can be exported from Eclipse to the US workstation. Hence co-registration and
superimposition of US and CT can be performed (Fig. 2.9), in which the positioning
reference volume (PRV) of the prostate gland is contoured. Thus the PRV defines prostate
position at the time of planning. In this study, the assisted segmentation in the Clarity
workstation was utilized for prostate delineation. Export/import from the treatment
planning system to the Clarity workstation, CT/US fusion and prostate delineation were
carried out by two radiographers and one physicist.
2.3.3 Image acquisition and prostate tracking in the treatment room
Initially, the patient is fixed in accordance with the CT set-up in the CT room. The patient
is then aligned to the room lasers by means of the skin marks (set-up tattoos from the CT
scan alignment). For each patient daily IGRT is performed by acquiring an EPID image
in order to adjust for prostate gland misalignment, i.e. interfractional set-up uncertainties.
The EPID images are used to align the prostate with DRR-images from planned CT by
means of fiducial markers’ matching. Consequently, any possible daily prostate positional
displacement is addressed and corrected for through applying a set of orthogonal shifts to
the therapy treatment couch prior to the delivery of radiation. After the prostate positional
correction, the radiation treatment is delivered.
Immediately after the delivery of each fraction, the patient is fixed in accordance with
the US setup in the CT room, where the autoscan-base is positioned under the patient’s
legs. The patient is then aligned to the room lasers using the same setup tattoos that were
used for the actual treatment alignment. Thereafter the autoscan probe is mounted on the
base and carefully attached to the patient (transperineally). Meanwhile, the 3D-US guide
scan is performed. Afterwards a copy of the PRV-contour was aligned to the acquired
prostate. Instantly, the outlined (the copy of the PRV) prostate is superimposed over the
initial reference PRV from the CT room. Finally the 4D-US scan is performed. Thus
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the magnitude and direction of prostate motion is quantified and recorded. Henceforth,
the intrafractional uncertainty, i.e. the motion of the prostate during the corresponded
radiation treatment time, can be retrospectively evaluated.
2.4 Statistical analysis
The phantom, volunteer, and clinical patient data (cervix and prostate patients) were
mostly evaluated by one observer (MB). Interfractional and intrafractional COM shifts,
in the I/S, L/R, and A/P directions, of uterine and prostate were retrospectively retrieved
using the Clarity workstation. Furthermore, the Euclidean distance (3D vector) was
computed and the maximal 3D vector was recorded for each fraction. Finally, the means
(± 1 standard deviation (SD)) of the displacements in each direction and for the 3D vector
were calculated.
For the data and statistical analysis the statistical program R (version 2.15.3) was used.
18
CHAPTER3
Interfractional uterine displacement
In this chapter, the implementation of the Clarity 3D probe at Herlev hospital is described
in detail. After a brief literature review, the procedure from day one to the US scanning of
the last patient is explained in three phases. Before starting this study, ethical approval
was obtained from "De Videnskabsetiske Komiteer" Appendix C
Phase I (Phantom study): Six operators, with no previous experience of US scanning,
were acquainted with the Clarity system by implementing the conventional 3D probe
(C-probe) to acquire images of a phantom, mimicking the female pelvic region. Based
on the phantom US scan, the impact of probe pressure, and inter-operator variability was
investigated, papers A and C.
Phase II (Volunteer study): Firstly, a volunteer study (a case study) was designed to
investigate daily uterine shifts, paper C.
In a clinical study, paper B, we concluded that, using the C-probe for transabdominal uter-
ine scan, the operators faced practical challenges when applying a sweep slide technique.
A volunteer study was conducted to compare a new prototype autoscan probe that had
been received from the vendor (A-probe) with the C-probe, paper E.
Phase III (Clinical study): A clinical study, for which five patients were enrolled, was
carried out to evaluate the C-probe for determining interfractional shifts of the uterus,
paper B. But, after concluding that the C-probe had limitations when used for uterine
TAUS-scanning, the new A-probe was applied instead in a clinical study. The results
of using of the A-probe are presented here. These results have not been submitted for
publication.
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3.1 Phantom study
The research project was initiated by installing the Clarity soft tissue visualization system
at Herlev hospital. The Clarity system in radiotherapy differs from other US scanning
systems, since it is integrated into radiotherapy by calibrating it to the same coordinate
system as in the CT and treatment room. The calibration is performed using a vendor
provided phantom (Fig. 2.2 C). The operators participated in two weeks of theoretical
and practical training arranged by a Clarity specialist. The practical training included
prostate and uterus transabdominal scanning using the C-probe to scan the volunteers.
First and foremost, all the operators found the system challenging, since US scanning
has not previously been implemented at our site. Secondly, the scanning of the uterus, by
applying a sweep-slide technique to capture the larger volume of the uterus, was perceived
to be cumbersome (Fig. 3.1). In addition, image interpretation was found to be difficult,
in terms of image orientation and organ identification. It is well-known that US probe
handling and recognition of the anatomical structures are serious issues for inexperienced
operators, due to difficulties with correct probe positioning and variable image quality.
To overcome these obstacles, we initiated the research study by scanning a commercial
phantom.
Figure 3.1: The TAUS scan of the uterus; Illustrates the sweep-slide technique required
to capture the uterus.
The ultrasound training phantom (CIRS 404, Universal Medical, Norwood, USA)
mimics the female pelvic region and contains a uterus, bladder and rectum representing
the standard female pelvic organs (Fig. 3.2). The organs are subjected to displacement by
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Figure 3.2: The Clarity ultrasound system; (A) The uterine phantom. (B) Phantom US
scanning by means of a C-probe in the CT room. (C) Clarity US console, in which the
phantom organs (bladder, uterus, and rectum) are easily identifiable. (D) The console is
utilized to optimize image contrast and brightness before acquiring the US images.
the exerted probe pressure. The phantom does not contain any skeletal structure, such
as the head of the femur or pelvic bone. The phantom is constructed of material that is
intended for ultrasound scans, thus all organs are easily defined in the acquired US-images.
Initially, the phantom was marked with small spherical ball bearings (laser alignment
markers), used to aid reproducibility of the daily set-up prior to each US-scan session.
Use of this technique requires acquisition of a reference US image data-set, and therefore
during an initial session the best possible US-scan was selected as the reference position
for the following sessions.
The aim of the initial study was to; (A) quantify the inter-operator variability, (B)
determine the uterine positional displacement induced by the probe pressure.
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3.1.1 Inter-operator variability
Different US imaging systems have been introduced into radiotherapy to visualize the soft
tissue sites such as the prostate, GYN, and the postoperative lumpectomy cavity in breast
cancer patients, (Boda-Heggemann et al. 2008; Cury et al. 2006; Pinkawa et al. 2008;
Scarbrough et al. 2006; Serago, Buskirk, et al. 2006). However, to our knowledge, very
few published papers have reported the application of 3D US in GYN patients (Ahmad, et
al. 2008). As with all other systems, there are some limitations to the implementation of
US imaging in radiotherapy. For instance, some challenges in terms of probe handling
difficulties and inter-observer variability have previously been reported (McGahan, Ryu,
and Fogata 2004; Serago, Chungbin, et al. 2002). In the current study, the inter-operator
variability was investigated through 21-US scans of the phantom by seven operators over
four sessions in different days (Fig. 3.3).
Figure 3.3: Positional uterine center of mass (COM) shifts of a phantom; The plot
shows uterine COM shifts in the L/R (A), A/P (B), and I/S (C) directions for daily scans
(D) (Day 1: 6 operators, Day 2: 6 operators, Day 3: 5 operators, and Day 4: 4 operators).
Positional uterine shifts in the L/R, A/P, and I/S directions demonstrates that there are
no statistically significant differences compared to the mean of COM shifts, i.e. mean
of the session scans for each day (Table. 3.1). All the acquired US-scans indicated that
uterine COM displacements are in the vicinity of zero, with a daily mean value of less
than 2 mm in all three cardinal directions. Since the interfractional positional variations
of the cervical region, vaginal canal, and the head of the uterus (fundus) can vary by
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Table 3.1: Tabulates values of one sample t.test of obtained uterine shifts using ultrasound
scans of a phantom
.
N SD1 [mm] Mean [mm] df2 t 95% CI3 P-value
Day Directions (Lower/upper)
L/R 6 0.86 -0.35 5 -1.00 -1.25/0.55 0.36
DAY 1 A/P 6 1.74 -0.02 5 -0.02 -1.84/1.81 0.98
I/S 6 2.62 -1.47 5 -1.37 -4.22/1.28 0.23
L/R 6 0.60 -0.32 5 -1.29 -0.95/0.31 0.25
DAY 2 A/P 6 0.71 0.08 5 0.29 -0.67/0.83 0.79
I/S 6 1.83 0.10 5 0.13 -1.82/2.02 0.90
L/R 5 1.17 -1.04 4 -1.99 -2.49/0.41 0.12
DAY 3 A/P 5 0.88 -0.98 4 -2.48 -2.08/0.12 0.07
I/S 5 1.15 0.06 4 0.12 -1.36/1.348 0.91
L/R 4 0.47 1.25 3 5.29 0.50/2.00 0.01
DAY 4 A/P 4 1.22 0.18 3 0.29 -1.76/2.11 0.79
I/S 4 3.14 0.45 3 0.29 -4.54/5.44 0.79
1 Standard Deviations; 2 Degree of Freedom; 3 Confidence Interval
more than 2 cm (Chan et al. 2008; Jurgenliemk-Schulz et al. 2011), these day to day
variations outweigh the magnitude of our inter-operator variability. In summary, the
present US-phantom study suggests that inter-operator variability in determining uterine
position is clinically irrelevant.
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3.1.2 Probe pressure displacement
While the inter-operator variability in use of the phantom was shown to be clinically
irrelevant, we conducted a new study to investigate the positional impact of probe pressure
on the uterine COM. The aim of the study was to compare the magnitude of the pressure
displacement with the daily uterine motion in a healthy volunteer. Variations in the
transducer probe pressure applied have previously been documented during 3D US on
prostate patients (Serago, Chungbin, et al. 2002; Taylor and Powell 2008), but, to our
knowledge, there is no published paper on the cervix.
The study was initiated by US scanning of the phantom (transabdominal US scan using the
C-probe) by seven operators in four sessions on different days. Each operator performed
two scans per session, one without pressure (WOP) or light probe pressure, and one with
maximum pressure (WP). A total of 42 scans were acquired.
In each phantom scan the US probe was performed on the first occasion with minimal
pressure and on the second with firm pressure in the region corresponding to the pubic
symphysis and rotated, after which it was swept cranially.
Positional shifts of the phantom uterus center of mass (COM) in the three orthogonal di-
rections WP (depicted as circles) and WOP (depicted as triangles) are presented (Fig. 3.4).
No statistically significant differences in any direction can be seen when comparing the
shifts between WP and WOP (Table 3.2). The largest recorded shift is in the I/S-direction;
+5 mm (WOP) and -5 mm (WP). The mean of the COM shifts in all three directions (L/R,
A/P, I/S) for WP and WOP are centered around zero (Fig. 3.4 D).
Table 3.2: Paired t-test values of the mean uterine shifts using ultrasound scans of the
phantom with pressure, and without pressure.
Number of SD1 [mm] Difference between 95 % CI2 p-value
Directions scans the means [mm] (lower/upper)
Left-Right 21 0.93 -0.29 -1.03/0.45 0.43
Anterior-posterior 21 2.13 0.10 -0.99/1.18 0.86
Inferior-superior 21 1.87 0.50 -0.85/1.85 0.45
1 Standard Deviations; 2 Confidence Interval
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Figure 3.4: Plots of the COM shifts based of ultrasound scans of the phantom uterus;
WP & WOP in (A) L/R, (B) A/P and (C) I/S directions. (D) Boxplot for WP and WOP for
all three cardinal directions (L/R, A/P, I/S). A: Anterior; I: Inferior; L: Left; P: Posterior; R:
Right; S: Superior; WOP: Without pressure; WP: With pressure.
3.1.3 Limitations and benefits of the current approach
The phantom study has limitations since it is not necessarily representative of a real GYN
patient. Daily bladder and rectal filling variations might induce large uterine positional
variations, which cannot be simulated by a phantom. However, each operator scanned
this phantom several times, and also the possibility of acquiring images of a volunteer
facilitated acquaintance with the Clarity system. The initial procedure with phantom
scanning was perceived by each operator as an effective method obtaining experience in
probe handling, image orientation, and ultrasound image interpretation. The American
Association of Physics in Medicine (AAPM) emphasizes that the clinical US training is
of the utmost importance, especially for inexperienced operators (Molloya et al. 2011).
Experienced US-users are reported to be more consistent in image acquisition and have
easier to recognize anatomical structures, leading to less inter-operator variability (Fuss
2003). In brief, a solid US training program is a necessity before implementing the
TAUS scan method as an IGRT system in cervical radiotherapy. Additionally, it is highly
recommended that an experienced ultrasound radiologist or oncologist are involved in
implementing a new ultrasound IGRT system, since they can be a major support for the
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Figure 3.5: Omnidirectional shifts of uterine center of mass of a volunteer; (A–C)COM
shifts for the volunteer on 3 days in the three cardinal directions. (D) Uterine COM shifts;
the daily ultrasound scans.
RTTs in terms of image interpretation. Unfortunately, we lacked this essential support
while conducting this project.
3.2 Case study (volunteer)
A healthy young volunteer was scanned by six operators in three sessions, leading to a
total of 16 scans, over a period of 3 weeks (one session per week). During the first session
the best scan, in which the organs were clearly definable, was selected as a reference
for the following three sessions. Prior to the scanning, the volunteer was asked to have
an empty rectum and full bladder prior to each US scan. The fixation was in supine
position by means of a Vac Fix fixation system to ensure position reproducibility between
sessions. Consistent positioning of the volunteer was enabled by the alignment of natural
skin markers to the isocenter lasers of the CT room. A US transabdominal scan of the
pelvic region was performed repeatedly by each operator until adequate image quality was
achieved. Initially, a best scan, in which the organs were clearly definable, was selected as
a reference for the following three sessions. No firm pressure was applied on the volunteer,
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Table 3.3: Mean values with standard deviations of the uterine shifts in the volunteer scanned
by six operators.
Nr. of Mean [mm] SD [mm]
Day Directions scans
Left-Right 6 0.27 1.09
DAY 1 Anterior-posterior 6 0.18 1.71
Inferior-superior 6 -7.65 2.64
Left-Right 4 -1.58 1.74
DAY 1 Anterior-posterior 4 -1.95 1.21
Inferior-superior 4 7.55 6.12
Left-Right 6 9.48 3.08
DAY 1 Anterior-posterior 6 -4.47 2.53
Inferior-superior 6 -6.85 2.47
as the focus was on obtaining clear images, where the complex pelvic structure could be
identified.
For the volunteer, the recorded mean COM shift on day three in the L/R direction is
approximately 10 mm relative to the reference, while on days 1 and 2 the lateral shift
is less than 2 mm (Fig. 3.5). The largest interfractional displacement is observed in the
I/S direction, with a mean value of -7.7 mm, +7.6 mm and -6.9 mm on days 1, 2 and 3,
respectively (Table 3.3), which is a clinically significant. This major divergence in the
shifts was mainly due to the bladder volume variation, especially from Day 1 to Day 2
(Fig. 3.6). Previous reports have confirmed that uterine positional changes are strongly
correlated with daily variation in bladder–rectum filling (Ahmad et al. 2011; Lee et al.
2007). The challenge experienced by most of our operators during 3D US acquisition was
to find an appropriate probe handling technique that captured the entire uterus from the
cervical os to the fundus, as the image quality was poor in some cases. Obviously, poor
image quality has an adverse influence on uterine delineation, thus leading to uncertainty
in COM shifts. Our experience of suboptimal image quality is confirmed by a previous
study, where assisted segmentation (employed in the present study) was compared to
manual segmentation of prostate patients using the Clarity 3D US system (Johnston et al.
2008). During quality classification of the acquired US images, they found that up to
33% were of bad quality, which hinders accurate outlining of the target. One limitation of
this study is that the statistical evaluation of the interfractional uterine positional changes
based on a single volunteer must be considered with caution, and a clinical study is needed
to validate the present result.
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Figure 3.6: Outlined organs (bladder, uterus and rectum), sagittal, transversal and
frontal cross-sections; The uterine positional shift is obvious from days 1 to 2.
3.3 Volunteer study to compare C-probe to A-probe
The implementation of 3D TAUS imaging, using the C-probe, on the GYN patients
was experienced as a challenge, since all the operators faced difficulty in applying the
sweep-slide technique. After conducting a clinical study of five cervical cancer patients,
paper B, we confirmed that using the C-probe is cumbersome and might lead to undesired
inter-operator variability in terms of variations in capturing the uterine volume, and
difficulty in identifying the uterine structure in the transversal plane, although normally
it is easily recognizable in the sagittal plane. Consequently, the Clarity manufacturer
provided us with a new suggested prototype autoscan probe (A-probe). A volunteer study
was designed to evaluate a novel A-probe by comparing it to the C-probe.
The semiautomatic A-probe inherits a mechanically motorized head, enabling auto-
matic transabdominal sweep scans after manual positioning of the probe above the pubis
symphysis. The A-probe is a modification of an autoscan probe (Lachaine and Falco
2013) that was initially designed for transperineal prostate scanning and real-time tracking
of the prostate, to address intrafractional prostate motion. The hypothesis of the volunteer
study was that the novel A-probe may be a better IGRT alternative than the C-probe in
cervical radiotherapy. In this approach, nine healthy volunteers were US scanned by seven
operators, using C-probe followed by an A-probe scan (Fig. 3.7). The volunteers were
asked to remain motionless, and instructed to follow a moderate bladder filling protocol.
After the superimposing reconstructed image sets from the C-probe over the A-probe
images, two observers (OBS 1 and OBS 2) delineated the uterine organ in the 72 acquired
scans; 36 from C-probe and 36 from A-probe. Thus, the outlined uterine structures served
to determine inter-observer contouring variability. OBS 1 delineated the same scans after
two weeks, to investigate intra-observer variations. Furthermore, the delineated uterine
structures were classified into two groups: one with all scans and the other with the best
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Figure 3.7: Transabdominal ultrasound imaging; (A) Using the C-probe, and (B) using
the A-probe.
scans. In the best scans, both C-probe and A-probe images showed the whole uterus.
We found out that A-probe images were slightly better in spatial resolution, the reason
being the higher transducer frequency (Fig. 3.8 A & B). Additionally, figure 3.8 C &
D exemplifies a uterine scan, where the image is incomplete using the C-probe, due to
difficulty identifying the uterus in the transversal plane while manually scanning the
pelvic region. As a result, the whole uterus was captured in only 19 (53 %) scans using
the C-probe, whereas the corresponding figure for the A-probe was 32 (89 %).
When comparing the C-probe to the A-probe, the calculated SD of inter-observer
(OBS 1- OBS 2) and intra-observer (OBS 1 - OBS 1) differences were smaller for the
A-probe in all three directions, the only exception being intra-observer delineations in the
A/P-direction (Table. 3.4). Application of the F-test showed that the reduction was statisti-
cally significant, verifying better inter-observer concordance while employing the A-probe
Figure 3.8: Ultrasound (US) images using C-probe, and A-probe; (A) Volunteer 1 ultra-
sound image of bladder and uterus using the A-probe. (B) The same volunteer but using the
C-probe, where image distortion and lower image quality can be observed. (C) Volunteer 2
using the A-probe, where the whole uterus is captured. (D) The same volunteer but using
the C-probe, where only half of the uterus is imaged.
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Figure 3.9: Median (horizontal line), 25th and 75th percentiles (box), and range
(whiskers) of Euclidean distances between uterine center of Mass (COM) delineated
by OBS 1 and OBS 2, and the same observer twice (OBS 1); (A, B) Distance differences
(OBS 1 minus OBS 2) for the C-probe and A-probe using all 36 scans and best 19 scans,
respectively. (C, D) Distance differences (two delineations by the same observer (OBS 1))
for the C-probe and A-probe using all 36 scans and best 19 scans, respectively.
While investigating set of all scans compared with the best scans, an F-test revealed
that the different SD for inter-observer COM, while using all scans and comparing the
C-probe with the A-probe, was statistically significant. In contrast, the corresponding
F-test on the best 19 scans indicated no significant differences, except for a weak dif-
ference in the A/P-direction (p <0.04) (Table. 3.5), yet again confirming that there is
better agreement in delineating the target when the entire uterus is captured (best scans).
This was verified by studying the Euclidean distance, where applying the F-test to the
inter-observer differences was revealed to be statistically significant, but not for the intra-
observer distance (last two rows in Table. 3.5).
Furthermore, the median of the Euclidean COM distances for inter-observer scans was
reduced by 2.5 mm (all scans) while using the A-probe instead of the C-probe, compared
with only 0.4 mm (best scans) (Fig. 3.9). However, the intra-observer graphs (Fig. 3.9
C & D) illustrate that for all scans and for the best scans, the median distance is around
5.0 mm, irrespective of whether the the C-probe or A-probe was employed. The smaller
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Figure 3.10: Comparison of the maximum uterine length by OBS 1 and OBS 2 on
C-probe and A-probe scans in Inferior-Superior (I/S); Left-Right (L/R); Anterior-
Posterior (A/P)-directions); Regression line fit (solid line) and predicted interval (dashed
lines) for 95 % confidence interval (CI) are indicated.
reduction in the best scans indicates that there is better target delineation concordance
when the entire uterus is captured, which is the case with the "best scan". Moreover,
the dice coefficient index (the volume overlap of the delineated uterus by the OBS1 and
OBS2) was calculated as 0.67 and 0.75 for the C-probe and A-probe scans, respectively,
verifying that there is good concordance using the A-probe but only modest concordance
with the C-probe. The highest inter-observer discordance stems from inaccurate uterine
segmentation in the missing part of the imaged uterus using the C-probe.
As one uterine COM point did not reveal substantial data on the outlined large uterine
volume, the maximum uterine length in all three directions was examined. The predictive
interval indicated better inter-observer concordance when applying the A-probe compared
to the C-probe (Fig. 3.10). However, the benefit was limited in the L/R-direction, which
can be attributed to the poor lateral image resolution in both the C-probe and the A-probe
scans. Yet again, this result suggests that the A-probe might be a better IGRT method
than using the C-probe in cervical radiotherapy.
In summary, all the operators in the current study reported that it was easier to handle
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Table 3.4: Mean inter and intra-observer differences in uterine COM for the three directions,
using C- and A-probes.
Mean ± 1SD1 [mm]
Inter-observer2 Intra-observer
Directions C-probe A-probe C-probe A-probe
I(+)/S 3.2 ± 6.3 1.8 ± 3.9 -0.9 ± 6.1 -1.3 ± 3.2
L(+)/R 0.9 ± 5.5 0.0 ± 3.6 0.2 ± 5.8 -2.1 ± 3.8
A(+)/P -0.4 ± 6.6 0.4 ± 3.6 -0.7 ± 3.5 0.8 ± 3.5
1Standard deviations 2Inter-observer: the differences between two observers;
Intra-observer: the differences between two delineations by the same observer.
Table 3.5: F-test of the SD for inter-observer uterine COM differences as well as inter and
intra-observer Euclidean COM distances in all the three orthogonal directions. The test is
done for all scans and the best scans.
All scans (n = 36) Best scans1 (n = 19)
Ratio of 95 % CI2 p-value Ratio of 95 % CI p-value
Directions variances Upper/Lower variances Upper/Lower
I(+)/S 2.61 (1.33 to 5.22) 0.006 1.16 (0.45 to 3.01) 0.7571
L(+)/R 2.38 (1.21 to 4.67) 0.012 1.84 (0.71 to 4.77) 0.2067
A(+)/P 3.29 (1.68 to 6.45) 0.001 2.83 (1.09 to 7.35) 0.0331
Euclidean 4.90 (2.50 to 9.61) 0.000006
(inter-observer)
Euclidean 1.83 (0.93 to 3.59) 0.077
(intra-observer)
1Best scans: The US scans where the whole uterus is captured both with the A-probe and the C-probe
2 Confidence Interval
the A-probe, particularly when identifying the uterus and bladder in the sagittal plane.
Furthermore, image acquisition was quicker and less probe pressure was exerted during
A-probe scanning. Moreover the image detail of the A-probe scan was slightly better than
that of the C-probe. Additionally, the study revealed that the A-probe is superior to the
C-probe for capturing the whole uterine volume.
Briefly, in this study we confirmed that A-probe imaging might be a better modality
than C-probe imaging in terms of better spatial resolution, facilitating capture of the
whole uterus, and requiring less applied probe pressure. While the sweep-slide technique
in using the C-probe was a challenge, the A-probe scans were performed faster and
more smoothly. As a result, the A-probe demonstrated less inter-operator variability and
consequently less contouring variations. In conclusion, the A-probe is confirmed to be
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a better IGRT system, with less uncertainties, than the C-probe for correcting for daily
uterine positional changes in cervical radiotherapy. As this conclusion was evident, we
changed the C-probe to the A-probe in our continuous clinical study for applying TAUS
scans of cervical cancer patients. The next section is a clinical comparison of the two
probes.
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Table 3.6: Uterine center of mass shifts (C-probe and A-probe)2 realtive to bony structures
(CBCT).
Mean ± 1SD1 [mm]
Maximum shift [mm] Overall uterine match
US C-probe A-probe
Directions (11 pts, 38 fractions) (11 pts, 38 fractions) (6 pts, 25 fractions) (5 pts, 13 fractions)
A(+)/P -19.7 -1.3 ± 7.4 -0.5 ± 8.2 -3.0 ± 6.3
I(+)/S -23.0 -2.5 ± 7.1 -4.1 ± 7.7 0.6 ± 4.5
L(+)/R 12.5 1.8 ± 4.3 1.6 ± 4.5 2.2 ± 3.8
1Standard deviations, 2Conventional and autoscan probes .
3.4 Clinical study using C-probe and A-probe
After several phantom and volunteer C-probe TAUS scans, clinical scans of cervical
cancer patients were initiated. First of all we conducted a clinical study of five patients,
paper B. Three more patients were incorporated in the TAUS C-probe study before the
conclusion that there were uncertainties in implementing the C-probe as an IGRT method.
Our feedback to the Clarity manufacturer, suggesting that they design a new automatic
probe that should be able to acquire US images in the sagittal plane rather than the
C-probe’s transversal plane, resulted in designation of a novel autoscan probe (A-probe).
The A-probe was implemented to determine the interfractional uterine displacements of
the cervical cancer patients through the TAUS scanning. In this section we will take up
some results from the first published paper, and also compare the C-probe results (six
patients) with the A-probe results (five patients).
The overall positional uterine COM shifts (± 1SD, 38 scans by C-probe and A-probe)
relative to the bone structure, was [mm]; ±7.4, ±7.1, and ±4.3, in A/P, I/S, and L/R,
respectively (Table. 3.6). When the uterine shifts of the C-probe was compared to the
shifts using the A-probe, we found that the standard deviations of the C-probe was larger
than of the A-probe (columns 4 & 5 in the table. 3.6). This can be due to the fact that
when using the C-probe there are challenges to identifying the pelvic structures, and also
to capturing the entire uterus, leading to larger inter-operator and inter-observer variability,
which was confirmed in the comparison volunteer study in the previous section. The
largest interfractional displacements using US were 19.7 mm, 23 mm, and 12.5 mm in the
posterior, superior, and left directions, respectively.
Generally, we showed that US-imaging is capable of identifying soft tissue structures,
especially on the bladder-uterus interface, which otherwise were difficult to distinguish
using CBCT imaging. At the same time, a comparison of the uterine shifts between the
C-probe and the A-probe confirmed the results of the previous volunteer study in that
there is greater uncertainty in using the C-probe as uterine IGRT method. The operators
experienced the A-probe as easier to employ, and the uterus, bladder and rectum could
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Figure 3.11: The bladder volume reduction; Showing that the bladder volume decreases
during the treatment course, due to radiation induced sideeffect.
easily be recognized, thus leading to a reduction of image acquisition time. Moreover, we
observed a bladder volume reduction during the treatment course, despite the fact that the
patients were following a moderate bladder filling protocol (Fig. 3.11). Bladder volume
reduction presents a challenge as it affects the daily uterine and bladder position as well
as making the use of ultrasound as a daily IGRT modality more difficult. The bladder
volume reduction might be attributed to the radiation induced urinary adverse effects.
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Probe pressure and intrafractional
prostate motion
In this chapter, the probe induced prostate displacement and intrafractional prostate motion
are addressed based on the two papers D & F.
In the probe pressure displacement study, the Clarity TPUS system was utilized
to monitor the prostate in real-time. During the prostate tracking, a TAUS scan was
simulated, using the C-probe. The aim of this study was to determine the magnitude of
prostate displacement while the probe simulation was being applied.
In the clinical study of intrafractional prostate motion, the prostate was tracked in real
time for about 2 to 2.5 minutes, a typical beam-on time required to deliver a RapidArc
plan in our site. The aim of the study was to investigate whether the intrafractional motion
is within 2.0 mm. 2 mm is a tolerance value recommended by the British Ionization
Radiation Medical Exposure Regulations 2000 (IRMER 2000).
4.1 Probe pressure displacement of the prostate during TAUS scan
TAUS imaging has previously been used in prostate IGRT at different sites (Heuvel
et al. 2003; Johnston et al. 2008; McNair et al. 2006; Scarbrough et al. 2006; Serago,
Buskirk, et al. 2006). There are two models for US IGRT systems, a intramodal Clarity
system and an intermodal BAT system (Cury et al. 2006; Feigenberg et al. 2007; Meer
et al. 2013; Peng et al. 2008; Pinkawa et al. 2008). In intermodal US, the US images
from the treatment room are matched to computed tomography (CT)-reference images,
whilst in intramodal US the US images are matched to the US-reference images from
the simulation room. Both systems are based on 3D TAUS scanning, using a 2D US
probe. One of the challenges in acquiring the TAUS imaging is variations in transducer
probe pressure (McGahan, Ryu, and Fogata 2004; Serago, Chungbin, et al. 2002). In
different phantoms, volunteers, and clinical studies, the pressure induced shift of the
prostate has been investigated (Artignan et al. 2004; Fargier-Voiron et al. 2014; McGahan,
Ryu, and Fogata 2004). The limitation of a phantom study is that a phantom cannot reflect
the patient’s organs. In the volunteer study by Artignan et al. (2004), the probe was
affixed to a robotic arm, capable of only vertical movement, which might not reflect the
sweep technique required to perform a TAUS scan. The most recently published paper
by Fargier-Viron et al. shows that the prostate displacement can be up to 8 mm, due to
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Figure 4.1: The TAUS simulation during TPUS monitoring of the prostate; (A) 4D
monitoring autoscan attached to the patient, (B) TAUS simulation using 2D probe, (C)
4D autoscan probe, (D) The 2D probe, (E) The prostate monitoring graph, indicating the
impact of applied probe pressure.
exerted vertical "strong pressure", but it was not possible to observe displacements during
the exertion of "soft pressure" adequate for acquiring sufficient image quality. Thus, a
study to simulate the daily in-room TAUS IGRT while, in real-time, recording the induced
prostate displacement is required, and this was the motive for our probe pressure study.
The aim of this study was to determine prostate displacement, due to applied TAUS probe
pressure, by continuously 4D monitoring the prostate utilizing the TPUS 4D real-time
autoscan.
4.1.1 Clinical study
Nine prostate cancer patients were US scanned weekly by two of our six experienced
RTTs, using the TPUS autoscan. The patients were instructed to follow a moderate
bladder-filling protocol. After the CT scan, a US scan was acquired. Afterwards, the
CT-US fusion was performed and the prostate gland was delineated as a reference for
subsequent weekly US scans in the treatment room. In this study, the US monitoring
images were used for research purposes only and not applied clinically. Immediately after
the treatment delivery, the patient was repositioned in preparation for autoscan monitoring.
A total of 42 US scans were acquired. The TAUS scan was simulated, using a C-probe,
while the prostate was continuously monitored using the TPUS autoscan (Fig. 4.1). The
figure shows an example of prostate displacements in I/S, L/R, and A/P directions during
the probe simulation. The simulation duration applying the TAUS probe was from 15 to
20 seconds. During the simulation, no US images were acquired with the C-probe, i.e. the
probe was used as a dummy. However, the trained RTTs were instructed to reproduce the
sweeping technique and associated applications of pressure required to acquire adequate
US image quality. Furthermore, the RTTs were asked to avoid observing the impact of
the pressure on the console screen.
The TPUS auatoscan was capable of tracking the prostate in real time. The TAUS
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Figure 4.2: The prostate displacement; (A-C) Monitoring graphs show the prostate dis-
placements due to applied probe pressure for total 42 US scans in I/S, L/R, and A/P
directions, (D) The graph over mean of the 42 scans in I/S, L/R, and A/P directions.
simulation was performed for all the patients, although some variations in probe handling
were observed. Results of the data analysis of the 42 scans, means and SDs of the
prostate displacements and the mean of the maximum Euclidean distance, are tabulated in
Table 4.1. Most of the displacements were observed to be smaller than 2 mm in all three
directions (Fig. 4.2). Furthermore, figure 4.2 D, reveals that the mean displacements are
within ± 0.2 in all three directions. Only 5 % (two scans in A/P direction), and 16 % of
the Euclidean distance were larger than 2 mm. In many cases, we observed a permanent
displacement of the prostate after releasing the probe.
Individual boxplots of all nine patients demonstrated some variations in prostate
displacements between them, and even for individual patients (Fig. 4.3). Additionally, the
boxplot of the overall displacements revealed that the first and the third quartiles were
within 1.0 mm in all three directions. Finally, the last boxplot in the figure indicates that
the median Euclidean distance is about 1.3 mm.
The TPUS autoscan was shown to be an excellent tool for real-time prostate tracking.
The uncertainty of the autoscan probe had previously been validated as less than 0.2 mm
in all three directions (Lachaine and Falco 2013). For some fractions (6 of 48 scans),
identification of the prostate was difficult, and therefore those 6 scans were excluded.
Surprisingly, the prostate displacements from our study were less than all previous
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Table 4.1: Mean, standard deviations (SD), max of prostate displacement, and displacements
larger than 0.5, 1.0, 2.0 mm in all three directions, including Euclidean distance Max(D(t)).
Directions
I(+)/S1 L(+)/R A(+)/P MaxD(t)1
Mean ± SD [mm] -0.1 ± 0.8 0.2 ± 0.7 -0.1 ± 1.0 1.3 ± 0.7
Max displacement [mm] 1.2/-1.8 1.6/-1.1 2.6/-2.2 2.9
Displacement > 0.5 mm 49 % 47 % 58 % 81 %
Displacement > 1.0 mm 16 % 14 % 33 % 60 %
Displacement > 2.0 mm 0 % 0 % 5 % 16 %
1A/P, anterior-posterior; I/S, inferior-superior; L/R, left-right;
2Max(D(t)): maximum Euclidean distance
reported displacements in all directions, except for one study (Dobler et al. 2006). The
reason might be that Dobler et al. were using a similar method as in our approach, i.e.
observing the pressure displacements in real-time (They tracked the inserted seeds in
Brachy therapy using the X-ray simulation, while applying TAUS probe) and, importantly,
not using a US scan with minimal pressure as reference. Most of the other studies were
implementing either US/US (Clarity system) or US/CT (BAT system) image matching in
order to measure the prostate COM displacements (Artignan et al. 2004; Fargier-Voiron
et al. 2014; Meer et al. 2013). For instance, in this study, the mean Euclidean distance of
the prostate COM displacement was 1.3 mm, compared to Fargier-Voiron et al. (3.3 mm),
Van der meer et al. (3.0 mm), and Artignan et al. (3.1 mm). Apart from the uncertainty of
not applying real-time prostate monitoring in these studies, there are two other factors that
might explain the greater Euclidean distances. Firstly, the US/US- and US/CT-matching
is inter-operator dependent. For example, Van der Meer et al. investigated the US/US
matching procedure to determine intra-, and inter-operator matching variability, and
discovered the intra-operator/inter-operator variability (1 SD) to be 0.8 mm/1.8 mm (I/S),
0.7 mm/1.3 mm (L/R), and 1.0 mm/1.4 mm (A/P), respectively. In another study (Langen
et al. 2008), the inter-operator variability in US/CT matching, among eight observers,
was found to be larger than 2.0 mm in 50 % of the matches (difference between any
two matches). Secondly, in these three studies they applied maximum pressure, not
soft pressure, perceived to be sufficient to achieve adequate image quality. Additionally,
Artignan et al. applied vertical pressure, using a rigid arm, enabling it to move towards the
prostate i graded steps, which cannot reflect a real sweep technique, required in acquiring
US images of the prostate.
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Figure 4.3: Boxplots of the prostate displacements; (A – C) Boxplots of the prostate
displacements for nine patients in I/S, L/R, and A/P directions (D) Boxplot of overall
prostate displacements in I/S, L/R, and A/P directions, including Euclidean distance. The
horizontal band indicates the median, the lower and the upper edges of the box explain the
first (25th), and third (75th) quartiles. The lower and the upper extremes of the whiskers,
display the minimum and maximum values in absence of single data point outliers.
4.1.2 Limitations and Conclusion
Despite that our results were considered to have less uncertainties than the previously
published studies, there are some limitations with the current study. First of all, it is
desirable to acquire real US images, using the C-probe during TPUS prostate monitoring
rather than using only a C-probe simulation. The question always remains as to whether
the operators had used enough pressure to acquire good images, or how one operator can
reproduce the same magnitude of pressure among the patients, or for different fractions of
the same patient. In the present study, we were unable to simultaneously acquire TAUS
images while TPUS monitoring, using the same US unit, since another Clarity system
was required to do this. Moreover, although a gentle transperineal attach of the autoscan
was carried out with caution, a counter-effect of the probe’s head might influence the
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position of the prostate, and hence changing the magnitude and likewise the direction of
the prostate displacements during TAUS simulation.
In summary, the 4D TPUS autoscan is able to track prostate motion during C-probe
TAUS simulation. We demonstrated that the probe pressure induces displacement of the
prostate mostly is less than 2 mm in all three directions, which is perceived to be clinically
irrelevant in prostate radiotherapy.
4.2. Intrafractional prostate motion 43
4.2 Intrafractional prostate motion
In prostate radiotherapy, it is important that the dose is delivered to the prostate, while
minimizing the dose to the OARs. To achieve this, different reliable prostate IGRT
methods are available, enabling positional correction for daily interfractional motion,
such as surrogate implanted fiducial markers (Johnston et al. 2008; McNair et al. 2006;
Scarbrough et al. 2006; Serago, Buskirk, et al. 2006). But, prostate displacement during
treatment delivery (intrafractional) remains a challenge (Dawson 2000; Padhani 1999).
Therefore, different real-time tracking methods are developed to monitor the prostate
during radiotherapy (Bittner et al. 2010; Chan et al. 2008; Curtis et al. 2013; Tong et al.
2015; Wilbert et al. 2013). In this project the Clarity 4D TPUS autoscan was utilized
to determine intrafractional prostate motion for approximately 2 to 2.5 minutes. To our
knowledge, there is only one previously published paper based on the Clarity autoscan, in
which six prostate patients were involved (Ballhausen et al. 2015).
The objective of the present study is to explore whether the intrafractional prostate
motion is smaller than 2 mm, for a period of approximately 2-2.5 minutes, corresponding
to the beam-on time for RapidArc delivery. The aim is also to investigate if there is any
correlation between the patients’ BMI-value and the magnitude of the displacement.
Ten prostate cancer patients were US scanned in the CT room (after CT scanning)
and once a week in the treatment room (after treatment delivery) using the Clarity TPUS
autoscan. The patients were aligned to the external lasers in the supine position, and
asked to remain motionless during image acquisition and prostate monitoring. They were
instructed to follow a moderate bladder-filling protocol. After CT scan and treatment
delivery the patient was repositioned in preparation for the autoscan monitoring using the
vendor provided autoscan base (Fig. 2.8), implying a different setup. The different setup
is assumed not to have adverse impact on the results, since the aim of this study was to
monitor the prostate during a certain time, corresponding to the duration of the treatment
delivery. Initially, the autoscan probe is attached to the TPUS base, fixation cushions
placed over the bases just under the patient’s knees, and the probe, transperineally, pushed
gently to the patient for scanning. The prostate monitoring was recorded for retrospective
statistical analysis.
The patients were cooperative, despite the extra time of about 10 minutes, needed
for patient repositioning in preparation to prostate monitoring. None of the patients
showed any discomfort during the US prostate tracking. The overall mean values (51
TPUS curves) of the maximal intrafractional prostate displacements (± 1SD [mm]) in
three directions were; I(+)/S: (-0.2 ± 0.9); L(+)/R: (-0.2 ± 0.8); and A(+)/P: (-0.2 ± 1.1)
(Table 4.2). The largest prostate displacement was 2.8 mm in posterior direction, and the
percentage of sessions with displacements larger than 2.0 mm was 4 % (I/S), 2 % (L/R),
and 10 % (A/P), respectively. The percentage of fractions with a Euclidean distance (3D
vector) larger than 2.0 mm was 12 %. We found no correlation between BMI-value and
the magnitude of the displacement.
We found pattern variations of the monitoring curves for different fractions, and we
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Table 4.2: Intrafraction prostate motion in three directions and 3D vector; a comparison of
the present study with previously published data using different systems.
Mean of max prostate
shifts (± SD) [mm]
Investigator N System Time [min] I(+)/S L(+)/R A(+)/P % 3D vector 3D vector
year fractions shift [mm]
Lometti et al., 200532 11(133) MV fluoroscopy: 1 > 2 mm 4 % 0.7 ± 0.5
real-time FM tracking
Li. HS et al., 20084 35(1267) Calypso 12 0.3 ± 0.7 0.0 ± 0.3 0.4 ± 0.6
Kupelian et al., 20082 17(550) Calypso 10 > 3 mm 14 %
Langen et al., 200818 17(550) Calypso 2 > 3 mm 3 %
Li et al., 200919 20(157) Calypso 11.4 > 3 mm 19 %
Vargas et al., 201028 7(68) Cine-MRI 4 0.41 ± 1.2
Wang et al., 201133 29(1061) Calypso 3 > 3 mm 9 %
Smeenk et al., 201129 15(576) Calypso 2.5 > 3 mm 1.4 %
Ng et al., 201218 10(268) Real-time kV 3-4 > 3 mm 5.6 %
FM tracking
Mayyas et al., 20139 8 pre- post treatment 0.8 ± 2.7 0.2 ± 2.1 -0.3 ± 2.4
kV images
Mayyas et al., 20139 19 Calypso 0.0 ± 1.5 0.0 ± 0.6 0.0 ± 1.3
Tong et al., 20158 236(8660 Calypso 2 > 2 mm 13 %
Choi et al., 201527 17(550) Transrectal US/3FMs 4.5 0.6 ± 0.6 -0.3 ± 0.3 -0.7 ± 0.6 > 2 mm 11 % 1.1 ± 0.8
Present study 10(51) Clarity real-time TPUS 2-2.5 0.2 ± 0.9 -0.2 ± 0.8 -0.2 ± 1.1 > 2 mm 12 % 0.9 ± 0.6
Intrafractional motion of prostate patients (N) in 3D vector, I/S, inferior-superior, L/R, left-right, and A/P, anterior-posterior directions, using TPUS
transperineal Clarity ultrasound (US) system, Calypso system, implanted fiducial markers, CINE-MRI, and endorectal balloon.
also observed larger prostate displacement with longer monitoring time (Fig. 4.4). This is
obvious in figure 4.4 D, in which the 3D vector distance shows the larger displacement
with monitoring time. Some of the fractions show that the prostate motion can be reversed,
in a certain direction, to the initial position. Furthermore, the boxplot graph, analysis of
maximal prostate displacements of 4-6 scans, displays variations between the patients and
in the different directions (Fig. 4.5). The overall maximal prostate displacement in three
directions and the Euclidean distances were shown to be less than 2.0 mm for most of the
fractions (Fig.4.5 D).
Previously, many researchers have struggled to determine intrafrational prostate
motion using pre- and post-treatment imaging methods (Adamson and Wu 2009; Kron
et al. 2010), but the disadvantage of this method is inter-observer matching variability
(Deegan et al. 2013). Another drawback with this method is that the prostate displacement
might revert back to the initial position, which cannot be detected by using the pre-
and post-treatment (Kotte et al. 2007). Therefore, a more favorable method is real-time
prostate monitoring, in which the entire 3D prostate volume can be tracked. Our results are
compared to other previously published data from different studies based on the utilization
of different techniques (Table 4.2). The Calypso 4D localization electromagnetic tracking
system has previously been confirmed to deliver precise and accurate tumor tracking,
using the surrogate implanted tiny transponders in the cancerous tissues, which sends a
signal to a station which tracks the 3D localization of the transponders (Shah et al. 2011).
In a previous phantom study, a group found good agreement between the TPUS autoscan
and Calypso system in tracking the embedded prostate-like sphere (Abramowitz et al.
2012).
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Figure 4.4: Intrafractional prostate displacement; (A-C) Monitoring graphs show the
prostate motion for the total 51 US scans in I/S, L/R, and A/P directions, (D) The 3D
vector displacement of the prostate center of mass.
In the current study, we observed that the prostate is not stationary during the tracking
time, and displacements tend to increase with elapsed monitoring time (2-2.5 minutes),
which is in line with the findings of other papers (Ballhausen et al. 2015). Furthermore,
we noticed that, for most of the fractions, the intrafractional prostate motion was mostly
smaller than 2 mm, and only 12 % of the 3D vector distances were larger than 2 mm,
which is comparable to a study (using transrectal ultrasound scans to track three implanted
fiducial markers) by (Choi et al. 2015), which observed that only 11 % of the 336 fractions
the 3D vector displacement was larger than 2 mm during 4-5 minutes of monitoring.
Similarly, in a Calypso study (35 patients and 1267 fractions) (Li et al. 2008), a research
group reported that the intrafractional prostate motion is predominantly below 2 mm.
Furthermore, in another study based on Cine-MRI imaging (Vargas et al. 2010), it was
shown that the intrafractional prostate motion is smaller during supine fixation than in the
prone position. In this project, all the US scans were carried out while the patients were in
the supine position. Moreover, in a Calypso tracking study (15 patients and 576 fractions)
(Smeenk et al. 2012), the prostate motion was shown to be larger than 3 mm in 1.4 %
of the fractions during 2.5 minutes monitoring, but the percentage increased up to 18 %
for a monitoring duration of 10 minutes. This increment of the prostate displacement
was also observed in another recently published Calypso study (236 patients and 8660
fractions) (Tong et al. 2015), in which prostate motion was confirmed to be larger than
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Figure 4.5: Boxplots of the intrafractional prostate displacements; (A-C) Boxplots of
the prostate displacements for ten patients in I/S, L/R, and A/P directions. (D) Boxplot
of overall prostate displacements in I/S, L/R, and A/P directions, including Euclidean (3D
vector) distance.
3 mm in 20 % of the fractions, for a tracking time of 12 minutes. But they ascertained
motion for the first three minutes is mostly smaller than 2 mm. Similarly, a research
group conducted a study (37 patients and 1332 fractions) (Shelton et al. 2011), once again
using the Calypso system, and concluded that the overall mean value of the 3D vector
displacement is less than 3 mm for three minutes monitoring, but grew to up to 6.5 mm
in the fourteenth minute. Likewise, once more in a Calypso study (17 patients and 550
fractions) (Kupelian et al. 2008), they detected that the prostate motion can be larger
than 3 mm in 14 % of the scans for a time of 10 minutes. Furthermore, in a study of
11 patients and 133 fractions (Ng et al. 2012), using a real-time tracking of the fiducial
markers, it was observed that in 62 % of the scans (3-4 minutes monitoring), the 3D
vector displacement of the prostate was less than 1 mm, and only 6 % of the shifts were
larger than 3 mm. In addition, Lometti et al. (32), using MV fluoroscopy and real-time
fiducial marker tracking (11 patients and 133 fractions), confirmed that in only 4 % of the
fractions was the displacement of the prostate larger than 2 mm while tracking for only
one minute. Last, Mayyas et al. (9), in a comparison study of four different systems (27
patients and 1100 fractions), found that the percentage of intrafractional prostate shifts
within ± 1.5 mm was 76 %, 94 %, and 82 % in the I/S, L/R, and A/P directions.
In short, the previously published results, in combination with our study, confirm
that the intrafractional motion of the prostate is mostly less than 2 mm during the first 2
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to 2.5 minutes of monitoring, and thus has insignificant adverse impact on the clinical
outcome of prostate radiotherapy while employing advanced VMAT/ RapidArc. However,
for conformal 3D planning and IMRT plans, the treatment delivery might last for up
to 10 minutes, within which the prostate displacement grow to up to 7 mm. This large
displacement might adversely affects the treatment response and outcome, and therefore
should be taken into consideration.
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Conclusion and Perspectives
First and foremost, all the operators found the entire system to be cumbersome, especially
performing the sweep-slide technique. Phantom scanning followed by volunteer imaging
was perceived to be a good practical tool to acquaint the user with the system. As a result
of several phantom scans, including two phantom studies, we recommend that if imple-
menting the US system in a radiotherapy center, without previous experience, one should
conduct similar phantom and volunteer scans to provide the responsible staff sufficient
knowledge and confidence, before implementing it clinically. We recommend also that a
US specialist (radiologist or oncologist) should be involved during the commencement
phase to assist with image interpretation. Unfortunately, we lacked the involvement of a
specialist while implementing the Clarity system in this project, resulting in frustrations
among the operators while struggling to identify anatomical structures.
In the phantom pressure study, we concluded that the uterine COM displacement due
to TAUS probe pressure is minimal and statistically insignificant. But, since a phantom
cannot represent a real patient, the conclusion must be taken with caution.
In another phantom study to determine inter-operator variability, we found that variability
in addressing the uterine position is small, thus clinically irrelevant. Once again, because
the phantom does not reflect the real patients’ pelvic structures, the employment of a
clinical study is a necessity.
In the interfractional study of the US-IGRT (uterine match) relative to the bone
structures, we found that the C-probe is capable of identifying daily uterine positional
variations, but with limitations when it came to capturing the entire uterus owing to the
difficulty of the sweep-slide technique. Consequently, this uncertainty impedes utilizing
the C-probe as a reliable cervical IGRT method. For this reason, we suggested that
the manufacturer design a prototype autoscan probe (A-probe), capable of automatic
sweeping over the uterus, acquiring images in the sagittal plane rather than C-probe’s
transversal plane.
In a comparison study between the C-probe and A-probe, based on US-scanning of
volunteers, the operators found the A-probe to be more user-friendly, and they realized
that it was easier to identify the anatomical structures in the sagittal plane, and image
acquisition was also performed smoothly, with less applied probe pressure. The results
were promising, since the A-probe was capable of capturing the entire uterus in almost all
of the scans. After this study we changed the C-probe to the A-probe for further uterine
scans.
While comparing A-probe patient results to the C-probe patient study, we found large
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delineation variability in C-probe images, yet again, confirming that the A-probe is a more
reliable IGRT tool than the C-probe.
In brief, the C-probe is not a recommended cervical IGRT method. In contrast, the
A-probe might replace the kV and MV IGRT systems, since it is capable of identifying
the daily uterine shifts relative to the bone structures.
In the probe pressure study, we found that during prostate TAUS scanning the prostate
displacement is, in most cases, clinically irrelevant. Since this conclusion was in oppo-
sition to most of the previously published results, which reported displacements of up
to 7 mm, we discovered that 4D real-time monitoring is the most reliable method for
determining pressure displacement compared to US/US or US/CT matching methods,
in which the considerable inter-observer variability, due to variations in applied probe
pressure and image/image match, limits the accuracy of the readings. Despite this clear
conclusion, the limited number of patients and fractions reduces the generalizability of
our statistical analysis.
In the intrafractional study, we confirmed that most intrafractional prostate motion is
less than 2 mm with a duration of monitoring of 2 to 2.5 minutes, which was in concor-
dance with previously reported data. Thus, during a RapidArc/VMAT plan delivery, the
intrafractional prostate motion is negligible. But, since the motion increases with longer
monitoring time, prostate displacement during 3D conformal and IMRT plans must be
taken into consideration.
In short, our research demonstrated that there is a potential for applying ultrasound
IGRT in cervical radiotherapy, especially using the A-probe. Despite our promising
results regarding the A-probe, the question still remains open as to whether this would
have any dosimetric advantages. Therefore, a study investigating the impact of uterine
positional shifts on dosimetric outcomes is recommended.
The autoscan probe was also shown to be a good tracking tool capable of addressing
prostate motion during treatment delivery. But a similar study based on the enrollment of
greater numbers of patients and longer monitoring time is recommended. Moreover, we
realized that the use of the US system in large radiotherapy centers will be a challenge,
since it must involve a solid training program to give adequate practical experience, in
order that the staff gain sufficient confidence before applying the system clinically.
Specifically, our conclusion in the probe pressure study with a phantom justifies a future
clinical study, based on TAUS scanning of real cervical cancer patients engaged in real-
time monitoring of the uterus, to observe the impact of probe pressure. One challenge of
such a study might be the difficulty of conducting the 4D real-time tracking.
In addition, we recommend that a study similar to our interfractional uterine study should
be conducted based on the enrollment of patient volunteers in greater numbers. Since
we do not have more than one or two cervical cancer patients a month at our site, we
could not perform a larger patient based study. But the principal question still remains,
whether US IGRT, like many other IGRT methods, survive clinically if the real-time MRI
guide, integrated into the MRI-LINAC, is in clinical use, unless the high cost of MRI is
an obstacle. Finally, conducting adaptive radiation treatment to investigate the dosimetric
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impact of interfractional uterine shifts (offline between fractions), and intrafractional
prostate motion (in real time during the fraction) always remains as an optimal goal for
further research.
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Appendix A. Information til patienter med livmoderhalskræft, om deltagelse i et
videnskabeligt studie (indeholder samtykkeerklæring/fuldmagt)
A.1 Vil du deltage i et videnskabeligt forsøg, der vedrører fremtidig
strålebehandlingaf livmoderhalskræft?
Du er henvist til Onkologisk Afdeling R med henblik på strålebehandling af livmoder-
halskræft. I denne deltagerinformation vil vi beskrive, hvad projektet går ud på, og hvad
en eventuel deltagelse vil betyde for dig. Det er derfor vigtigt, at du læser informationen
grundigt igennem. Du vil også blive informeret mundtligt om projektet af en læge og få
mulighed for at stille spørgsmål. Du har ret til betænkningstid før du beslutter dig for, om
du vil deltage i forsøget.
Vi vil spørge dig, om du vil deltage i et videnskabeligt projekt. Projektet bliver
udført ved at bruge et ultralydssystem, kaldet Clarity. Clarity er udviklet af Elekta, som
producerer teknisk medicinsk udstyr. Vi forventer, at i alt 30 patienter deltager i studiet,
som foregår i stråleterapien på Herlev Hospital.
A.2 Frivillig deltagelse
Det er frivilligt at deltage, og du kan først deltage kan, efter at vi har modtaget dit skriftlige
samtykke. Du kan til enhver tid trække dit samtykke tilbage og udstræde af projektet. Du
skal blot give besked til lægen eller en fra personalet i Stråleterapien. Du vælger selv, om
du vil angive årsagen til, at du ønsker at stoppe din deltagelse i projektet. Uanset om du
siger ja eller nej til at deltage i dette projekt, eller fortryder senere, vil din nuværende
behandling ikke blive påvirket. Hvis du beslutter dig for at sige ja til at deltage, skal du
underskrive et skriftligt informeret samtykke. Vi beder dig også om at læse det vedlagte
materiale Forsøgspersonens rettigheder i et biomedicinsk forskningsprojekt.
A.3 Formål
Clarity-systemet er beregnet til at lokalisere livmoderens placering ved hjælp af ultralyd.
Du får ikke direkte gavn af ultralydsscanningerne og modtager heller ikke svar på disse,
men din deltagelse i projektet vil, give ny viden om lokalisering af behandlingsområdet
og hermed forhåbentlig forbedre strålebehandlingen for andre med samme sygdom.
A.4 Studiets praktiske forløb
For at planlægge din strålebehandling, får du foretaget en CT-scanning. Denne scanning
giver vi alle patienter, der skal have strålebehandling. Umiddelbart efter CT-scanningen,
vil du blive ultralydsscannet. I praksis betyder det, at en radiograf eller sygeplejerske fører
en ultralydsscanner hen over din mave, så din livmoderhals kan ses på en skærm. Det
tager ca. 60 minutter i alt. Når du starter dit strålebehandlingsforløb vil du ca 2 gange om
uge blive behandlet og ultralydsscannet på apparat ?Odin?. Disse dage vil den samlede
behandlingstid være ca. 30 minutter.
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A.5 Bivirkninger
Scanningen gør ikke ondt, og der er ingen bivirkninger ved ultralydsscanning.
A.6 Fortrolighed
Al opbevaring af oplysninger vil ske i henhold til gældende regler i persondataloven.
Dit navn og CPR-nummer bliver ikke givet videre til nogen. Din anonymitet vil blive
sikret således, ingen oplysninger vil kunne føres tilbage til den enkelte deltager ved
offentliggørelse af resultaterne. Du kan til hver en tid trække dit samtykke tilbage,
hvilket betyder, at der herefter ikke vil blive foretaget yderligere dataindsamling om dig i
forbindelse med projektet.
A.7 Information til din egen læge
Din egen læge vil blive orienteret om din deltagelse, hvis du giver din tilladelse.
A.8 Økonomi
Du vil ikke modtage betaling for at deltage i projektet. Studiet er sponsoreret af Elekta.
Elektas sponsorat omfatter finansieringen af en Ph.d.-stilling til forskning i forbedring af
teknologiens muligheder til fordel for patienterne.
A.9 Kompensation for skader
Du er omfattet af patientforsikringsordningen jf. lov om patientforsikring. Som deltager i
kliniske forsøg, er du tillige omfattet af de samme offentlige forsikringsordninger som
ved al anden behandling i det danske sundhedsvæsen.
A.10 Adgang til studieresultater
Resultaterne af studiet søges udgivet i et anerkendt engelsksproget tidsskrift samt ved
internationale konferencer, hvis de viser sig brugbare. Hvis du er interesseret, kan du efter
afslutning af projektperioden og færdiggørelse af dataanalysen, kontakte den ansvarlige
-fysiker/Ph.d.-kandidat Mariwan Baker, for yderligere information.
Vi håber, du med denne information har fået tilstrækkeligt indblik i, hvad det vil sige at
deltage i projektet, og at du på denne baggrund kan afgøre, om du vil medvirke.
Forsøgsansvarlig for projektet er:
Hospitalsfysiker, PhD-student, Mariwan Baker
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Appendix A. Information til patienter med livmoderhalskræft, om deltagelse i et
videnskabeligt studie (indeholder samtykkeerklæring/fuldmagt)
Onkologisk Afdeling R, 51AA
Herlev Hospital
e-mail: mariwan.baker@regionh.dk
Lægeansvarlig, Overlæge, Trine Juhler-Nøttrup
Onkologisk Afdeling R, 51AA
Herlev Hospital
Tlf.: 38684856
e-mail: trine.juhler-noettrup@regionh.dk
Informeret samtykke til deltagelse i et biomedicinsk forskningsprojekt.
Registrering af livmoderens placering ved hjælp af ultralyds-scanning under udvendig
strålebehandling hos patienter med livmoderhalskræft
A.11 Erklæring fra forsøgspersonen:
Jeg har fået skriftlig og mundtlig information og jeg ved nok om formål, metode, fordele
og ulemper til at sige ja til at deltage. Jeg ved, at det er frivilligt at deltage, og at jeg
altid kan trække mit samtykke tilbage uden at miste mine nuværende eller fremtidige
rettigheder til behandling. Jeg giver samtykke til, at deltage i forskningsprojektet og har
fået en kopi af dette samtykkeark samt en kopi af den skriftlige information om projektet
til eget brug.
Forsøgspersonens navn:——————————————————-
Dato:——————– Underskrift: ————- Hvis der kommer nye væsentlige helbred-
soplysninger frem om dig i forskningsprojektet vil du blive informeret. Vil du frabede dig
information om nye væsentlige helbredsoplysninger, som kommer frem i forskningspro-
jektet, bedes du markere her: (sæt x)
ønsker du at blive informeret om forskningsprojektets resultat samt eventuelle kon-
sekvenser for dig?:
Ja ———- (sæt x) Nej ———-(sæt x)
APPENDIXB
Information til prostatapatienter,om
deltagelse i et videnskabeligt
forsøg(indeholder
samtykkeerklæring/fuldmagt)(In Danish)
Responsible for the project: Medical Physicist, MSc, PhD-candidate, Mariwan Baker.
Kontrol af lejring af prostata patienter under udvendig strålebehandling ved hjælp
af ultralyd
Onkologisk Afdeling R, Herlev Hospital
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Appendix B. Information til prostatapatienter,om deltagelse i et videnskabeligt
forsøg(indeholder samtykkeerklæring/fuldmagt)
B.1 Vil du deltage i et videnskabeligt forsøg, der vedrører fremtidig
stråle-behandlingen af af prostata-cancer?
I denne deltagerinformation vil vi beskrive, hvad forsøget går ud på, og hvad deltagelse
vil betyde for dig. Det er derfor vigtigt, at du læser informationen grundigt igennem. Du
vil også blive informeret mundtligt om forsøget af en læge og få mulighed for at stille
spørgsmål. Det vil være en god idé at have en pårørende med, når du bliver informeret, så
I er to til at stille spørgsmål og tale om din eventuelle deltagelse. Du har ret til betænkn-
ingstid før du beslutter dig for, om du vil deltage i forsøget.
Du er henvist til onkologisk afdeling med henblik på strålebehandling af din prostata-
cancer. Når du skal have strålebehandling, er det vigtig at skåne så meget af det omgivende
normale væv som muligt.
Vi vil spørge dig om du vil deltage i et videnskabeligt forsøg Forsøget bliver udført
ved at bruge et nyt ultralyd billede-system, kaldet Clarity (som er udviklet af Elekta) . I
praksis betyder det, at en radiograf eller sygeplejerske anbringer en ultralydsscanner på
lejet imellem dine ben, og ultralydssscanner mod mellemkødet lige under testiklerne, så
din prostata kan ses på en skærm. Det gør ikke ondt, og der er ingen bivirkninger . Det
forventes, at i alt 30 patienter deltager i forsøget, som foregår i stråleterapien på Herlev
Hospital.
B.2 Frivillig deltagelse
Det er frivilligt at deltage, og du kan først deltage kan, efter at vi har modtaget dit skriftlige
samtykke. Du kan til enhver tid trække dit samtykke tilbage og udstræde af projektet. Du
skal blot give besked til lægen eller en fra personalet i Stråleterapien. Du vælger selv, om
du vil angive årsagen til, at du ønsker at stoppe din deltagelse i projektet. Uanset om du
siger ja eller nej til at deltage i dette projekt, eller fortryder senere, vil din nuværende
behandling ikke blive påvirket.
Hvis du beslutter dig for at sige ja til at deltage, skal du underskrive et skriftligt informeret
samtykke. Vi beder dig også om at læse det vedlagte materiale (Forsøgspersonens
rettigheder i et biomedicinsk forskningsprojekt).
B.3 Formål
Formål med forsøget er at vurderer kapaciteten af den nye ultralyd systemet til at evaluere
prostata bevægelse i løbet af selve strålebehandlingen.
Clarity-ultralyd-systemet er beregnet til at lokalisere prostatas placering i kroppen og
monitorere denne placering under strålebehandlingen.
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B.4 Forsøget forløb
Hvordan foregår det?
Ved planlægningen af din strålebehandling, får du foretaget en CT-scanning med henblik
på planlægning af behandlingen. Denne skanning er normal procedure hos alle patienter
der skal have strålebehandling.
Umiddelbart efter CT scanning, vil du blive ultralyd scannet . I hele behandlingsforløbet
(typisk 39 behandlinger) vil der før hver strålebehandling, blive taget digitale-røntgen
billeder til kontrol af opstillingen. I løbet af disse behandlinger, vil du blive behandlet
på apparat Odin, hvor vi umiddelbart efter afslutningen af selve stråle-behandlingen, vil
ultralyds-scanne dig. Selve scanningen tager få minutter og er ikke forbundet med ubehag.
I forbindelse med de strålebehandlinger, hvor du skal ultralydscannes vil behan-
dlingstiden være 10 minutter.
B.5 Nytte ved forsøget
Din deltagelse i forsøget vil forhåbentligt bibringe information som i fremtiden kan
hjælpe andre med lignende sygdomme. Resultaterne vil give øget viden om lokalisering
af behandlingsområdet under selve behandlingen.
B.6 Bivirkninger, risici, komplikationer og ulemper
Undersøgelsen er ufarlig og udføres af kvalificeret personale. Der er ingen kendte
skadelige effekter ved ultralydsskanning. Der er ingen ulemper forbundet med forsøget,
udover at nogen patient kan føle lidt ubehag under selve ultralyde- scanningen.
Den øvrige del af planlægningen og behandlingen ændres ikke p.g.a. forsøget.
B.7 Fortrolighed
Al opbevaring af oplysninger vil ske i henhold til gældende regler i persondataloven.
Dit navn og CPR-nummer bliver ikke givet videre til nogen. Din anonymitet vil blive
sikret således, at ingen oplysninger vil kunne føres tilbage til den enkelte deltager ved
offentliggørelse af resultaterne.
Du kan til hver en tid trække dit samtykke tilbage, hvilket betyder, at der herefter ikke
vil blive foretaget yderligere dataindsamling i forbindelse med forsøget.
B.8 Information til din egen læge
n egen læge vil blive orienteret om din deltagelse i forsøget, hvis du giver din tilladelse.
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Appendix B. Information til prostatapatienter,om deltagelse i et videnskabeligt
forsøg(indeholder samtykkeerklæring/fuldmagt)
B.9 Nye oplysninger
Du vil blive informeret om eventuelle nye fakta eller data, der fremkommer under forsøget,
og som kan have indflydelse på, hvorvidt du fortsat ønsker at deltage i forsøget.
B.10 Økonomi
Du vil ikke modtage betaling for at deltage i forsøget. Forsøget er sponsoreret af Elekta
(et firma som udvikler medicinsk tekniske udstyr).
Elekta lægger op til at finansiere for en helt PhD-stilling til forskning i teknologiens
muligheder for patienterne.
B.11 Kompensation for skader
Du er omfattet af patientforsikringsordningen jf. lov om patientforsikring.
Som deltager i kliniske forsøg, er du tillige omfattet af de samme offentlige forsikringsor-
dninger som ved al anden behandling i det danske sundhedsvæsen.
B.12 Adgang til forsøgsresultater
Forsøgsresultaterne søges publiceret i anerkendt engelsksproget tidsskrift samt ved inter-
nationale konferencer, såfremt de viser sig brugbare. Efter afslutning af forsøgsperioden,
dvs. afslutning af alle opfølgningsbesøg for alle deltagere og færdiggørelse af dataanal-
ysen, kan deltagerne kontakte den forsøgsansvarlige investigator fysiker/PhD-kandidat
Mariwan Baker. Vi håber, du med denne information har fået tilstrækkeligt indblik i,
hvad det vil sige at deltage i forsøget, og at du føler dig rustet til at tage beslutnin-
gen om din eventuelle deltagelse. Vi beder dig også om at læse det vedlagte materiale
?Forsøgspersonens rettigheder i et biomedicinsk forskningsprojekt?.
B.13 Ansvarlig for projektet
Forsøgsansvarlig for projektet er:
Hospitalsfysiker, PhD-student, Mariwan Baker
Onkologisk Afdeling R, 51AA
Herlev Hospital
e-mail: mariwan.baker@regionh.dk
Lægeansvarlig, Overlæge, Henriette Lindberg
Onkologisk Afdeling R, 51AA
Herlev Hospital
e-mail: henriette.lindberg@regionh.dk
B.14. Erklæring fra forsøgspersonen: 73
Informeret samtykke til deltagelse i et biomedicinsk forskningsprojekt.
Registrering af livmoderens placering ved hjælp af ultralyds-scanning under udvendig
strålebehandling hos patienter med livmoderhalskræft
B.14 Erklæring fra forsøgspersonen:
Jeg har fået skriftlig og mundtlig information og jeg ved nok om formål, metode, fordele
og ulemper til at sige ja til at deltage. Jeg ved, at det er frivilligt at deltage, og at jeg
altid kan trække mit samtykke tilbage uden at miste mine nuværende eller fremtidige
rettigheder til behandling. Jeg giver samtykke til, at deltage i forskningsprojektet og har
fået en kopi af dette samtykkeark samt en kopi af den skriftlige information om projektet
til eget brug.
Forsøgspersonens navn:——————————————————-
Dato:——————– Underskrift: ————- Hvis der kommer nye væsentlige helbred-
soplysninger frem om dig i forskningsprojektet vil du blive informeret. Vil du frabede dig
information om nye væsentlige helbredsoplysninger, som kommer frem i forskningspro-
jektet, bedes du markere her: (sæt x)
ønsker du at blive informeret om forskningsprojektets resultat samt eventuelle kon-
sekvenser for dig?:
Ja ———- (sæt x) Nej ———-(sæt x)
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APPENDIXC
The project’s ethics approval by
"De Videnskabsetiske Komiteer"
(In Danish)
Responsible for the project: Medical Physicist, MSc, PhD-candidate, Mariwan
Baker.
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To projekter: 
3D-ultralyd ved strålebehandling af cervix kræftpatienter  
4D-ultralyd ved strålebehandling af prostata kræftpatienter 
 
 
 
Du har ved mail af 11. marts 2013 spurgt, om ovennævnte projekt skal anmeldes til det videnskabse-
tiske komitesystem.  
 
Jeg har vurderet, at projektet ikke er anmeldelsespligtigt, da der er tale om en sundhedsvidenskabelig 
intervention af så lille et omfang, at der ikke er tale om et sundhedsvidenskabeligt forskningsprojekt 
som dette er defineret i komitélovens § 2,1. Jeg lægger til grund, at den patienterne alene få nogle ult-
ralydsscanninger udover standardbehandlingen. 
 
Projektet er derfor ikke anmeldelsespligtigt, jf. komitélovens § 1, stk. 4 og kan iværksættes uden til-
ladelse fra De Videnskabsetiske Komiteer for Region Hovedstaden. 
 
I Danmark har det videnskabsetiske komitesystem til opgave at vurdere sundhedsvidenskabelige 
forskningsprojekter.  
 
Ved et sundhedsvidenskabeligt forskningsprojekt forstås projekter, der indebærer forsøg på levende-
fødte menneskelige individer, menneskelige kønsceller, der agtes anvendt til befrugtning, menneske-
lige befrugtede æg, fosteranlæg og fostre, væv, celler og arvebestanddele fra mennesker, fostre og 
lign. eller afdøde. Herunder omfattes kliniske forsøg med lægemidler på mennesker og klinisk af-
prøvning af medicinsk udstyr. . 
  
                                                     
1
 Lov nr. 593  af 14. juni 2011 om videnskabsetisk behandling af sundhedsvidenskabelige forskningsprojekter som ændret ved 
L 2012-06-18 nr. 604. 
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Sundhedsvidenskabelig forskning omhandler primært forskning inden for de lægevidenskabelige fag, 
den kliniske og den socialmedicinsk-epidemiologiske forskning. Begrebet omfatter, udover forskning 
af de somatiske sygdomme, tillige de psykiatriske og de klinisk-psykologiske sygdomme og til-
standsformer. Herudover inddrages tilsvarende odontologisk og farmaceutisk forskning under begre-
bet. 
 
Registerforskningsprojekter, interviewundersøgelser og spørgeskemaundersøgelser skal kun anmel-
des, hvis der indgår menneskeligt biologisk materiale i projektet.  
 
Undersøgelser af anonymt biologisk humant materiale skal dog ikke anmeldes til en videnskabsetisk 
komité, med mindre der er tale om et forskningsprojekt vedrørende befrugtede menneskelige æg samt 
kønsceller, jf. §§ 25 og 27, stk. 2 i lov om kunstig befrugtning i forbindelse med lægelig behandling, 
diagnostik og forskning m.v. Det er et krav, at materiale er fuldstændig anonymt (der må ikke være 
en identifikationskode til data), og at materialet er indsamlet i overensstemmelse med lovgivningen 
på indsamlingsstedet. 
 
Forsøg på cellelinier eller lignende, der stammer fra et forsøg med indsamling af celler eller væv, 
som har opnået den nødvendige godkendelse, skal heller ikke anmeldes.  
 
Forsøg, der alene har til formål at fastlægge et kemikaliums toksikologiske grænse i mennesket, er 
ikke anmeldelsespligtige. Ved et kemikalium forstås i denne forbindelse et stof, der ikke finder tera-
peutisk anvendelse.  
 
Der ligger således ikke i afvisningen af at bedømme projektet nogen etisk stillingtagen eller negativ 
vurdering af dets indhold. 
 
Vi gør opmærksom på, at Sundhedsstyrelsen i visse tilfælde skal godkende videregivelse af oplysnin-
ger fra patientjournaler. Nærmere oplysning kan findes på Sundhedsstyrelsens hjemmeside.  
 
Behandling af personhenførbare oplysninger er omfattet af persondataloven. Nærmere oplysning her-
om findes på Datatilsynets hjemmeside. 
 
Klagevejledning: 
 
Komitéens afgørelse kan, jf. komitélovens § 26, stk. 1, indbringes for Den Nationale Videnskabse-
tiske Komité, senest 30 dage efter afgørelsen er modtaget. Den Nationale Videnskabsetiske Komité 
kan, af hensyn til sikring af forsøgspersonernes rettigheder, behandle elementer af projektet, som ikke 
er omfattet af selve klagen.  
Klagen skal indbringes elektronisk og ved brug af digital signatur og kryptering, hvis protokollen in-
deholder fortrolige oplysninger.  
Dette kan ske på adressen: dketik@dketik.dk  
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Klagen skal begrundes og være vedlagt kopi af Den Regionale Videnskabsetiske Komités afgørelse 
samt de sagsakter, som Den Regionale Videnskabsetiske Komité har truffet afgørelse på grundlag af. 
 
 
Med venlig hilsen 
 
 
 
 
Lone Gundelach 
Sekretariatsleder, cand.jur. 
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Abstract
In radiotherapy the treatment outcome of gynecological (GYN) cancer patients is
crucially related to reproducibility of the actual uterine position. The purpose of this
study is to evaluate the inter-operator variability in addressing uterine position using a
novel 3-D ultrasound (US) system. The study is initiated by US-scanning of a uterine
phantom (CIRS 404, Universal Medical, Norwood, USA) by seven experienced
US operators. The phantom represents a female pelvic region, containing a uterus,
bladder and rectal landmarks readily definable in the acquired US-scans. The organs
are subjected to displacement by applied operator-pressure that mimics an actual GYN
patient. The transabdominal scanning was performed using a 3D-US system (Clarity
Model 310C00, Elekta, Montreal, Canada). It consists of a US acquisition-station,
workstation, and a 128- element 1D array curved probe. The iterated US-scans were
performed in four subsequent sessions (totally 21 US-scans) in a period of four weeks
to investigate the randomness of the inter-operator variability. An additionally US-
scan was performed as a reference target volume to the consecutive scans. At first, the
phantom was marked with ball bearings for daily laser alignment. In each session the
US-scans were acquired by the seven operators. The uterus was outlined in each of the
US imagesets using Clarity autosegmentation in the workstation. Further, the shifts
in the uterine centre of mass relative to the reference were measured for the three
orthogonal directions; left (+)-right (LR), anterior (+)-posterior (AP), and inferior
(+)-superior (IS), respectively. The same operator delineated the target volumes.
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The average inter-operator deviation ±1SD of the daily US scans was (in mm);
LR: day 1 (-0.4±0.9), day 2 (-0.3±0.6), day 3 (- 1.0±1.2), day 4 (1.3±0.5); AP:
day 1 (0.0±1.7), day 2 (0.1±0.7), day 3 (-1.0±0.9), day 4 (0.2±1.2); IS: day 1
(-1.5±2.6), day 2 (0.1±1.8), day 3 (0.1±1.1), day 4 (0.5±3.1), respectively. The
largest inter-operator discordance was observed to be 4.7 mm in the IS-direction in
day 4. Published studies report significantly larger inter-fractional uterine positional
displacement, in some cases up to 20 mm, which outweighs the magnitude of current
inter-operator variations. Thus, the current US-phantom-study suggests that the
inter-operator variability in addressing uterine position is clinically irrelevant.
Inter-operator Variability in Defining Uterine
Position Using Three-dimensional Ultrasound
Imaging
Mariwan Baker∗†‡, Jørgen Arendt Jensen† and Claus F. Behrens∗
∗Herlev Hospital, Department of Oncology(R) Herlev Ringvej 75, DK-2730 Herlev, Denmark
†Center for Fast Ultrasound Imaging, Dept. of Elec. Eng., Technical University of Denmark, DK-2800 Lyngby, Denmark
‡Center for Nuclear Technologies, Technical University of Denmark, DTU Risø Campus, DK-4000 Roskilde, Denmark.
Abstract—In radiotherapy the treatment outcome of gyneco-
logical (GYN) cancer patients is crucially related to reproducibil-
ity of the actual uterine position. The purpose of this study is
to evaluate the inter-operator variability in addressing uterine
position using a novel 3-D ultrasound (US) system. The study
is initiated by US-scanning of a uterine phantom (CIRS 404,
Universal Medical, Norwood, USA) by seven experienced US oper-
ators. The phantom represents a female pelvic region, containing
a uterus, bladder and rectal landmarks readily definable in the
acquired US-scans. The organs are subjected to displacement by
applied operator-pressure that mimics an actual GYN patient.
The transabdominal scanning was performed using a 3D-US
system (Clarity® Model 310C00, Elekta, Montreal, Canada). It
consists of a US acquisition-station, workstation, and a 128-
element 1D array curved probe. The iterated US-scans were
performed in four subsequent sessions (totally 21 US-scans) in
a period of four weeks to investigate the randomness of the
inter-operator variability. An additionally US-scan was performed
as a reference target volume to the consecutive scans. At first,
the phantom was marked with ball bearings for daily laser
alignment. In each session the US-scans were acquired by the
seven operators. The uterus was outlined in each of the US image-
sets using Clarity autosegmentation in the workstation. Further,
the shifts in the uterine centre of mass relative to the reference
were measured for the three orthogonal directions; left (+)-right
(LR), anterior (+)-posterior (AP), and inferior (+)-superior (IS),
respectively. The same operator delineated the target volumes.
The average inter-operator deviation ±1SD of the daily US scans
was (in mm); LR: day 1 (-0.4±0.9), day 2 (-0.3±0.6), day 3 (-
1.0±1.2), day 4 (1.3±0.5); AP: day 1 (0.0±1.7), day 2 (0.1±0.7),
day 3 (-1.0±0.9), day 4 (0.2±1.2); IS: day 1 (-1.5±2.6), day 2
(0.1±1.8), day 3 (0.1±1.1), day 4 (0.5±3.1), respectively. The
largest inter-operator discordance was observed to be 4.7 mm in
the IS-direction in day 4. Published studies report significantly
larger inter-fractional uterine positional displacement, in some
cases up to 20 mm, which outweighs the magnitude of current
inter-operator variations. Thus, the current US-phantom-study
suggests that the inter-operator variability in addressing uterine
position is clinically irrelevant.
I. INTRODUCTION
In modern adaptive conformal radiotherapy with tight
margins and steep dose gradients, such as intensity-modulated
radiotherapy (IMRT), it is essential that the position of the
clinical target volume (CTV) is precisely defined prior to each
treatment fraction throughout the entire course of treatment.
Recent technical innovations have enabled the direct integration
of various image verification methods into the linear accelerator
(LINAC). This allows patient and tumour positioning to be
addressed and corrected. Nowadays, kilovoltage (kV) and mega-
voltage (MV) planar radiographic imaging, and kV volumetric
cone beam CT imaging are standard image verification systems
in many radiotherapy centres. Generally, these systems are
implemented as Image Guided Radiation Therapy (IGRT) for
daily target alignment, which enables correction of position
misalignment, thereby improving the precision of radiation
treatment [1]. However, the challenge of using these ionizing
systems is insufficient soft tissue visualization, for instance of
the uterus of GYN cancer patients. In some cases these systems
require invasive methods, such as implanted fiducial markers in
prostate radiotherapy [2]. Therefore, different non-ionizing 3D
ultrasound (3D-US) systems, such as the Elekta 3D Clarity®
Soft Tissue Visualization system and the NOMOS B-mode
Acquisition and Targeting (BAT) ultrasound system have been
developed and introduced into radiotherapy for different cancer
sites [3]–[5]. However, these US-systems have been found to
be only applicable for cancer sites in soft tissue environments
such as in GYN, prostate and postoperative lumpectomy cavity
cancer patients. The uterus, where internal position variations
are dependent on rectal and bladder filling, is an ideal site
for US-scans. Some uncertainty factors such as inter-operator
variability due to probe handling are present when using the US-
system. Variations in the transducer probe pressure applied have
previously been documented during 3D-US scan on prostate
patients [6], [7].
The aim of the present study was to quantify the inter-operator
variability using the Clarity US-system on a commercial GYN-
phantom.
II. MATERIALS AND METHODS
A phantom was scanned by seven operators in the course
of four sessions over a period of four weeks (one session per
week), a total of 21 scans (All the operators were not presented
for each session). Each radiation therapist (RTT) participated in
two weeks of intensive training provided by the manufacturer
of Clarity as well as several practice sessions before the start
of the study.
A. Phantom
The ultrasound training phantom (CIRS 404, Universal
Medical, Norwood, USA) mimics the female pelvic region and
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Figure 1. Phantom scanning is performed by means of a convex array probe in
the CT-room. Real-time images can be visualized on the US console mounted
on the US station.
contains a uterus, bladder and rectum representing the standard
female pelvic organs (Fig. 1). The organs are subjected to
displacement of the exerted probe pressure. The phantom does
not contain any skeletal structure such as femur head or pelvic
bone. The phantom is constructed of material that is intended
for ultrasound scans, thus all organs are easily defined in the
acquired US-images. Initially, the phantom was marked with
small spherical ball bearings (laser alignment markers), used
to aid reproducibility of daily set-up prior to each US-scan
session. Use of this technique requires acquisition of a reference
US image data-set, and therefore during an initial session the
best possible US-scan was selected as position reference to the
following four consecutive sessions.
B. Clarity Ultrasound System
The Clarity ultrasound system (Clarity® Model 310C00,
Elekta, Montreal, Canada)consists of two US-units: one located
in the Computed Tomography (CT) simulation room and one
in the treatment room. The two units are connected through a
workstation/server. In this study all US-scans were performed
in the CT room. Since the objective of the ongoing project at
Herlev hospital is to implement the Clarity 3D-US system for
both GYN and prostate patients throughout the course of their
treatment, the treatment room unit will be utilized for daily
IGRT. Each US-unit is equipped with a convex array probe
for trans-abdominal 3D US-scanning. Every station consists
of a ceiling-mounted infrared (IR) camera that can track the
US-probe by monitoring the IR-reflectors/emitters mounted on
it. The transducer probe consists of a 128-element 1-D array.
To enable superimposition of the acquired 3D-US images to
the reference US-image sets, the 3D-US system is calibrated
to the same coordinate system as the CT and treatment rooms,
respectively. The calibration procedure is accomplished by
means of an alignment phantom. Quality assurance checks
confirm the system calibration on each day of use. The daily
check is passed only when the calibration precision is less than
1 mm.
C. Image Acquisition
The ultrasound image of the phantom (trans-abdominal US-
scan) was acquired by all the seven experienced RTTs using
the convex array probe. In each phantom scan the US-probe
Figure 2. Daily US scans (day 1: 6 operators, day 2: 6 operators, day 3: 5
operators, and day 4: 4 operators). The plot shows uterine COM shifts in the
L/R, A/P and I/S directions.
was placed on the first occasion with moderate pressure in the
region corresponding to the pubic symphysis and rotated, after
which it was swept cranially. Afterwards, the acquired image-
sets were reconstructed, and the uterus, bladder and rectum
were identified.
D. Organ Delineation and Data Analysis
The uterus, bladder and rectum were delineated in the
reconstructed 3D US-image data sets using the Clarity work-
station supplied by the manufacturer. In the workstation the
delineation can be performed either manually or with aid
of auto-segmentation. In this study the assisted segmentation
was utilized for all outlined organs. A single operator (MB)
conducted a retrospective analysis of the acquired US-image
sets and delineated the organs. Descriptive statistics and a single-
sample t-test was conducted for the phantom scans. Background
variables such as alpha, null and alternative hypothesis, standard
deviation (SD) and variance are described using descriptive
statistics.
III. RESULTS
A total of 21 US-scans were acquired by the same seven
operators over the four sessions.The daily US scans is plotted
during the four days and for all presented operators (Fig. 2).
Positional uterine Center of Mass (COM) shifts, in three
orthogonal directions and of four days are plotted (Fig. 3).
Positive shifts are left, anterior, and inferior. Qualitatively, these
plots demonstrate that there are not significant differences in the
shifts comparing mean of COM shifts, i.e. mean of the session
scans for each day. One can observe that, in each direction
(L/R, A/P, and I/S), the results are roughly centred about zero.
The mean ±SD of the daily phantom COM-shifts (average
inter-operator deviation) was (mm): LR: day 1 (-0.4±0.9), day
2 (-0.3±0.6), day 3 (-1.0±1.2), day 4 (1.3±0.5); AP: day 1
(0.0±1.7), day 2 (0.1±0.7), day 3 (-1.0±0.9), day 4 (0.2±1.2);
IS: day 1 (-1.5±2.6), day 2 (0.1±1.8), day 3 (0.1±1.1), day 4
(0.5±3.1), respectively. The largest inter-operator discordance
was observed to be 4.7 mm in the IS-direction in day 4. None
of the p-values for the three directions is smaller than 0.05.
The largest lower/upper range of 95% CI is in I/S-direction in
day 4 (-4.54–+5.44) (Fig. 4).
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Figure 3. (A), (B) and (C): box-plots of uterine COM-shifts for the phantom
on four days in the three cardinal directions; L/R, A/P, and I/S.
IV. DISCUSSION
Inter-fractional positional uncertainty of the uterus, rec-
tum and bladder of GYN patients has been a challenge in
radiotherapy, and leads to larger applied set-up margins to
account for the target displacement. Recently developed highly
conformal (IMRT) treatment enables better dose conformity,
thus steeper dose gradients. This means that the delineated CTV
and organ at risks (OAR) are more susceptible to the uterine
positional displacement. Uterine positional changes have been
confirmed in previous reports to be strongly correlated to the
daily variations in rectal-bladder filling [8], [9].
Recently, 3D-US is more frequently applied as IGRT-
method. It has been used mostly in prostate alignment prior to
the treatment fraction. Only few published papers are reporting
the application of 3D-US on GYN-patients [10]–[12], but
the focus is on quantifying inter-fractional bladder motion
and variation in bladder volume rather than uterine positional
change. Herlev Hospital is a pioneer in the application of a
Figure 4. Tabulates values of one sample t.test of obtained uterine shifts
using ultrasound scans of a phantom.
novel Clarity 3D-US system with focus on GYN diagnoses.
The present study started by applying Clarity on a phantom
and it will subsequently be used for GYN patients at Herlev.
Different studies on the prostate have concluded that one
of the drawbacks of using 3D-US as the IGRT method is
probe pressure induced uncertainty of the target and OAR,
and the variation in the probe handling by the observers. The
challenge experienced by most of our operators during 3D US
acquisition was to find an appropriate probe handling technique
that captured the entire uterus from the cervical os to the fundus,
as the image quality was poor in some cases. Obviously, poor
image quality has an adverse influence on uterus delineation,
thus leading to uncertainty about COM shifts.
In the present phantom study, we found no statistically
significant differences in uterine COM shifts in the term of
inter-observer variability (sample t-test with a 95% CI). All the
acquired US-scans indicated that uterine COM displacements
are in the vicinity of zero, with a daily mean value of less
than 2 mm in all three cardinal directions (L/R, A/P and I/S).
The recent study paper by Jurgenliemk-Schultz et al., [13],
which investigated vaginal positional change and the correlation
between vaginal shift and bladder-rectal filling, reported a daily
vaginal CTV positional change of up to 2.3 cm in the A/P
direction. In another study Chan et al., [14], report that the
uterine head (fundus) can vary from day to day by over 24
mm. This large inter-fractional vaginal and uterine positional
displacement outweighs the magnitude of our inter-operator
variability.
V. CONCLUSIONS
Published studies report significantly larger inter-fractional
uterine positional displacement, over 20 mm in some directions,
which outweighs the magnitude of the current inter-operator
variations. Thus, the current US-phantom-study suggests that
the inter-operator variability in determining uterine position is
clinically irrelevant.
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Abstract
Uterine positional changes can reduce the accuracy of radiotherapy for cervical
cancer patients. The purpose of this study was to; 1) Quantify the inter-fractional
uterine displacement using a novel 3D ultrasound (US) imaging system, and 2)
Compare the result with the bone match shift determined by Cone- Beam CT (CBCT)
imaging. Five cervical cancer patients were enrolled in the study. Three of them
underwent weekly CBCT imaging prior to treatment and bone match shift was applied.
After treatment delivery they underwent a weekly US scan. The transabdominal scans
were conducted using a Clarity US system (Clarity Model 310C00). Uterine positional
shifts based on soft-tissue match using US was performed and compared to bone
match shifts for the three directions. Mean value (±1 SD) of the US shifts were (mm);
anterior-posterior (A/P): (3.8±5.5), superior-inferior (S/I) (-3.5±5.2), and left-right
(L/R): (0.4±4.9). The variations were larger than the CBCT shifts. The largest inter-
fractional displacement was from -2 mm to +14 mm in the AP-direction for patient
3. Thus, CBCT bone matching underestimates the uterine positional displacement
due to neglecting internal uterine positional change to the bone structures. Since the
US images were significantly better than the CBCT images in terms of soft-tissue
visualization, the US system can provide an optional image-guided radiation therapy
(IGRT) system. US imaging might be a better IGRT system than CBCT, despite
difficulty in capturing the entire uterus. Uterine shifts based on US imaging contains
relative uterus-bone displacement, which is not taken into consideration using CBCT
bone match.
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ABSTRACT 
Uterine positional changes can reduce the accuracy of radiotherapy for cervical cancer patients. The 
purpose of this study was to; 1) Quantify the inter-fractional uterine displacement using a novel 3D 
ultrasound (US) imaging system, and 2) Compare the result with the bone match shift determined by Cone-
Beam CT (CBCT) imaging.Five cervical cancer patients were enrolled in the study. Three of them underwent 
weekly CBCT imaging prior to treatment and bone match shift was applied. After treatment delivery they 
underwent a weekly US scan. The transabdominal scans were conducted using a Clarity US system (Clarity® 
Model 310C00). Uterine positional shifts based on soft-tissue match using US was performed and compared to 
bone match shifts for the three directions. Mean value (±1 SD) of the US shifts were (mm); anterior-posterior 
(A/P): (3.8±5.5), superior-inferior (S/I) (-3.5±5.2), and left-right (L/R): (0.4±4.9). The variations were larger 
than the CBCT shifts. The largest inter-fractional displacement was from -2 mm to +14 mm in the AP-direction 
for patient 3. Thus, CBCT bone matching underestimates the uterine positional displacement due to neglecting 
internal uterine positional change to the bone structures. Since the US images were significantly better than the 
CBCT images in terms of soft-tissue visualization, the US system can provide an optional image-guided 
radiation therapy (IGRT) system. US imaging might be a better IGRT system than CBCT, despite difficulty in 
capturing the entire uterus. Uterine shifts based on US imaging contains relative uterus-bone displacement, 
which is not taken into consideration using CBCT bone match.  
 
1 INTRODUCTION 
Local recurrence of cervical cancer remains a challenge worldwide despite using advanced treatment 
techniques [1].  In addition to surgery and chemotherapy, radiotherapy is an effective treatment modality. 
However, radiation complications, such as gastrointestinal toxicity, are experienced by patients undergoing 
radiation treatment [2]. Modern conformal radiotherapy with tight margins and steep dose gradients, such as 
intensity-modulated radiotherapy (IMRT) and volumetric conformal arc therapy, allows a reduction of 
undesired radiation doses to healthy organs but requires more precise daily tumour alignment prior to each 
fraction throughout the entire course of the treatment. 
Today’s Image Guided Radiation Therapy (IGRT) methods, such as the electronic portal image device 
(EPID) and the kV volumetric cone beam CT (CBCT), are widely utilized for daily patient alignment and 
enable online correction of positional tumor misalignments, thereby improving the precision of the delivery of 
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the prescribed radiation dose to the delineated target [3]. However, the weakness of using these ionizing system 
are insufficient soft tissue visualization, for instance in visualizing the uterus of gynecological (GYN) cancer 
patients or identifying the prostate gland and surrounding soft tissue organs at risk (OARs) in prostate cancer 
patients. As a result, bone matching is frequently applied as a daily tumor alignment method in cervical cancer 
treatment. For cervical cancer patients, large margins are applied around delineated gross tumor volume (GTV), 
to ensure target radiation dose coverage. The large margin is due to the complexity of the pelvis with its tumor 
and normal organ motion as well as deformation dynamics, which adversely impacts on the irradiated healthy 
tissues [4]. Additionally, tumor volume regression is reported to be substantial, with up to 80% reduction by the 
end of the treatment period [5-7]. Different imaging methodologies such as implanted fiducial markers as a 
reference point [8-10] are employed in patients with cervical cancer to determine uterus and/or target motion. 
Use of the tumor surrogate method limits analysis of uterine shifts, because implanted fiducial markers can fall 
out, migrate, or be displaced due to tumor shrinkage and organ deformation. On the other hand, MRI imaging 
provides an outstanding visualization of the uterus and cervix, enabling discrimination from other organs [4, 9, 
11]. The application of MRI as IGRT for daily tumor alignment requires MRI/LINAC accessibility, which is 
costly and rarely used clinically [12-13]. Therefore, various cheaper non-ionized 3D US systems have been 
developed, such as the 3D Clarity® Soft Tissue Visualization system (Clarity® Model 310C00, Elekta, 
Montreal, Canada) and the NOMOS B-mode Acquisition and Targeting (BAT) ultrasound system [14-16]. 
However, these US systems can only be used for cancer sites in a soft tissue environment such as GYN, prostate 
and postoperative lumpectomy cavity in breast cancer patients. The prostate and uterus, where internal position 
variations are partly dependent on rectal-bladder filling, are ideal sites for US-scans. Furthermore, different 
uncertainty factors such as probe handling, image quality, and inter-operator variability are involved in the use 
of a US system. Inter-operator variations in US transducer probe pressure have been documented earlier for 
prostate patients [17-18]. In the present study, the main purpose was to quantify the magnitude of the inter-
fractional uterine displacement, based on soft tissue match, using a novel 3D US imaging system. A specific 
purpose was to compare the US results with the bone match shifts determined by means of CBCT imaging.  
 
2  MATERIALS AND METHODS 
Five cervical cancer patients, mean age 60 years (51/68), were enrolled in this study. All underwent 
radiotherapy at Herlev hospital. One patient was excluded due to incontinence, while a second was excluded 
after acquisition of US images in the CT simulation room. The patient in question had a nephrostomy with an 
implanted catheter, which resulted in very poor image quality.Each of the patients underwent daily EPID and 
weekly CBCT setup verification imaging. Since the uterus cannot be visualized using either EPID or CBCT, all 
the shifts are based on bone match. Immediately after treatment the patients underwent a weekly US scan 
performed by two experienced operators. Seven RTTs participated in an extensive two week training program 
provided by the commercial vendor as well as several practice sessions prior to the start of the study. 
 
2.1  Clarity ultrasound system 
The Clarity ultrasound system consists of two US-units: one located in the CT simulation room and the 
second in the treatment room. The two units are connected through a workstation/server. The treatment room 
unit is utilized as intra-modality IGRT. Each US unit is equipped with a convex-probe for trans-abdominal 3D 
US scanning. A ceiling-mounted infrared (IR) camera tracks the US-probe by monitoring the IR-reflectors 
mounted on each probe (Fig. 1. A). To enable superimposition of the 3D US images of the treatment room onto 
the reference US image sets of the CT room, the US system is calibrated to the same coordinate system as the 
CT and treatment rooms. The calibration procedure is accomplished by means of a dedicated alignment 
phantom provided by the vendor. Quality assurance checks confirm the calibration on each day of use. 
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All the patients underwent a CT scan. Two radiographers with experience of the Clarity system were 
responsible for each patient. The patient alignment was performed by means of the room lasers. A US image 
was acquired immediately after the CT scan (Fig. 1.A-B). For each scan the US probe was placed in the pubic 
symphysis region and then rotated/swept followed by a probe slide in the cranial direction. This US image 
acquisition method is known as the sweep/slide technique and enables capture of the entire uterus. The sweep 
technique alone is a proper scan on prostate cancer patients, as the prostate is smaller and the entire target can 
be captured by a transabdominal sweep scan.  Firm pressure, which might lead to uterus displacement, was 
avoided when performing the scan, as the focus was on obtaining clear images to facilitate identification of the 
complex pelvic structure. Since the CT images were to be superimposed onto US images, the same patient setup 
is necessary for CT and US scans. All the cervical cancer patients underwent MRI scans after CT image 
acquisition. The GTVand OARs were delineated on CT-MR fusion image datasets by the gynecological 
oncologist. The CT datasets were transferred to the planning system for 3D treatment planning.  
 
2.3 Organ delineation 
Initially the delineated target and normal structures were exported from the treatment planning system to the 
Clarity workstation. Moreover, the previously delineated bladder and rectum, based on standard MRI, were 
copied to the CT-US fusion to assist the US based target delineation. Subsequently, the CT-US image fusion was 
performed and the uterus delineated in the reconstructed 3D US-image data sets. Finally, the delineated uterus, 
including the cervix, uterine body and fundus, was approved as the Planning Reference Volume (PRV) for 
subsequent weekly US scans in the treatment room. In this study the assisted segmentation in the Clarity 
workstation was utilized for uterus delineation. Export/import from the treatment planning system to the Clarity 
workstation, CT/US fusion and uterus delineation were performed by one of two radiographers or one physicist. 
In addition, a single operator (MB) conducted a retrospective analysis of the acquired US image sets and 
delineated the organs. 
 
2.4 Treatment room 
The patient was prepared for daily treatment by aligning her to the lasers by means of marks on the skin, i.e. 
to reproduce the patient setup position in the CT-simulation room. In this study and prior to the treatment, the 
weekly CBCT images were acquired, and clinical alignment was performed based on bone matching. The 
weekly US scans were performed immediately after acquiring CBCT and treatment delivery. Further, the soft 
tissue match performed by superimposing the segmented uterus in the 3D US image acquired at the treatment 
unit onto the reference PRV from the CT-simulation, thus potential uterus shifts, uterine center of mass (COM) 
shifts, of the target were recorded. Finally, the correlated differences in shifts from the US and CBCT matches 
were compared. 
 
2.5 Statistical analysis 
A paired t-test was applied to compare US with CBCT shifts to check probability differences between the 
paired values of the two samples. This was determined by screening the variation of values within each sample 
and producing a single digit t-value. Despite the different type of image matching in this test, soft tissue versus 
bone matches, the t-test is applicable, since the aim was to investigate inter-fractional displacements using two 
different imaging modalities. Furthermore, the p-values were calculated for a 95% confidence interval (CI). Due 
to the low number of patients the t-test assumption of normal distribution must be treated with caution. 
 
3 RESULTS 
Positional uterine center of mass (COM) shifts detected by ultrasound imaging and shifts based on bone 
alignment using CBCT images in three orthogonal directions are presented in Fig. 2. Positive shifts are anterior, 
inferior and right. The figure shows 14 scans of each CBCT and US for the three patients, patient 1 five scans, 
patient 2 four scans, and patient 3 five scans. The plot reveals larger displacement shifts for US than CBCT, 
2.2 CT-US simulation and treatment planning 
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especially in the case of patient 2. This can be explained by the fact that US soft tissue matching takes uterus to 
bone shifts into account compared to only bone matching using CBCT. In this study a great effort was made to 
perform soft tissue matching based on acquired CBCT, but it was not possible due to poor image quality and thus 
discrimination of the soft tissue organs was almost impossible. As a result all the performed CBCT matches are 
based on bone match. The difference between US and CBCT can be clearly observed by examining the box-plots 
of the shifts for each patient (Fig. 3 A, B, C). These differences are obvious for patients 1 and 2 in the AP- and 
SI-directions, while for patients 2 and 3 the larger deviations can be seen in the LR-direction. In the plot for the 
three patients based on a total of 14 scans, the larger deviation was visible in US scans in all three directions 
(Fig. 3 D). The overall mean (± 1SD) of the weekly uterine COM-shifts (US) and bone match shifts (CBCT) was 
(mm); US/CBCT: AP (3.8±5.5)/(2.8±2.0), SI (-3.0±5.2)/(2.8±2.0), LR (-2.7±1.7)/(-1.0±3.3), respectively 
(Table.1). The results demonstrate that inter-fractional displacements are greater with US than CBCT. The 
largest inter-fractional displacement using US was from -2 mm to +14 mm in the AP-direction for patient 3, 
while with CBCT the largest shift was from -5 mm to +5 mm in the LR-direction also for patient 3.  
The t-values and mean of differences were individually calculated for each patient, while the overall values for 
all three directions were estimated by means of the paired t-test (Table. 2). No significant differences between 
US and CBCT shifts (p > 0.05) were found in any direction, which might be explained by the low number of 
scans. The largest lower/upper range of 95% CI was in the LR-direction in patient 3 (-6.7 to +10.8). 
 
4 DISCUSSION 
Inter-fractional positional uncertainty of the uterus, rectum and bladder in GYN patients has been a 
challenge in radiotherapy, leading to the application of larger set-up margins to account for target displacement. 
Modern conformal treatment (IMRT and volumetric modulated arc therapies) enables better dose conformity, 
and thus steeper dose gradients. The delineated target and OARs are more susceptible to daily uterine positional 
displacements and rectal-bladder filling variations. These variations should be taken into account prior to each 
treatment throughout the course of treatment. The challenge involved in using CBCT and EPID, the most 
common IGRT imaging modalities today, is the difficulty identifying the soft tissue organs in the pelvis, due to 
the inability of these systems to visualize soft tissue, making it difficult to compensate for daily internal shifts. In 
most radiotherapy centers the daily target alignment of cervical cancer patients is based on bone matching, which 
is also standard in our department. However, bone matching does not take the relative uterine positional 
displacement into account.  
Recently, 3D US has been more frequently applied as an IGRT method and mainly used for prostate alignment 
prior to the treatment fraction [19-20]. The advantage of ultrasound imaging is believed to be the capacity of this 
method to visualize soft tissue in the pelvis, especially on the bladder-uterus and bladder-prostate intersections. 
Very few published papers have reported the application of 3D US in GYN patients [21]. The published data in 
this study mostly quantifies inter-fractional bladder motion and variations in bladder volume rather than uterine 
positional changes. For instance, in a US study of 24 patients, Ahmed et al. (2008) concluded that the bladder 
volume decreased dramatically by a mean of 71% compared to the planning CT scan. This phenomenon was also 
observed in our study. Fig. 5 illustrates the reduction in bladder volume from the start of the treatment until week 
5, the final week of treatment, despite the fact that the patients adhered to a standard bladder-rectum filling 
protocol. A moderately full bladder provides better propagation of US-waves and hence a clearer US image by 
sharpening the interface between bladder and uterus. Bladder volume reduction presents a challenge as it affects 
the daily uterine and bladder position as well as making the use of ultrasound as a daily IGRT modality more 
difficult. Tumor regression during radiotherapy is also a challenge. In a study based on weekly CT image 
acquisition, Lee’s group [9] found an average tumor volume reduction greater than 27% in the third week 
compared to the initial CT planning image set.   
A number of US studies on the prostate conclude that one of the drawbacks of using 3D US such as the IGRT 
method is probe pressure induced uncertainty on the target and OARs. In one study, Chan et al.’s 2008 [4] MRI-
based study divided the uterus into three sections; cervical os, uterine canal, and uterine fundus. They reported 
that the fundus can vary from day to day by over 24 mm. Our result from patient 3 revealed an inter-fractional 
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displacement of the uterine center of mass by 16 mm in the AP-direction, which supports the result of Chan et al. 
The recent study by Jurgenliemk-Schultz et al. [22], which investigated vaginal positional change and the 
correlation between vaginal shift and bladder-rectal filling, reported a daily vaginal CTV positional change of up 
to 23 mm in the AP-direction. In the present study we observed that the inter-fractional variation was larger with 
US than CBCT. This can be explained by the fact that CBCT is based on bone matching, which does not take the 
effect of the relative uterine displacement on the bone structure into account. Initially, the goal of acquiring 3D 
CBCT in this study was to perform soft tissue matches. However, the poor image quality was an obstacle to 
distinguishing the target from the organs. White et al. conducted a study [23] of inter-observer variations in 
delineation of the prostate, based on five CBCT scans performed by five genitourinary oncologists. They found 
that the standard deviation for volume determination of the prostate was 8.93 cm3 with large variability (3.98-
19.00 cm3), but the average standard deviation for center of mass displacement was small, measuring 0.7, 1.8, 
and 2.8 mm in the LR, AP, and SI-directions. Despite disagreement about how best to delineate the prostate 
gland, the small inter-observer variability in COM displacement suggests the potential of CBCT as soft tissue 
image guidance, thus replacing the tumor surrogate method of implanted fiducial markers. However, it should be 
noted that the study was conducted on a small number of scans and the matches were performed by expert 
observers, which is not a clinical reality today. Since the pelvis of GYN patients is more complex due to multiple 
structures moving relative to each other as well as deformation and tumor regression during radiation therapy, 
replicating the study on GYN patients is almost impossible.  
In the present study some of the operators experienced difficulty applying the sweep/slide technique for 
capturing the entire uterus. First of all, the bladder must be identified, which is always easier in the sagittal plane 
and then the probe rotated by 90 degrees to the transversal plane, in which the scan was performed. An auto-scan 
probe would be a better solution, since after identifying the uterus in sagittal plane through a single click, the US 
scan and reconstruction of the uterine region could be conducted. Another challenge was the decrease in bladder 
filling during the treatment period, which adversely affected the image quality. This made it more difficult to 
identify the uterine-bladder interface and thus inducing errors in determining the uterine position and 
consequently variations in the inter-fractional displacements. 
 
5 CONCLUSION 
US imaging might be a better IGRT system than CBCT, despite difficulty in capturing the entire uterus. Uterine 
shifts based on US imaging contains relative uterus-bone displacement, which is not taken into consideration 
using CBCT bone match. A trial study based on more patients is required to validate statistical differences 
between CBCT and US.  
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Figure 1. (A) Scanning a patient by sweeping the probe and sliding cranially. (B) The display of the US unit, where the real-
time images can be observed. (C), (D), and (E) The fusion of acquired US images with the CT images sets to obtain a planning 
reference volume (PRV). (F) The US image, acquired in the treatment room is compared with the PRV to detect the uterine 
shift.   
 
 
 
Figure 2. Plot of the uterine shifts in mm (14 weekly scans of three patients) obtained by means of ultrasound imaging (soft 
tissue matches) and corresponding shifts using CBCT imaging (bone match) for the three cardinal directions; anterior-posterior 
(AP), superior-inferior (SI), and left-right (LR).  
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Figure 3. (A), (B), and (C): Box-plots of uterine shifts based on CBCT bone matches and US soft tissue matches for the three 
patients in the three cardinal directions; LR, AP, and SI. (D): The overall shifts for the patients in all directions. 
 
Table. 1 The overall mean (3 patients, 14 scans), median, and standard deviations of the uterine inter-fractional shifts for 
ultrasound and CBCT matches in all three directions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ultrasound CBCT 
 Anterior/ 
Posterior 
Superior/ 
Inferior 
Left/ 
Right 
Anterior/ 
Posterior 
Superior/ 
Inferior 
Left/ 
Right 
Median 4.6 -3.2 2.2 3.0 -3.0 -0.5 
Mean 
(±1SD) 
3.8 (±5.5) -3.0 (±5.2) 0.4 (±4.9) 2.8 (±2.0) -2.7 (±1.7) -1.0 (±3.3) 
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Table2. Values of paired t-test of obtained matching shifts using weekly ultrasound and CBCT scans of cervical cancer patients.  
The p-values are calculated for a 95% confidence interval (CI). 
  N Mean 
Of 
diff. 
df t 95% CI 
(lower/upper) 
P-value 
 Direction       
Patient 
1 
Anterior-
Posterior 
5 -0.92 4 -
0.43 
-6.93/5.09 0.692 
Superior-
Inferior 
5 1.64 4 0.72 -4.65/7.93 0.509
Left-Right 5 2.4 4 2.74 -0.03/4.83 0.052
        
Patient 
2 
Anterior-
Posterior 
4 1.40 3 0.57 -6.35/9.15 0.606
Superior-
Inferior 
4 -2.68 3 -
1.22 
-9.66/4.31 0.310
Left-Right 4 -0.55 3 -
2.67
-7.11/6.01 0.807
        
Patient 
3 
Anterior-
Posterior 
5 2.67 4 1.41 -2.57/7.92 0.230
Superior-
Inferior 
5 -0.49 4 -
0.28 
-5.39/4.40 0.793
Left-Right 5 2.05 4 0.65 -6.74/10.85 0.552
        
Three 
patients 
Anterior-
Posterior 
14 1.03 13 0.84 -1.60/3.65 0.414 
Superior-
Inferior 
14 -0.36 13 -
0.29 
-2.96/2.25 0.773 
Left-Right 14 1.43 13 1.14 -1.29/4.16 0.276 
 
 
 
Figure. 5 The bladder volume reduction in patient 1 from week 2 to week 5 of treatment.       
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Abstract
Aim: The aim of this study was to quantify the uterine positional displacement
induced by ultrasound probe pressure on a phantom and address the daily uterine
motion in a healthy volunteer.
Materials & methods: The phantom mimics the female pelvic region. The incorpo-
rated organs were subjected to displacement. A total of 42 phantom scans and 16
volunteer scans were acquired. The uterine shifts were measured in three directions.
Results & discussion: The difference of uterine positional displacements, using
pressure versus without pressure on the phantom, was not statistically significant. The
daily uterine positional variations of the volunteer were larger than the probe pressure
induced displacements.
Conclusion: The larger daily uterine shifts of the volunteer outweighed the submil-
limeter impact of the probe pressure in all directions.
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Aim: The aim of this study was to quantify the uterine positional displacement induced 
by ultrasound probe pressure on a phantom and address the daily uterine motion in a 
healthy volunteer. Materials & methods: The phantom mimics the female pelvic region. 
The incorporated organs were subjected to displacement. A total of 42 phantom scans 
and 16 volunteer scans were acquired. The uterine shifts were measured in three 
directions. Results & discussion: The difference of uterine positional displacements, 
using pressure versus without pressure on the phantom, was not statistically significant. 
The daily uterine positional variations of the volunteer were larger than the probe 
pressure induced displacements. Conclusion: The larger daily uterine shifts of the 
volunteer outweighed the submillimeter impact of the probe pressure in all directions.
Keywords:  phantom • positional displacement • probe pressure • ultrasound • uterus
In modern conformal radiotherapy with tight 
margins and steep dose gradients, such as 
intensity-modulated radiotherapy, it is essen-
tial that the position of the clinical target 
volume is precisely defined prior to each treat-
ment fraction throughout the entire course of 
treatment.
Technical innovations have enabled the 
direct integration of various image verifica-
tion methods into the treatment unit. In many 
cases this allows for patient and tumor moni-
toring and position correction. Nowadays, 
kV and MV planar radiographic imaging and 
volumetric cone beam computed tomogra-
phy (CT) imaging are standard image verifi-
cation systems in many radiotherapy centers. 
Generally, these systems are implemented as 
image-guided radiotherapy (IGRT) for daily 
target alignment, and thereby improving 
the precision of the radiotherapy treatment. 
However, one of the challenges of using these 
ionizing systems is insufficient soft tissue 
visualization (e.g., of the uterus of gyneco-
logic [GYN] cancer patients or identification 
of the prostate gland and surrounding organs 
at risk [OAR] in prostate cancer patients). 
In some cases these systems require invasive 
methods, such as implanted fiducial markers 
in prostate radiotherapy. Therefore, different 
nonionizing 3D-ultrasound (US) systems, 
such as the Elekta 3D Clarity® Soft Tissue 
Visualization system (Elekta, Montreal, Can-
ada) and the NOMOS B-mode Acquisition 
and Targeting ultrasound system (NOMOS 
Corporation, PA, USA) have been developed 
and introduced into radiotherapy [1–5]. The 
prostate and uterus, for which internal posi-
tion variations are dependent on rectal and 
bladder filling, are ideal sites for US scans. 
However, different uncertainty factors in 
terms of probe handling, image quality and 
interoperator variability are present when 
using the US systems. Variations in the trans-
ducer probe pressure applied have previously 
been documented during 3D US on prostate 
patients [6,7].
The aim of the present study was to quan-
tify the magnitude of probe pressure induced 
uncertainty using the Clarity US system on 
a commercial GYN phantom. An additional 
aim was to compare the pressure induced 
uncertainty with the overall interfractional 
variations by utilizing the US system on a 
healthy volunteer.
Impact of ultrasound probe pressure 
on uterine positional displacement in 
gynecologic cancer patients
Mariwan Baker*,1,2,  
Trine Juhler-Nøttrup1  
& Claus F Behrens1
1Department of Oncology(R), 
Radiotherapy Research Unit,  
Herlev Hospital, Herlev Ringvej 75,  
Herlev, Denmark 
2Center for Nuclear Technologies, 
Technical University of Denmark,  
DTU Risø Campus, Roskilde, Denmark 
*Author for correspondence:  
mariwan.baker@regionh.dk
For reprint orders, please contact: reprints@futuremedicine.com
584 Womens Health (2014) 10(6)
Figure 1. Clarity ultrasound system. (A) Phantom. (B) Phantom US scanning by means of a curve probe in the 
computed tomography room. (C) Clarity US console, in which the phantom organs (bladder, uterus and rectum) 
are easily recognizable. (D) The Clarity workstation, in which the fusion and organ delineation are performed.  
(E) 2D curve probe. (F) The Clarity unit and ceiling-mounted infrared camera in the treatment room. 
US: Ultrasound.  
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Materials & methods
A phantom was scanned by seven operators in four 
sessions on different days. Each operator performed 
two scans per session, one without pressure (WOP) 
or light probe pressure and one with maximum pres-
sure (WP). All the US experienced operators were not 
presented in all sessions, thus, only a total of 42 scans 
were acquired. A healthy volunteer was scanned by the 
available Clarity operators in three sessions, leading to 
a total of 16 scans, over a period of 3 weeks (one ses-
sion per week). Each operator participated in 2 weeks 
of intensive training provided by the manufacturer of 
Clarity, as well as several practice sessions before the 
start of the study.
Phantom
The US training phantom (Model CIRS 404) mimics 
the female pelvic region and contains a uterus, blad-
der and rectum representing the standard female pel-
vic organs (Figure 1A & B). The organs are subjected to 
displacement due to the exerted probe pressure. The 
phantom does not contain any skeletal structure, such 
as femur head or pelvic bone. The phantom is intended 
for US scans, thus all organs are easily defined in the 
acquired US images (Figure 1C). Initially, the phantom 
was marked with small spherical ball bearings (laser 
alignment markers), used to aid reproducibility of 
daily setup prior to each US scan session. During an 
initial session the best possible US scan was selected as 
position reference to the following four sessions. 
Volunteer
The volunteer, a healthy young woman, was instructed 
to have an empty rectum and full bladder prior to each 
session. A moderately full bladder ensures better propa-
gation of the US waves and hence a clearer US image 
by enhancing the image and sharpening the interface 
between bladder and uterus/cervix/vaginal canal. The 
fixation was in supine position by means of a Vac Fix fix-
ation system to ensure position reproducibility between 
sessions. The volunteer was instructed to remain still 
throughout each session. Consistent positioning of the 
volunteer was enabled by the alignment of natural skin 
markers to the isocenter lasers of the CT room. A US 
transabdominal scan of the pelvic region was performed 
repeatedly by each operator until adequate image quality 
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Figure 2.  Plots of the COM shifts based of ultrasound scans of the phantom uterus. WP & WOP in (A) L/R, (B) A/P and (C) I/S 
directions. (D) Boxplot for WP and WOP for all three cardinal directions (L/R, A/P, I/S). 
A: Anterior; I: Inferior; L: Left; P: Posterior; R: Right; S: Superior; WOP: Without pressure; WP: With pressure.
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was achieved. During the first session the best scan, in 
which the organs were clearly definable, was selected as 
a reference for the following three sessions.
Clarity US system
The Clarity Soft Tissue Visualization system (Clarity 
Model 310C00) consists of two US units: one located 
in the CT simulation room and one in the treatment 
room. The two units are connected through a worksta-
tion/server. In this study all US scans were performed 
in the CT room. Since the objective of the ongoing 
project at Herlev Hospital is to implement the Clar-
ity 3D US system for both GYN and prostate patients 
throughout the course of their treatment, the treatment 
room unit will be utilized only for daily IGRT.
Each US unit is equipped with a curve probe 
for transabdominal 3D US scanning. Each station 
consists of a ceiling-mounted infrared camera that 
can track the US probe by monitoring the infrared 
reflectors/emitters mounted on it (Figure 1E & F).
To enable superimposition of the acquired 3D US 
images and the reference US image, the 3D US system 
is calibrated to the same room coordinate system as the 
CT and treatment room, respectively. The calibration 
procedure is accomplished by means of an align-
ment phantom. Quality assurance checks confirm the 
system calibration on each day of use.
Image acquisition
The US image of the phantom (transabdominal US 
scan) was acquired by the seven experienced operators 
using the curve probe (Figure 1B). In each phantom 
scan the US probe was placed on the first occasion with 
minimal pressure and on the second with firm pressure 
in the region corresponding to the pubic symphysis 
and rotated, after which it was swept cranially. No firm 
pressure was applied on the volunteer, as the focus was 
on obtaining clear images, where the complex pelvic 
structure could be identified.
Organ delineation & data analysis
The uterus, bladder and rectum were delineated in the 
reconstructed 3D US image datasets using the Clarity 
workstation supplied by the manufacturer. In the work-
station the delineation can be performed either manually 
or with aid of autosegmentation. In this study the assisted 
segmentation was utilized for all outlined organs. A 
single operator (MB) conducted a retrospective analysis 
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of the acquired US image sets and delineated the organs 
for both the phantom and the volunteer.
Descriptive statistics and the paired sample t-test 
were employed to evaluate the statistical significance 
of the mean differences between probe pressure and 
no probe pressure. The p-value was calculated for a 
95% CI, (i.e., the significance at α = 0.05).
Results
Positional shifts of the phantom uterus center of 
mass (COM) in the three orthogonal directions WP 
(depicted as circles) and WOP (triangles) are presented 
(Figure 2A–C). Positive shifts are left, anterior and infe-
rior. Qualitatively, these plots demonstrate that there 
are no significant differences when comparing the 
shifts between WP and WOP.
The overall mean (±1 SD) of the phan-
tom COM shifts are (mm); WP/WOP: LR 
(0.1 ± 1.2)/(-0.2 ± 1.1), AP (-0.3 ± 2.1)/(-0.2 ± 1.2) 
and IS (-0.8 ± 2.1)/(-0.3 ± 2.2). The largest recorded 
shift is observed in the I/S-direction; +5 mm (WOP) 
and -5 mm (WP). The mean of the COM shifts in 
all three directions (L/R, A/P, I/S) for WP and WOP 
are centered around zero (Figure 2D). The spread in 
the recorded shifts, (i.e., the standard deviations) 
for WP is larger than WOP in all directions. This is 
caused by larger interoperator variations while apply-
ing strong probe pressure. For each of the three direc-
tions a paired two sample t-test was utilized to test 
whether there are any statistical significant differences 
in the means of the shifts between WP and WOP. No 
statistical significant differences in any direction are 
observed (i.e., none of the p-values are below 0.05). 
The largest lower/upper 95% CI range was found in 
the I/S-direction (-0.85/-1.85) (Table 1).
For the volunteer the recorded mean COM shift on 
day 3 in L/R direction is approximately 10 mm rela-
tive to the reference, while on days 1 and 2 the lateral 
shift is less than 2 mm (Figure 3). Furthermore, in the 
A/P direction the mean shifts are less than 2 mm on 
days 1 and 2, but more than 5 mm on day 3. The larg-
est interfractional displacement is observed in the I/S 
direction, with a mean value of -7.7 mm, +7.6 mm and 
-6.9 mm on days 1, 2 and 3, respectively (Table 2). This 
clinically critical shift is visible in Figure 4. One can 
clearly see that the bladder is fuller on day 2 than on 
day 1, causing correlated uterine positional displace-
ment. It is worth mentioning that on day 2 only four 
US scans (four operators) took place compared with six 
on days 1 and 3.
Discussion
Interfractional positional uncertainty of the uterus, 
rectum and bladder in GYN patients is a challenge in 
radiotherapy as it leads to the application of large plan-
ning target volume (PTV) margins. Previous reports 
have confirmed that uterine positional changes are 
strongly correlated with daily variation in bladder–rec-
tum filling [8–10]. Thus, there is a need to incorporate 
IGRT methods into radiotherapy to identify and cor-
rect possible uterine and OAR positional changes. At 
present the 3D US IGRT method has mainly been used 
for prostate alignment prior to treatment [11–17]. Only 
a few published papers have reported the application of 
3D US in GYN patients [18–20], and with the focus on 
quantifying interfractional bladder motion and varia-
tion in bladder volume rather than uterine positional 
change. For instance, in a US study of 24 cervical can-
cer patients, Ahmad et al. concluded that the mean 
bladder volume decreased dramatically by 71% com-
pared with the treatment planning CT scan [18]. Herlev 
Hospital is a pioneer in the application of the Clarity 
3D US system with a focus on GYN diagnoses. The 
present study started by applying Clarity on a phan-
tom and a healthy volunteer and it will subsequently be 
tested for GYN patients at Herlev Hospital.
Different studies on the prostate have concluded 
that one of the drawbacks of using 3D US as the 
IGRT method is probe pressure-induced uncertainty 
of the target and OAR locations. However, to our 
knowledge, no specific probe pressure study on GYN 
patients has been published. In the present phantom 
study, we found no statistically significant differences 
in uterine COM shifts using pressure versus no pres-
sure. All the acquired US scans indicated that uterine 
COM displacements were in the vicinity of zero, with 
a daily mean value of less than 1 mm in all three car-
dinal directions (L/R, A/P and I/S). Since the shifts of 
the bladder–uterus interface is interesting to study – as 
a portion of the bladder receives an undesirable high 
Table 1. Paired t-test values of the mean uterine shifts using ultrasound scans of the phantom with 
pressure & without pressure.
Directions Number of 
scans
Standard 
deviation (mm)
Difference between 
the means (mm)
95% CI  
(lower/upper)
p-value
Left–right 21 0.93 -0.29 -1.03/0.45 0.43
Anterior–posterior 21 2.13 0.10 -0.99/1.18 0.86
Inferior–superior 21 1.87 0.50 -0.85/1.85 0.45
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Figure 3.  Omnidirectional shifts of uterine center of mass of a volunteer. (A–C) Boxplots of uterine COM shifts for the volunteer on 
3 days in the three cardinal directions; L/R, A/P and I/S. (D) Plot of uterine COM shifts; the daily ultrasound scans (day 1: six scans, day 
2: four scans and day 3: six scans) in the L/R, A/P and I/S directions. 
A: Anterior; I: Inferior; L: Left; P: Posterior; R: Right; S: Superior; 
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radiation dose owing to its proximity to the uterus − 
further studies focusing on the bladder–uterus inter-
face are necessary. In an MRI study by Chan et al., 
the uterus was divided into three sections; cervical os, 
uterine canal and uterine fundus [21]. GYN patients 
underwent a pelvic MRI scan before treatment fol-
lowed by weekly scans. The interfractional displace-
ment was largest at the fundus, moderate along the 
canal and smallest at the cervical os. A similar study 
using 3D US is recommended to verify these findings.
Our volunteer study revealed a clinically critical 
large interfractional displacement in all three direc-
tions. The largest uterine positional displacement was 
15 mm in the I/S direction between days 1 and 2. 
Although our volunteer US scans are limited to three 
sessions, the result agrees well with a recent study by 
Jurgenliemk-Schultz et al., which investigated vaginal 
positional change and the correlation between vagi-
nal shift and bladder–rectal filling [22]. These authors 
reported a vaginal clinical target volume positional 
change of up to 2.3 cm in the A/P direction. However, 
in contrast to previous studies, they did not find any 
correlation between vaginal positional displacement 
and bladder–rectal filling, except an extremely weak 
one in the case of A/P position shift and rectal filling.
The challenge experienced by most of our operators 
during 3D US acquisition was to find an appropriate 
probe handling technique that captured the entire 
uterus from the cervical os to the fundus, as the image 
quality was poor in some cases. Obviously, poor image 
quality has an adverse influence on uterine delineation, 
thus leading to uncertainty in COM shifts. This chal-
lenge is illustrated in the boxplots (Figure 3) and by the 
SD (Table 2) of the uterine COM shifts on day 2, which 
was more than 6 mm in the I/S direction. The plot 
in Figure 3D illustrates the large dispersion of COM 
shifts on day 2 in the I/S direction. Our experience of 
suboptimal image quality is confirmed by the study of 
Johnston et al., who compared assisted segmentation 
(employed in the present study) and manual segmenta-
tion of prostate patients using the Clarity 3D US sys-
tem [23]. During quality classification of the acquired 
US images, they found that up to 33% were of bad 
quality, which hinders accurate outlining of the target.
Finally, it should be noted that the phantom used 
is not necessary representative of a real GYN patient, 
588 Womens Health (2014) 10(6)
Figure 4. Outlined organs (bladder, uterus and rectum), 
sagittal, transversal and frontal cross-sections, in the 
Clarity workstation. The uterine positional shift is 
obvious from days 1 to 2.
Day 1 Day 2
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therefore a clinical study is needed to validate the 
results of this study. The daily bladder and rectal vol-
ume variations can strongly affect the position of the 
uterus, which cannot be simulated by our phantom. 
Furthermore, statistical evaluation of the interfrac-
tional uterine positional changes based on a single vol-
unteer must be considered with caution, and a clinical 
study is needed to validate the present result.
Conclusion
The large daily uterine positional displacement of the 
volunteer outweighs the submillimeter impact of probe 
pressure in all directions. The difference in phantom 
uterine COM shifts using probe pressure versus no 
probe pressure is not statistically significant. Based on 
a single volunteer case, a large uncertainty in using 3D 
US on GYN patients is the poor quality of the acquired 
image due to the challenge of handling the probe. A 
clinical study is required to validate phantom probe 
pressure-induced uncertainty. The large interfractional 
variations based on a single volunteer warrant further 
investigation.
Future perspective
In radiotherapy, it is vital that the daily target align-
ment is correctly applied prior to each treatment. 
Today’s widely used X-ray IGRT techniques are poor 
in terms of visualizing soft tissue in the female pelvic 
region and for this reason bone match instead of soft 
tissue match is employed. However, it has been previ-
ously demonstrated that uterine mobility relative to the 
bone structure can be several centimeters in all direc-
tions. In the present study we have shown daily uterine 
positional displacements of several centimeters using 
the novel Clarity US system. US is nonionizing, fast, 
inexpensive and good for visualizing soft tissue organs. 
Despite challenges in probe handling to obtain opti-
mal images, the US is a good choice as a future IGRT 
system for cervical cancer patients.
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Table 2. Mean values with standard deviations of the uterine shifts in the volunteer scanned by 
seven operators.
 Directions Number of 
operators/scans
Mean (mm) Standard deviation 
(mm)
Day 1
 
 
Left–right 6 0.27 1.09
Anterior–posterior 6 0.18 1.71
Inferior–superior 6 -7.65 2.64
Day 2
 
 
Left–right 4 -1.58 1.74
Anterior–posterior 4 -1.95 1.21
Inferior–superior 4 7.55 6.12
Day 3
 
 
Left–right 6 9.48 3.08
Anterior–posterior 6 -4.47 2.53
Inferior–superior 6 -6.85 2.47
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divided	into	three	regions;	uterine	head,	uterine	body	and	
uterine	opening.	The	largest	displacement	was	observed	
in	the	uterine	head,	which	requires	a	minimum	margin	
of	4	cm	to	ensure	inclusion	of	the	target	in	the	treatment	
field.	This	large	margin	is	not	applied	in	any	radiotherapy	
centers,	therefore	rescanning	of	cervical	cancer	patients	
during	the	course	of	treatment	is	essential	to	ensure	that	
they	derive	maximum	benefit	from	the	treatment.
22 Jürgenliemk-Schulz IM, Toet-Bosma MZ, De Kort G 
et al. Internal motion of the vagina after hysterectomy for 
gynaecological cancer. Radiother. Oncol. 98(2), 244–248 
(2011).
23 Johnston H, Hilts M, Beckham W, Berthelet E. 3D 
ultrasound for prostate localization in radiation therapy: 
a comparison with implanted fiducial markers. Med. Phys. 
35(6), 2403–2413 (2008).
••	 Compares	prostate	shifts	in	ultrasound	scans	with	those	of	
fiducial	markers	implanted	into	the	prostate.	Ultrasound-
based	shifts	are	larger	than	fiducial	marker	shifts	in	all	
three	directions;	therefore	transabdominal	ultrasound	is	
not	an	optimal	alternative	to	the	widely	applied	fiducial	
markers	image-guided	radiotherapy.
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Abstract
Background: Transabdominal ultrasound (TAUS) imaging is currently available
for localizing the prostate in daily image-guided radiotherapy (IGRT). The aim of
this study was to determine the induced prostate displacement during such TAUS
imaging. The prostate displacement was monitored using a novel transperineal four-
dimensional (4D) US (TPUS) system.
Material and methods: Ten prostate cancer patients, with a mean age of 68 years
(58/76), were US scanned in the computed tomography (CT) room utilizing the Clar-
ity 4D TPUS monitoring system. The patients were asked to comply with a moderate
bladder fi lling protocol. After US-CT fusion, the prostate volume was delineated
and used as a reference for weekly US imaging in the treatment room. Immediately
after treatment delivery the TPUS monitoring system was set up. During real-time
monitoring of the prostate, a conventional 2D probe was applied to simulate a TAUS
scan. The time dependent prostate displacements induced by the 2D probe pressure
were recorded for the three orthogonal directions. In total 42 monitoring curves with
applied 2D probe were recorded.
Results: Data analysis of 42 US scans resulted in pressure induced prostate dis-
placements with mean values ( ± 1 SD) (mm); inferior (+)-superior (I/S): (-0.1 ±
0.8); left (+)-right (L/R): (0.2 ± 0.7); and anterior (+)-posterior (A/P): (-0.1 ± 1.0).
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Paper D. Prostate displacement during transabdominal ultrasound image-guided
radiotherapy assessed by real-time four-dimensional transperineal monitoring
The majority of the displacements were within 1-2 mm. Only two scans (5%) (A/P
direction) and 16% of Euclidean distances were larger than 2.0 mm. The largest
displacement was 2.6 mm in the anterior direction.
Conclusion: The novel 4D TPUS system was capable of tracking and recording the
prostate positional displacements. The study demonstrated that the prostate induced
displacements due to applied TAUS IGRT are small, and in most cases clinically
irrelevant to prostate radiotherapy.
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 Prostate displacement during transabdominal ultrasound 
image-guided radiotherapy assessed by real-time four-dimensional 
transperineal monitoring 
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 1 Department of Oncology, Radiotherapy Research Unit, Herlev Hospital, University of Copenhagen, Herlev, 
Denmark and  2 Center for Nuclear Technologies, Technical University of Denmark, DTU Ris ø Campus, 
Roskilde, Denmark 
 ABSTRACT 
 Background. Transabdominal ultrasound (TAUS) imaging is currently available for localizing the prostate in daily 
image-guided radiotherapy (IGRT). The aim of this study was to determine the induced prostate displacement during 
such TAUS imaging. The prostate displacement was monitored using a novel transperineal four-dimensional (4D) US 
(TPUS) system. 
 Material and methods. Ten prostate cancer patients, with a mean age of 68 years (58/76), were US scanned in the 
computed tomography (CT) room utilizing the Clarity 4D TPUS monitoring system. The patients were asked to comply 
with a moderate bladder fi lling protocol. After US-CT fusion, the prostate volume was delineated and used as a refer-
ence for weekly US imaging in the treatment room. Immediately after treatment delivery the TPUS monitoring system 
was set up. During real-time monitoring of the prostate, a conventional 2D probe was applied to simulate a TAUS scan. 
The time dependent prostate displacements induced by the 2D probe pressure were recorded for the three orthogonal 
directions. In total 42 monitoring curves with applied 2D probe were recorded. 
 Results. Data analysis of 42 US scans resulted in pressure induced prostate displacements with mean values (   1 SD) 
(mm); inferior (  )-superior (I/S): (0.1    0.8); left (  )-right (L/R): (0.2    0.7); and anterior (  )-posterior (A/P): 
(0.1    1.0). The majority of the displacements were within 1 – 2 mm. Only two scans (5%) (A/P direction) and 16% 
of Euclidean distances were larger than 2.0 mm. The largest displacement was 2.6 mm in the anterior direction. 
 Conclusion. The novel 4D TPUS system was capable of tracking and recording the prostate positional displacements. 
The study demonstrated that the prostate induced displacements due to applied TAUS IGRT are small, and in most cases 
clinically irrelevant to prostate radiotherapy. 
 In external beam radiotherapy for the prostate cancer, 
it is imperative to minimize damage to surrounding 
healthy tissues while delivering a high dose to the pros-
tate. As the position of the prostate can vary substan-
tially between treatment fractions and possibly even 
during treatment delivery [1 – 3], methods for precise 
localization on the prostate are warranted. Different 
kilovoltage (kV) and megavoltage (MV) image-guided 
radiotherapy (IGRT) methods have been developed. 
However, the kV and MV imaging modalities have 
poor soft tissue visualization, therefore, in many clin-
ics, implanted fi ducial markers (FM) in the prostate 
utilized as a surrogate for the prostate localization [4]. 
However, implanting FMs are an invasive method and 
not available in all clinics. 
 Ultrasound (US), a non-ionizing and non-inva-
sive imaging modality, has been introduced as an 
alternative inexpensive IGRT method. Clinically, 
two models of US-IGRT systems, intermodal US 
(BAT system) and intramodal US (Clarity system) 
have been introduced [5] . In intermodal US, the US 
images from the treatment room are matched to 
computed tomography (CT)-reference images, 
whilst in intramodal US the US images are matched 
to the US-reference images from the simulation 
room. Both systems are based on transabdominal 
US (TAUS) imaging, using a two-dimensional (2D) 
US probe. Several studies have been conducted 
comparing the US-based IGRT to the FM-based 
IGRT [6 – 10]. 
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2 M. Baker & C. F. Behrens 
 One of the disadvantages of TAUS imaging is the 
inter-operator variability. For example, variations in 
exerted probe pressure have been reported to have 
an impact on prostate position in various studies. 
One study was designed to investigate pressure 
induced displacement of the prostate by US scanning 
of a phantom mimicking a male pelvic area [11]. The 
disadvantage of such tissue-equivalent phantoms is 
that the static anatomical structures cannot represent 
the uniqueness of a patient ’ s organs, in which daily 
variations in bladder, rectal fi lling, and shape occur. 
In another approach, volunteers were TAUS scanned 
using a fi xed 2D probe on a robotic arm [12]. The 
probe was fi rst placed above the pubis symphysis, 
and moved vertically towards the prostate step by 
step, acquiring images at each stage. One limitation 
of this test is that the TAUS scan of the prostate 
requires a sweep technique, as opposed to only a 
vertical probe movement. Moreover, a recently pub-
lished work, based on TAUS scan of volunteers and 
prostate patients, demonstrated that applied probe 
pressure may cause up to 8 mm of prostate displace-
ment while applying  “ strong pressure ” [13]. How-
ever, it was impossible in the study to observe any 
prostate displacements while applying  “ soft pres-
sure ” defi ned as the minimum pressure required for 
acquiring suffi cient image quality. Thus, a study to 
simulate the daily in-room TAUS IGRT while record-
ing the induced prostate displacement is required, 
and this was the motive for our study. 
 Currently, a system based on an automatic 
mechanically sweeping US probe, the Clarity trans-
perineal US (TPUS) autoscan (Elekta, Stockholm, 
Sweden), is being introduced into radiotherapy. The 
system offers 4D real-time tracking of the prostate. 
 The aim of this study was to determine prostate 
displacement, due to applied TAUS probe pressure, 
by continuously 4D monitoring the prostate utilizing 
the TPUS autoscan. 
 Material and methods 
 Patients 
 Ten prostate cancer patients, with a mean age of 
68 years (the age range of 58 – 76), were scanned 
weekly by two of six experienced radiation therapists 
(RTTs), using the TPUS autoscan. The study was 
approved by the ethical committee according to 
 “ World medical association declaration of Helsinki ” . 
Every patient was verbally informed of the objective 
of the study, and signed a printed statement of 
informed consent before participation. Furthermore, 
the patients were instructed to follow a moderate 
bladder fi lling protocol, which involved not urinating 
after leaving their home on their way to their daily 
radiation treatment. In this study, the US monitoring 
images were used for research purposes only and not 
applied clinically. One patient was excluded after 
1 fraction owing to his unwillingness to participate 
anymore. A total of 48 US scans were acquired, from 
which six US scans were excluded due to inferior 
image quality. 
 Clarity ultrasound (US) system 
 The Clarity US system consists of two mobile US 
units: one located in the CT simulation room and 
the second in the treatment room. The two units are 
connected through a workstation. The workstation 
was used for prostate delineation, as well as for 
retrieving the prostate monitoring curves. 
 The US unit has a console screen, where anatom-
ical structures can be observed and image quality opti-
mized, using different brightness and contrast settings. 
The unit also has a conventional convex 2D probe and 
the novel autoscan probe for TAUS and TPUS 
scanning, respectively (Supplementary Figure 1C, D, 
available online at http://www.informahealthcare.com/
doi/abs/10.3109/0284186X.2015.1061208). Details 
of the Clarity characteristics, 3D image reconstruc-
tions, and system calibration are described in another 
paper [14]. In short, a ceiling-mounted infrared (IR) 
camera can track the US probes by monitoring the 
IR-refl ectors attached to them. This is essential for 
determining the geographical position of the recon-
structed anatomical structures. 
 CT-simulation, autoscan imaging and CT-US fusion 
 After the CT scan acquisition, the patient was pre-
pared for the US scan using vendor provided knee 
cushions resting over the autoscan base (a kit to which 
the autoscan probe was attached) (Supplementary 
Figure 1A available online at http://www.informa
healthcare.com/doi/abs/10.3109/0284186X.2015.
1061208). The patient was instructed to remain still 
during image acquisition. Afterwards, the CT-US 
image fusion was performed and the prostate gland 
delineated. Finally, the delineated prostate was 
approved as a reference volume for subsequent weekly 
US scans in the treatment room. 
 Image acquisition and prostate monitoring in the 
treatment room 
 The patient was prepared for daily treatment using 
FM-IGRT. Immediately after the treatment, the 
patient was repositioned in preparation for autoscan 
monitoring. The TAUS scan was simulated, using a 
2D probe, while the prostate was continuously mon-
itored using the TPUS autoscan (Supplementary 
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  Induced prostate displacement during TAUS  3
only two scans (5%) (A/P direction) and 16% of 
Max(D(t)) were larger than 2.0 mm. 
 The simulation time employing the TAUS probe 
was from approximately 15 to 20 seconds (Supple-
mentary Figure 2A – C, available online at http://www.
informahealthcare.com/doi/abs/10.3109/0284186X.
2015.1061208). The largest dispersal was observed 
to be in the A/P direction. It was also observed that, 
after releasing the 2D probe, the prostate could be 
permanently displaced. Moreover, the mean displace-
ment was shown to be within    0.2 mm in all three 
directions (Figure 1). Additionally, the mean lateral 
displacement was about 0.2 mm to the left. 
 Individual boxplots of all nine patients demon-
strated some variations in prostate displacements 
between them and even for individual patients 
(Figure 2A – C). The fi rst patient (pt1) showed the 
largest day-to-day variations in A/P direction, which 
can, fi rst of all, be attributed to daily changes in the 
patient and, second, to the inter-operator pressure 
variability. Additionally, the boxplot of the overall 
displacements revealed that the fi rst and the third 
quartiles were within    1.0 mm in all three directions 
(Figure 2D). Finally, the last boxplot in the fi gure 
indicates that the median of the Euclidean distance 
is about 1.3 mm. 
 Discussion 
 Transabdominal US-IGRT in prostate radiotherapy 
poses some challenges concerning variations in 
applied probe pressure, and US image interpretation. 
This can lead to inter-operator variability, in particu-
lar among users with little or no US experience. The 
American Association of Physicists in Medicine 
(AAPM) emphasizes that US training is essential and 
can be divided into  “ initial vendor-provided training 
and continuous clinical training ” [15]. Experienced 
US users were reported to be more consistent in 
Figure 1E available online at http://www.informa
healthcare.com/doi/abs/10.3109/0284186X.2015.
1061208). The autoscan, unique in its positioning in 
relation to the patient ’ s perineal region, and hence 
outside of the irradiated area, is designed to address 
the intra-fractional prostate motion during radiation 
delivery, which was not the aim of this study. During 
the simulation, no US images were acquired with the 
2D probe, i.e. the probe was used as a dummy. How-
ever, the trained RTTs were instructed to reproduce 
the sweeping technique and associated applications 
of pressure required to acquire adequate US image 
quality. Furthermore, the RTTs were asked to avoid 
observing the impact of the pressure on the console 
screen. The prostate displacements due to the exerted 
probe pressure were recorded for retrospective anal-
ysis. Supplementary Figure 1E shows an example of 
prostate displacements in inferior-superior (I/S), left-
right (L/R), and anterior-posterior (A/P) directions 
during the 2D probe simulation. 
 Data collection and statistical analysis 
 The recorded curves, showing the real-time prostate 
center of mass (COM) position in all three direc-
tions, were retrieved from the Clarity server by one 
observer (MB). For each curve the displacement as 
function of time (t) was analyzed relative to a chosen 
reference position at time t 0 , a start time shortly 
before the 2D probe was applied. The overall mean 
[   1 standard deviation (SD)], maximum, and min-
imum of the prostate displacements (relative to the 
prostate position at t 0 ) were derived for the three 
directions. Furthermore, the maximum Euclidean 
distance [Max(D(t))] was computed as the length of 
the vector between the position of the COM of the 
prostate at t, the time where the prostate displace-
ment is largest, and t 0 . The statistical program R was 
used to analyze the data. 
 Results 
 All patients encompassed in this study were coop-
erative, and none of them expressed any discomfort 
during the autoscan setup, or from the applied probe 
pressure. Data analysis of 42 US scans resulted in 
pressure induced prostate displacements with mean 
values (   1 SD) of -0.1 mm (   0.8 mm), 0.2 mm 
(   0.7 mm), and -0.1 mm (   1.0 mm) in I(  )/S, 
L(  )/R, and A(  )/P directions, respectively. In addi-
tion, the mean of maximum Euclidean distance 
[(D(t))>] was computed to be 1.3 mm (   0.7 mm) 
(Table I). Furthermore, the largest displacement was 
calculated to be 2.6 mm in the anterior direction and 
2.9 mm for D(t). Moreover, the majority of the dis-
placements were found to be within 1 – 2 mm, and 
 Table I. Mean, standard deviations (SD), max of prostate 
displacement, and displacements larger than 0.5, 1.0, 2.0 mm in 
all three directions, including Euclidean distance Max(D(t)). 
 Directions 
 I(  )/S a  L(  )/R  A(  )/P  Max(D(t)) b 
Mean   SD 
(mm)
0.1    0.8 0.2    0.7 0.1    1.0 1.3    0.7
Max (mm) 1.2/1.8 1.6/1.1 2.6/2.2 2.9
Displacement
    0.5 mm
49% 47% 58% 81%
Displacement
    1.0 mm
16% 14% 33% 60%
Displacement
    2.0 mm
0% 0% 5% 16%
 a A/P, anterior-posterior; I/S, inferior-superior; L/R, left-right; 
 b Max(D(t)) maximum Euclidean distance. 
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4 M. Baker & C. F. Behrens 
image acquisition and better at identifying anatomical 
structures, with less inter-operator variability [16]. 
 This study was designed to determine the infl uence 
of TAUS probe pressure on prostate location by utiliz-
ing continuous tracking of the prostate employing the 
novel 4D TPUS autoscan. The accuracy of the prostate 
monitoring algorithm was validated by Lachaine et  al. 
[17]. They utilized a robotic stage regulator on a US 
phantom with certain motion patterns. They discov-
ered the mean and standard deviation of the differ-
ences between the measured and the regulator to be 
0.0    0.2 mm, 0.2    0.4 mm, and 0.2    0.2 mm in 
the I/S, L/R, and A/P directions, respectively. Another 
comparison study between the TPUS autoscan system 
and the Calypso system (Varian Medical Systems, Palo 
Alto, CA, USA) was performed by Abramowitz et  al. 
[18]. The Calypso system utilizes transponders 
implanted into the prostate for positional tracking. 
Abramowitz et  al. designed a motorized phantom com-
bined with a prostate-equivalent structure. They found 
good agreement between the two systems in tracking 
the embedded prostate-like sphere. 
 Figure 1. Prostate displacement; Monitoring graphs show the prostate displacement due to applied probe pressure (mean of 42 scans) in 
I/S, L/R, and A/P directions. 
 Figure 2. Boxplots of the prostate displacements; (A – C) Boxplots of the prostate displacements for nine patients in I/S, L/R, and A/P 
directions (D) Boxplot of overall prostate displacements in I/S, L/R, and A/P directions, including Euclidean distance. The horizontal band 
indicates the median, the lower and the upper edges of the box explain the fi rst (25th) and third (75th) quartiles. The lower and the upper 
extremes of the whiskers, display the minimum and maximum values in absence of single data point outliers. 
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  Induced prostate displacement during TAUS  5
 In a study by Fargier-Voiron et  al. [13], the impact 
of probe pressure on prostate displacement was 
investigated in 16 volunteers and eight patients. They 
applied soft, moderate and strong TAUS probe pres-
sure to displace the prostate. The induced displace-
ment was then quantifi ed by comparing the position 
of the prostate under moderate and strong pressure 
with the prostate position under soft pressure. Thus 
only the difference between prostate position under 
soft pressure and the prostate position under moder-
ate or strong pressure could be assessed. They 
reported the mean and standard deviations of the 
Euclidean prostate displacements of 2.5    1.2 mm 
and 3.3    1.6 mm for moderate and strong pressure 
(relative to soft pressure), which are greatly larger 
than our Euclidean displacement of 1.3    0.7 mm. 
Furthermore, Fargier-Voiron et  al. measured the 
maximum prostate displacement to 7.5 mm, using 
strong pressure, in the inferior direction, compared 
to our maximal displacement of only 2.6 mm in the 
anterior direction. However, in our study the mea-
sured prostate displacement is between no probe 
pressure (rest position) and soft probe pressure, 
which refl ects the clinical routine practice of TAUS-
IGRT. Another limitation of Fargier-Voiron et  al. 
study was that they only had one TAUS scan per 
volunteer/patient. In our study we observed large 
day-to-day variations in pressure displacements for 
individual patients. In another study, Van der Meer 
et  al. [14] used TAUS probe pressure applied at four 
levels; no, low, intermediate, and high. As in the 
study by Fargier-Voiron et  al ., prostate displacement 
was measured relative to the US scan applying the 
least amount of pressure (level of  “ no pressure ” ). 
Applying a low pressure, defi ned by them as 1 cm 
skin displacement, suffi cient to achieve good image 
quality, yielded a mean prostate displacement of 
0.0 mm, -0.5 mm, and -0.7 mm in I(  )/S, L(  )/R, 
and A(  )/P directions, respectively. This is compa-
rable to our corresponding sub-millimeter results of 
0.1 mm, 0.2, and -0.1 mm. However, Van der Meer 
et  al. reported the average Euclidean distance for the 
prostate displacement, for low pressure, to be about 
3.0 mm, which is larger than our outcome of 1.3 mm. 
Artignan et  al. [12] performed a similar TAUS scan 
study of volunteers, in which the probe was affi xed 
to a rigid arm, enabling it to move towards the pros-
tate in graded steps. As in the studies by Van der 
Meer et  al. and Fargier-Voiron et  al., the reference 
image was the US scan with the least amount of 
pressure. Artignan et  al. defi ned a skin displacement 
of 1.2 cm, of the same magnitude as Van der Meer 
et  al., as suffi cient for obtaining adequate US image 
quality. This pressure resulted in a mean Euclidean 
vector displacement of 3.1 mm. According to Artig-
nan et  al., the displacement is not limited to one 
direction as was also the case in our study, hence 
displacements opposite to the direction of the probe 
pressure were observed. 
 The result of mean lateral displacement of 
0.2 mm (Figure 1) might be explained by the fact 
that the probe simulation was applied from the right 
hand side of the patient (Supplementary Figure 1B 
available online at http://www.informahealthcare.
com/doi/abs/10.3109/0284186X.2015.1061208), 
resulting in the probe being slightly tilted to the 
right, and hence inducing partial lateral pressure to 
the left rather than a strictly vertical pressure. Fur-
thermore, the maximal displacement was showed to 
be 1.2 mm, 1.6 mm, and 2.6 mm in I/S, L/R, and 
A/P directions, which conforms to a study by Dobler 
et  al. [19] that resulted in corresponding measures 
of 3.0 mm, 0.8 mm, and 2.8 mm. Dobler et  al. 
investigated displacement of eight iodine seeds, 
inserted into the prostate during Brachy therapy. 
The seeds ’ positions were tracked by using real-time 
x-ray simulation while applying TAUS probe imag-
ing using minimum probe pressure. They calculated 
the absolute displacement of the seeds to be larger 
than 2.0 mm in 7% of cases for all three directions 
which was consistent with our obtained results of 
0%, 0%, and 5% in I/S, L/R, and A/P directions. In 
another study, Serago et  al. [20] initiated a probe 
simulated study (no US scans were performed but 
a Styrofoam dummy was used) using two consecu-
tive CT scans of 16 prostate patients; one without 
probe simulation and one with probe simulation. 
They discovered that in nine of the patients there 
was no measurable prostate movement, and the 
remaining seven patients had  “ discernible ” dis-
placements. In the patients with prostate displace-
ment, they calculated the average displacement to 
be 3.1 mm. 
 Surprisingly, the prostate displacements from 
our study were less than all previous reported dis-
placements in all directions, except for the results 
obtained by Dobler et  al. The reason might be that 
Dobler et  al . were using a similar method as in our 
approach, i.e. observing the pressure displacements 
in real-time and, importantly, not using a US scan 
with minimal pressure as reference. Most of the 
other studies were implementing either US/US 
(Clarity system) or US/CT (BAT system) image 
matching in order to measure the prostate COM 
displacements. Van der Meer et  al. [14] studied the 
US/US matching procedure to determine intra-, and 
inter-operator matching variability through investi-
gating 817 matches of a total of 376 US-scans. They 
discovered the intra-operator/inter-operator vari-
ability (1 SD) to be 0.8 mm/1.8 mm (I/S), 
0.7 mm/1.3 mm (L/R), and 1.0 mm/1.4 mm (A/P), 
respectively. In another study, Langen et  al. [21] 
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6 M. Baker & C. F. Behrens 
investigated US/CT matching and found inter-
operator variability, among eight observers, to be 
larger than 2.0 mm (difference between any two 
matches) in about 50% of the matches in all three 
directions. The variability in US/US-, and US/CT-
matching might adversely affect the accuracy of the 
measured prostate displacements, and consequently 
generate larger values. 
 As with all such studies, there are limitations that 
offer opportunities for further research. For exam-
ple, the monitoring algorithm was validated as fairly 
precise in all cardinal directions, but the sub-
millimeter uncertainty, admittedly, corresponded to 
approximately 10% of the magnitude of the prostate 
displacements measured in this study. Another lim-
itation was that the TAUS simulations may not 
refl ect a real routine clinical practice, in which ana-
tomical structures can be visualized. We were unable 
to simultaneously acquire TAUS images while TPUS 
monitoring, using the same US unit, since another 
Clarity system was required to do so. In our 
approach, the operators followed specifi c instruc-
tions to simulate a TAUS scan with the amount of 
pressure that they would normally use. However, it 
was not possible to validate that the operators in fact 
used enough probe pressure. Moreover, although a 
gentle transperineal attach of the autoscan was car-
ried out with caution, a counter-effect of the probe ’ s 
head might infl uence the position of the prostate, 
and hence changing the magnitude and likewise the 
direction of the prostate displacements during TAUS 
simulation. In brief, further similar research, by 
enrollment of a larger patient population and acquir-
ing larger number of real TAUS scans per patient, 
are recommended to validate and to strengthen this 
study. 
 In conclusion, the novel 4D autoscan US system 
was able to track and record positional displacements 
of the prostate. In this study we demonstrated that 
the displacements of the prostate induced by the 
applied TAUS IGRT were small, and in most cases 
clinically irrelevant to prostate radiotherapy. 
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Abstract
Background: In cervical radiotherapy, it is essential that the uterine position is
correctly determined prior to the treatment delivery. The aim of this study was to
evaluate a novel autoscan ultrasound (A-US) probe by comparing it to a conventional
US (C-US) probe.
Methods: Nine healthy volunteers were US scanned by seven operators, using the
Clarity system (Clarity, Elekta, Stockholm, Sweden). In total 72 scans; 36 from the
C-US (manual sweeping) and 36 from the A-US probe (automatic sweeping), were
acquired. Two observers delineated the uterine structure. One observer re-delineated
the same structure for evaluating intraoperator variability. Data of uterine volume,
uterine centre of mass (COM), and maximum uterine lengths, in three orthogonal
directions, were analyzed.
Results: In 53% of the C-US probe scans the whole uterus was captured, compared
with 89% using the A-US probe. F-test on 36 scans demonstrated statistically sig-
nificant differences in interobserver COM SD when comparing the C-US with the
A-US probe for the I/S (p < 0.006), L/R (p < 0.012) and A/P-directions (p < 0.001).
The median of the inter-observer COM distance (Euclidean distance for 36 scans)
was reduced from 8.5 mm (C-US) to 6.0 mm (A-US). An F-test on 36 scans showed
strong significant differences (p < 0.000006) in SD of the Euclidean interobserver
distance when comparing the C-US with the A-US scans. The average dice coefficient
when comparing the two observers was 0.67 (C-US) and 0.75 (A-US). The predictive
interval demonstrated better inter-observer delineation concordance using the A-US
119
120
Paper E. Evaluation of uterine ultrasound imaging in cervical radiotherapy; a comparison of
autoscan and conventional probe
probe.
Conclusions: The A-US probe imaging might be a better choice of image-guided
radiotherapy system for correcting for daily uterine positional changes in cervical
radiotherapy.
Keywords: Ultrasound, uterus, target, radiotherapy, 3D probe, delineation variability,
inter-observer, intra-observer.
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TCARTSBA  
dnuorgkcaB  : civrec nI a laitnesse si ti ,yparehtoidar l   yltcerroc si noitisop eniretu eht taht
denimreted   ot roirp  eht  etaulave ot saw yduts siht fo mia ehT .yreviled tnemtaert  levon a
 dnuosartlu nacsotua (A- SU  eborp )  yb ti gnirapmoc   lanoitnevnoc a ot ( SU C- SU ) eborp . 
:sdohteM  erew sreetnulov yhtlaeh eniN  SU  dennacs  ,srotarepo neves yb   gnisu  eht  ®ytiralC
®ytiralC( metsys  .)nedewS ,mlohkcotS ,atkelE ,  latot nI  27 C eht morf 63 ;snacs - SU   launam(
)gnipeews  A eht morf 63 dna - SU  .deriuqca erew ,)gnipeews citamotua( eborp   srevresbo owT
t detaeniled u eh erutcurts eniret  . r revresbo enO e- as eht detaeniled erutcurts em  artni gnitaulave rof -
 .ytilibairav rotarepo )MOC( ssam fo ertnec eniretu ,emulov eniretu fo ataD ,  eniretu mumixam dna
l shtgne ,snoitcerid lanogohtro eerht ni ,  dezylana erew  .  
:stluseR   eht fo %35 nI C- SU   %98 htiw derapmoc ,derutpac saw suretu elohw eht snacs eborp
 eht gnisu A- SU  .eborp  F-  no tset  ni secnereffid tnacifingis yllacitsitats detartsnomed snacs 63 retni -
revresbo   MOC  DS C eht gnirapmoc nehw - A eht htiw SU - ( S/I eht rof eborp SU  p ( R/L ,)600.0 <  p
0.0 < 1 P/A dna )2 - ( snoitcerid  p 100.0 < )  ehT .  eht fo naidem retni - revresbo  ecnatsid MOC  
ecnatsid naedilcuE(  snacs 63 rof ) ( mm 5.8 morf decuder saw C- SU ( mm 0.6 ot ) A- SU  .) F nA -  tset
 snacs 63 no dewohs  gis gnorts  secnereffid tnacifin (  p 000.0 < 600 ni )  eht fo DS   naedilcuE retni -
revresbo   ecnatsid C eht gnirapmoc nehw - A eht htiw SU - SU  snacs  .  ehT  egareva  tneiciffeoc ecid
srevresbo owt eht gnirapmoc nehw  ( 76.0 saw C- SU ( 57.0 dna ) A- SU  lavretni evitciderp ehT .)
detartsnomed   retteb retni - revresbo   eht gnisu ecnadrocnoc noitaeniled A- SU   .eborp  
:snoisulcnoC  ehT  A- SU   gnigami eborp  eb thgim  a retteb   eciohc fo  egami -  yparehtoidar dediug
.yparehtoidar lacivrec ni segnahc lanoitisop eniretu yliad rof gnitcerroc rof metsys  
sdrowyeK ,tegrat ,suretu ,dnuosartlU :  retni ,ytilibairav noitaeniled ,eborp D3 ,yparehtoidar - artni ,revresbo - .revresbo  
 
 
dnuorgkcaB  
 yparehtoidar lacivrec nI putes dna noisserger ruomut ,noitom nagro   ,rucco yam snoitairav  dna
 erofereht  yliad erp - tnemtaert   si gnigami noitacifirev elbarised  )2,1(  .  ,yltneceR  suoirav  SU D3 smetsys  
evah   evisnepxeni evitanretla sa decudortni neeb  yparehtoidar dediug egami ( TRGI )  eht sa hcus ,  ®ytiralC
 metsys  ,mlohkcotS ,atkelE ,00C013 ledoM ®ytiralC( )nedewS  3( – )5 . 
 lacivrec nI  TRGI  gnisu ni segnellahc emos era ereht SU   metsys gnigami retni sa hcus -  rotarepo
 gnimrofrep elihw ytilibairav lanimodbasnart  snacs  )6( .  yliad taht si kcabward rehtonA SU   erusserp eborp
 nagro esuac thgim snoitairav at dna  tegr tnemecalpsid  )7(  . rec no erutaretil detimil si erehT  tub ,nacs SU xiv
 .gninnacs SU etatsorp no srepap ynam  rucco thgim tnemecalpsid etatsorp taht demialc evah seiduts emoS
erusserp eborp ot eud  8( – )01  elihw ,  taht detaluceps evah srehto  suretu no tcapmi eht tnemecalpsid   ssel si
 tnacifingis )11(  .  
 ehT ( SU lanoitnevnoc C- SU )  desu yltneuqerf a si eborp SU   ytiralC eht ,elpmaxe roF .metsys TRGI C-
SU   a ,eborp lanimodbasnart  loot gnigami , eriuqca nac  SU  segami  etatsorp eht fo  enalp lasrevsnart eht ni  ,
 .euqinhcet peews launam a gnisu SU  eriuqer suretu eht fo gninnacs  a peews -  saw hcihw ,euqinhcet edils
 eb ot nwohs emosrebmuc  dnu ot dael thgim dna retni derise - tilibairav rotarepo y )21( .  srotarepo ,revoeroM
etu eht gniyfitnedi ni egnellahc lausiv a ecneirepxe hguoht ,enalp lasrevsnart eht ni sur   ylisae si ti yllamron
ttigas eht ni elbazingocer  .enalp la lC levon a ,yduts siht nI A( SU nacsotua ytira -  eborp )SU  ot dezilitu saw
  .enalp lattigas eht ni segami eriuqca  ehT  citamotuaimes A- SU  eborp   a stirehni  yllacinahcem  dezirotom
 gnilbane ,daeh  citamotua lanimodbasnart   retfa snacs peews launam  gninoitisop  eborp eht fo   evoba  eht
sisyhpmys sibup . A ehT -  SU  eborp a fo noitacifidom a si   nacsotua  eborp )31(  taht   saw yllaitini   dengised
 rof dna gninnacs etatsorp laenirepsnart  laer -  fo gnikcart emit  eht etatsorp ,  sserdda ot lanoitcarfartni   etatsorp
 .noitom A levon eht taht saw yduts tneserp eht fo sisehtopyh ehT - yam eborp SU   TRGI retteb a eb
naht evitanretla  C lanoitnevnoc eht - .yparehtoidar lacivrec ni eborp SU  
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sdohteM  
 
sreetnuloV  
 ,sreetnulov yhtlaeh eniN  htiw  a ega naem  fo  sraey 44  /72( 75 ) xis yb dennacs erew ,   ypareht noitaidar
stsigolonhcet  ( sTTR )  gnisu ,tsicisyhp eno dna C- SU   dna A-  SU  .seborp  eht yb devorppa saw yduts ehT
eettimmoc lacihte lanoitan dna ,  v i yratnulo nesnoc demrofn  hcae rof deniatbo saw t tnapicitrap   ot gnidrocca
 eht dlroW  D noitaicossA lacideM knisleH fo noitaralce i )0002/5791( .  a ni decalp erew sreetnulov ehT
eht tuohguorht llits niamer ot detcurtsni dna noitisop enipus   tneuqesbus nacs s  . T  egami retteb erusne o
reddalb etaredom a htiw ylpmoc ot detseuqer erew sreetnulov eht ,ytilauq -  .locotorp gnillif  
 
dnuosartlu ytiralC  metsys  
ehT  ytiralC  fo stsisnoc   owt  elibom stinu   ni eno( )TC( yhpargomot retupmoc eht   dnoces eht dna moor
 tnemtaert eht ni moor ) hcihw ,  cennoc era revres/noitatskrow a hguorht det ehT .   rof desu saw noitatskrow
 ,noitaeniled tegrat  gnirusaem htgnel eniretu  emulov eht gniveirter sa llew sa  )ytiralC yb detaluclac(  ,
 dna ecnatsid retni - revresbo  .palrevo emulov eniretu  fo sliateD   SU  D3  egami noitcurtsnocer  noisicerp dna s
era metsys eht fo   ylhguoroht denialpxe  yduts suoiverp a ni )6( trohs nI . gniliec a , -  )RI( derarfni detnuom
 eht gnikcart fo elbapac ,aremac SU  tinom yb seborp RI eht gniro - srotcelfer   rof lartnec si ,meht ot dexiffa
snocer eht fo noitisop lacihpargoeg eht gninimreted rt serutcurts lacimotana detcu  f .lppuS( )1 erugi  .  
 
C- SU   dna A- SU  seborp  
 ehT C- SU   a fo stsisnoc eborp  fo yarra recudsnart emele 821 lartnec gnisu ,stn   ycneuqerf fo  zHM 4.3  .
 ehT si eborp  htiw dedivorp  srotcelfer RI   dexif  ni yaw a  eb nac taht   eht yb detceted  detnuom gniliec RI -
aremac  f .lppuS( ))F ,D ,A( 1 erugi  ,ecnatsni rof ,eborp eht fi srotcelfer eht tceted tonnac aremac ehT .
 denrut siht ,suht ,seerged 09  gnitcirtser   noitisiuqca egami ot   eht enalp lasrevsnart  ylno  .  eborp eht ,yllaitinI
 sdrawkcab detlit si lanigav eht ezilacol ot  noiger yb dewollof ,   lacitrev eht ot gnipeews  .noitisop
lov eniretu eht fo flah yletamixorppA peews eht yb derutpac eb nac emu  si euqinhcet edils lainarc a suht ,
.suretu eht fo tser eht revoc ot deriuqer  
 ehT A- SU  s eht sesirpmoc eborp  fo epyt ralimi htiw tub ,recudsnart   a ycneuqerf lartnec  fo  zHM 5  .
 ehT .enalp lattigas eht ni deifitnedi si erutcurts eniretu derised eht ,nacs eht gniriuqca ot roirp dna yllaitinI
 citamotuaimes lanimodbasnart   si nacs deveihca  tnec eht gnizilacol yb r  la ecils   neht dna suretu eht fo
peews yllacitamotua ot daeh dezirotom eht gniwolla       .emulov eniretu eht revo  
               
 noitaeniled nagro dna noitisiuqca egamI  
C ehT - erew segami eborp SU  pmirepus A eht otno deso - segami eborp SU  .  dna BM( srevresbo owT
DT )C ,tsilaiceps SU a dna tsicisyhp a ,   erutcurts eniretu eht detaeniled yltnednepedni  deriuqca 27 eht ni
C eht morf 63 ;snacs - A eht morf 63 dna SU - SU  .eborp   enimreted ot devres serutcurts eniretu deniltuo ehT
retni - revresbo   .ytilibairav gniruotnoc  ,skeew owt yletamixorppa retfA  eht revresbo  BM  uotnocer  eht der
 etagitsevni ot suretu artni - revresbo  ytilibairav .  sa tuo deirrac syawla saw erudecorp noitaeniled suretu ehT
 :swollof  ni secils eerht ni detaeniled tsrif saw suretu ehT o ;enalp lasrevsnart eht lainarc eht ni ecils en ,  dna
 ni ecils eno sgnidne larehpirep eniretu laduac eht  a dna ,  eht fo ertnec eht ni driht suretu  eht ,yldnoceS .
 saw suretu  eht ni deniltuo  lartnec  lattigas ecils  ,yllaniF .  sruotnoc nward yllaunam no desab  eht metsys ’  s
a noitatnemges  eht fo sgnittes level dna wodniw emas ehT .suretu elohw eht tnemges ot desu saw mhtirogl
srevresbo htob rof desu erew mhtirogla noitatnemges .  cimanyd etercsid a no desab si mhtirogla ehT
.mhtirogla )CDD( gniruotnoc   yllacisaB , ti  ruotnoc laitini na htiw strats   ni stniop eht sevom dna  dedarg a
ecneuqes   secrof lanretni dna )egami eht ni stneidarg sdrawot stniop hsup taht( secrof lanretxe ecnalab ot
)ssenhtooms niatniam taht(  )51,41( . ew serutcurts eniretu detaeniled ehT o :spuorg owt otni deifissalc er  en
snacs tseb eht htiw rehto eht dna snacs lla htiw   htob erehw snacs( C- A dna SU -  SU ami seg   eht dewohs
suretu elohw ). 
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sisylana lacitsitats dna noitcelloc ataD  
ehT  retni - revresbo   revresbo dna )1 SBO( eno revresbo neewteb noitisop MOC eniretu ni secnereffid
roirefnI eht ni detaluclac erew )2 SBO( owt - tfeL ,)S/I( roirepuS - roiretnA dna )R/L( thgiR -  )P/A( roiretsoP
d dradnats 1 ±( naem llarevo eht ,eromrehtruF .ylevitcepser ,snoitcerid  secnereffid eht fo ))DS( noitaive
 eht erapmoc ot detaluclac saw C- SU   dna A- SU  htgnel eniretu mumixam eht ,revoeroM .snacs eborp  
( )suretu detaeniled eht fo htgnel tsegral  ni derusaem saw  snoitcerid eerht eht  . t ,yllaniF eh   ecaps naedilcuE
ecnatsid  rotcev D3( ) b MOC fo  saw 2 SBO dna 1 SBO neewte  eht htob rof detaluclac C- SU   eht dna A- SU  
 .snacs eborp  
F na ,noitidda nI - deilppa saw tset   ni ecnairav eht erapmoc ot retni - revresbo   eht rof secnereffid MOC
C- SU   eht dna A- SU   on saw ereht taht saw sisehtopyh llun ehT .snoitcerid lanidrac eerht lla ni seborp
p ehT .ecnairav ni ecnereffid tnacifingis -  .)IC( lavretni ecnedifnoc %59 a rof detaluclac erew seulav
S itciderp eht etartsulli ot deilppa saw ecnerefni evitciderp lacitsitat  ni 2 SBO dna 1 SBO rof lavretni no
 eht gnirapmoc nehw ,emulov eniretu eht gninimreted C- SU   dna A- SU   evitciderp eht ,ylralimiS .seborp
nesnerøS ro tneiciffeoc eciD eht ,yllaniF .htgnel eniretu mumixam eht no deilppa saw ecnerefni -  eciD
ID( xedni  ) ezilitu saw  1 SBO yb deniltuo emulov eniretu fo palrevo eht kcehc ot d  )1V( 2 SBO dna   )2V(
1 noitauqe( tsitats dna atad eht roF  .)  lacitsitats eht sisylana laci margorp  R ( 3.51.2 noisrev ) .desu saw  
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stluseR  noissucsid dna  
1 erugiF  )B ,A( setartsulli   eht taht A- SU   eborp  htiw segami dleiy nac  ylthgils  retteb  laitaps  noituloser
 eht naht C- SU  1 erugiF ,yllanoitiddA .eborp   )D ,C(  seifilpmexe a  suretu nacs ,  si egami eht erehw
 eht gnisu etelpmocni C- SU   elihw enalp lasrevsnart eht ni suretu eht gniyfitnedi ytluciffid ot eud ,eborp
noiger civlep eht gninnacs yllaunam ni derutpac saw suretu elohw eht ,tluser a sA .  ylno   snacs )%35( 91
 eht gnisu C- SU   eht rof erugif gnidnopserroc eht saerehw ,eborp A- SU   .)%98( 23 saw eborp  
1 elbaT  t sezirammus  eh  detaluclac  fo naem llarevo retni - revresbo   eht gnisu secnereffid MOC C- SU  
 dna A- SU  seborp  eht ,ylralimiS .snoitcerid lanogohtro eerht lla ni  detupmoc   fo naem artni - revresbo   MOC
secnereffid  detalubat era  eht gnirapmoc nehW . A- SU   eht htiw C- SU   ,eborp  saw DS ni noitcuder eht
lacitsitats yl  ingis  tnacif F( -  )tset oitcerid eerht lla ni t ,sn  gnieb noitpecxe ylno eh artni - revresbo   snoitaeniled
P/A eht ni -  tsegral eht ,yllanoitiddA .noitcerid retni - revresbo  P/A eht ni mm 32 saw ecnereffid -  noitcerid
 eht gnisu C- SU  S/I eht ni mm 9 saw eulav tsegral eht saerehw ,eborp -  eht gnisu nehw noitcerid A- SU  
t ,yllaniF .eborp  eb ot dnuof saw DS tsegral eh  rof mm 6.6 retni - revresbo  P/A eht ni secnereffid MOC -
 eht gnisu noitcerid C- SU   .eborp  
F eht fo noitacilppA - itats detartsnomed snacs 63 lla no tset rof DS tnereffid tnacifingis yllacits  retni -
revresbo  hw MOC  eht gnirapmoc ne C- SU   eht htiw A- SU  ( S/I eht rof eborp  p ( R/L ,)600.0 <  p 0.0 < 1  )2
P/A dna - ( snoitcerid  p 100.0 < F gnidnopserroc eht ,tsartnoc nI .).2 elbaT( ) - s 91 tseb eht no tset  snac
 on detacidni secnereffid tnacifingis  kaew a rof tpecxe ,  ni ecnereffid P/A eht - ( noitcerid  p  .)40.0<  
 dna retni rof secnatsid MOC naedilcuE artni - revresbo  ( detaluclac erew snacs 2 erugiF .)   roF retni -
revresbo  snacs lla dna  )A( ( mm 5.8 morf decuder saw secnatsid eht fo naidem eht , C- SU ( mm 0.6 ot ) A-
SU acs tseb eht rof saerehw ,) ( mm 3.5 morf ylno saw noitcuder eht )B( sn C- SU ( 9.4 ot ) A- SU  ,revewoH .)
 eht artni - revresbo   si ecnatsid fo naidem eht ,snacs tseb eht rof dna lla rof taht etartsulli )D ,C( shparg
 eht rehtehw fo evitcepserri ,mm 0.5 dnuora C- SU   ro A- SU   .deyolpme saw eborp F na ,revoeroM -  tset
 dna snacs lla rof taht delaever retni - revresbo   ni secnereffid tnacifingis gnorts erew ereht ,ecnatsid MOC
DS   eht gnirapmoc nehw C- SU   eht htiw A- SU  ( snacs eborp  p  ton saw ecnereffid eht ,revewoH .)1000.0 <
 rof tnacifingis artni - revresbo  .secnatsid  
detaluclac saw emulov eniretu naem ehT  mc 95 ± 711 sa 3 mc 46 ± 521 dna 3  eht rof C- SU   eht dna A-
SU  xedni tneiciffeoc ecid ehT .ylevitcepser ,snacs eborp   naem( retni - revresbo )  dna 76.0 sa detaluclac saw
 eht rof 57.0 C- SU   dna A- SU  ,snacs eborp  ylevitcepser  sisylana noisserger gniylppa nehw ,eromrehtruF .
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 lavretni detciderp eht ,2 SBO fo emulov eniretu eht fo noitcnuf a sa 1 SBO fo emulov eniretu eht rof
degnahcnu tsomla deniamer )senil dehsad(  irapmoc nehw  lla gn C- SU   dna A- SU  3 erugiF( snacs   ,A  .)B
 eht rof rellams ylsuoivbo saw lavretni eht ,snacs tseb eht rof ,revewoH A- SU   eht rof naht C- SU   snacs
3 erugiF(   rof emulov eniretu eht gnisylana nehw ,revoeroM .)D ,C artni - revresbo  lavretni detciderp eht ,
 eht rof decuder yltnacifingis saw A- SU  derapmoc   eht htiw C- SU  snacs tseb eht rof dna lla rof ,snacs  
3 erugiF(  E- )H . 
htgnel eniretu mumixam no deilppa saw lavretni evitciderp eht ,yllaniF  4 erugiF( snacs 63 lla rof  ehT .)
A- SU   eht htiw derapmoc lavretni evitciderp reworran/rellams delaever snacs C- SU   eht ni yllaicepse ,snacs
P/A dna S/I             .snoitcerid  
 lanimodbasnarT SU   neeb sah gnigami retni etatsorp sa desu -  ,egdelwonk ruo ot ,tub TRGI noitcarf
gami hcus gniyolpme seiduts wef yrev era ereht  gni lanretxe ni  lacivrec  airt lacinilc A .yparehtoidar  a rof l
 lacivrec yparehtyhcarb   291 gnisirpmoc yduts  no desab ,stneitap lanimodbasnart  SU  nacs  yltnecer saw ,
 dehsilbup )61(  derapmoc yduts ehT . SU   htiw gnigami ( gnigami ecnanoser citengam IRM )  dna ytiladom
 eht taht detartsnomed SU   rehtonA .ytiladom dediug egami evitanretla na sa IRM ecalper nac nacs
yhcarb ypareht  yduts  )71(  ,  osla  gniylppa SU  gnigami IRM susrev nacs lanimodbasnart  dna   02 gnidulcni
 esaesid lartnec dna lacivrec ,eniretu ni seitiladom eht neewteb noitalerroc gnorts a deifirev ,stneitap
 suoiverp a nI .snoitaeniled  yduts SU  ytiralC eht fo C- SU   dna sorp eht ,stneitap recnac lacivrec no eborp
 eht fo snoc C- SU   desserdda erew metsys eborp 21( ) retnI . - po  ni ytluciffid ot eud seitniatrecnu rotare
peews gnimrofrep -  eht fo esu eht timil erusserp eborp ni noitairav ot noitidda ni gnigami edils C- SU   eborp
a sa  .metsys TRGI lacivrec  eht fo ytilauq llarevo eht ,suhT  deriuqca  a si egami SU  a fo tluser   noitanibmoc
gnimmets srotcaf tnereffid fo ylralucitrap ,  rotarepo eht s’  .ecnamrofrep   fo noitaicossA naciremA ehT
fo gniniart SU lacinilc taht sesserts )MPAA( enicideM ni stsicisyhP  si srotarepo eht   ecnenimorp tsomtu fo
81( )  .  
A ehT -  desu recudsnart SU stirehni yduts siht ni   lacitnedi  eht sa scitsiretcarahc laer -  gnirotinom emit
 nacsotua )31(  laenirepsnart rof dengised yllaitini , gnikcart etatsorp  , tub   ot deifidom mrofrep  
 lanimodbasnart gnigami saw metsys eht ecniS .   htiw dedivorp ton  a  dna ,mra citobor saw erawtfos ruo   ton
er rof detpada la - saw eborp eht ,gnirotinom emit   fo elbapacni laer -  emit  gnikcart  fo ,suretu eht   elbanu suht
artni enimreted ot .etagitsevni ot dleif gnitseretni na eb dluow esiwrehto hcihw ,noitom lanoitcarf   nevE
 on si ereht hguoht yduts  gniylppa gnidrager   laenirepsnart rof nacs  NYG eht - stneitap  ,  siht fi luftbuod si ti
yllacinilc si euqinhcet   eniretu egral eht dna serutcurts lacimotana elamef eht fo ytixelpmoc ot eud elbissop
.emulov    
srotarepo eht llA  yduts tnerruc eht ni   taht detroper  eht eldnah ot reisae saw ti A- SU   ylralucitrap ,eborp
 saw noitisiuqca egami ,eromrehtruF .enalp lattigas eht ni reddalb dna suretu eht gniyfitnedi nehw
 erusserp eborp ssel dna ylkciuq erom demrofrep  saw  gnirud detrexe A- SU   eht revoeroM .gninnacs eborp
 eht fo liated egami A- SU  s saw nacs eborp ylthgil   eht fo taht naht retteb C- SU  1 erugiF( eborp  nosaer eht ,)
 rehgih eht gnieb recudsnart   retteb sedivorp ycneuqerf rehgih ehT .remrof eht ni desu ycneuqerf  laitaps
retal dna laixa( )la  noituloser .  eht taht delaever yduts eht ,yllanoitiddA A- SU  roirepus si   eht ot C- SU   eborp
emulov eniretu elohw eht gnirutpac rof  ( f .lppuS 1 erugi   .)D ,C  
 eht taht detartsnomed secnereffid MOC eht fo DS ehT A- SU  retni ssel ni detluser snacs eborp -  dna
ni art - revresbo  ytilibairav T .  eh A- SU  osla dedleiy eborp   eerht lla ni ecnereffid MOC naidem rewol a
snoitcerid . snacs tseb eht rof ,revewoH   eht F- detacidni tset   ot eud secnereffid tnacifingis yllacitsitats on
 retteb retni - revresbo   eht fo evitcepserri ,degami suretu elohw eht htiw snacs rof ecnadrocnoc noitaeniled
 eht gninimaxe yb tniop MOC eniretu eht fo noitagitsevni rehtruf detnarraw sgnidnif esehT .eborp fo epyt
 eht neewteb ecnatsid ecaps naedilcuE C- SU   dna A- SU  ehT .MOC eniretu  retni - revresbo   fo tolpxob
secnatsid naedilcuE   eht htiw mm 5.2 fo noitcuder ecnatsid naidem a delaever A- SU  eborp .  ,revewoH
 eht yb dedivorp tifeneb eht ,)snacs tseb( degami saw emulov eniretu elohw eht nehw A- SU   si eborp
nim ( lami 2 erugiF  B)  .  
iretu eno sA  eht ,emulov eniretu egral deniltuo eht no atad laitnatsbus laever ton did tniop MOC en
 retteb detacidni lavretni evitciderp ehT .denimaxe saw snoitcerid eerht lla ni htgnel eniretu mumixam
retni - revresbo   eht gniylppa nehw ecnadrocnoc A- SU   eht ot derapmoc C- SU   tifeneb eht ,revewoH .eborp
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R/L eht ni detimil saw -  eht htob ni noituloser egami laretal roop eht ot detubirtta eb nac hcihw ,noitcerid C-
SU   eht dna A- SU   tcatni na htiw stneitap no desab yduts suoiverp a htiw llew seerga sihT .snacs eborp
 suretu 91( )  eht fo noituloser laitaps retteb ot eud ,sselehtreveN . A- SU  ami eborp  ,enalp lattigas eht ni seg
reddalb ,sudnuf eht fo ytiniciv eht ni yllaicepse -  srevresbo eht ,suretu eht fo trap roiretsop eht dna suretu
 eht gnisu nehw naht tnetsisnoc erom erew C- SU   .segami eborp  
ehT  DS egral  emulov eniretu eht fo   tnacifingis smrifnoc tni re - revresbo   sihT .ytilibairav gniruotnoc
 eht ni taht tcaf eht morf tluser dluoc “ snacs lla ”  a ,puorg snacs fo rebmun   eht fo egami na niatnoc ton od
oitairav regral ot gnidael ,trap gnissim eht detamitse srevresbo eht erofereht dna suretu elohw  rehtonA .sn
r  erutcurts eniretu eht gniruotnoc ni egnellahc eht eb thgim nosae  regral erehw ,noiger lanigav eht ni retni -
revresbo   ot senilediug noitaeniled tegrat rof deen eht tseggus stluser esehT .detapicitna erew snoitaived
gih suht dna ycnetsisnoc gniruotnoc evorpmi  reh retni - revresbo   siht ezisahpme oT .ecnadrocnoc laitaps
a dewollof ylekil tsom revresbo emas eht taht detacidni lavretni evitciderp eht ,ytissecen   ralimis
ot gnidael erudecorp noitaeniled   ssel artni - revresbo   ni ecnadrocsid eht htiw derapmoc ytilibairav i retn -
revresbo  .noitaeniled   
 eht gnisu ecnadrocnoc doog deifirev xedni tneiciffeoc ecid ehT A- SU   ylno tub )57.0 = IC( eborp
 eht htiw ecnadrocnoc tsedom C- SU  eborp  )76.0 = IC(  tsehgih ehT . retni - revresbo   morf smets ecnadrocsid
 eht gnisu suretu degami eht fo trap gnissim eht ni noitatnemges eniretu etaruccani C- SU   ehT .eborp
 tluser tneserp  elbarapmoc si   yduts noitaeniled airtemarap dna anigav ,suretu ,xivrec desab TC/IRM a ot
02( ) eirepxe 91 yb demrofrep appak eht erehw ,srevresbo decn - eulav , t citsitats a  erusaem ot loo retni -
revresbo  ,tnemeerga palrevo  .75.0 saw noitaeniled eniretu rof  
 eht gnisu fo stluser gnisimorp etipseD A- SU   ,TRGI rof eborp  morf gnireffus yduts tneserp eht
snoitatimil lacitsitats c no detacilper eb dluohs yduts reetnulov siht ,yltsriF . stneitap recnac lacivre  ,
regral gnidulcni   dna stnapicitrap fo rebmun fo rebmun retaerg a  snacs deriuqca  ,nac ruomut lacivrec ehT .
tu eht fo epahs lautca eht mrofed dna egral eb ,ecnatsni rof retaerg ot gnidael ylbissop ,sure  retni - revresbo  
 sreetnulov ruo fo taht naht rehgih yllamron si stneitap fo ega naem eht ,yldnoceS .ytilibairav noitaeniled
taht decneirepxe ew ,yduts tneserp eht nI .)sraey 44(   ni yllausiv yfitnedi ot reisae saw erutcurts eniretu eht
sreetnulov regnuoy eht grat ,yldrihT .  dezilaiceps lareves yb demrofrep eb ylbareferp dluohs gniruotnoc te
 .stsigolocno ro/dna stsigoloidar sisylana egami evitatitnauq a ,yltsaL   eht fo C- SU   dna A- SU   segami eborp
 si yduts erutuf rof dednemmocer .      
 
noisulcnoC s 
 ehT A- SU  orp  eb thgim gnigami eb a retteb   eht naht ytiladom C- SU   retteb fo smret ni gnigami eborp
 ,noituloser laitaps fo erutpac eht gnitatilicaf  suretu elohw eht , ppa ssel dna  ruo nI .erusserp eborp deil
t ,stluser  eh A- SU   eborp dael  retni ssel ot - tneuqesnoc dna ytilibairav rotarepo  .snoitairav gniruotnoc ssel yl
 eht ,noisulcnoc nI A- SU   ot derapmoc eborp C- SU   eborp SU  eb thgim gnigami   retteb  rof metsys TRGI
.yparehtoidar lacivrec ni segnahc lanoitisop eniretu yliad rof gnitcerroc  
 
 :stseretni gnitepmoC h yeht taht eralced )s(rohtua ehT stseretni gnitepmoc on eva  
 
 :snoitubirtnoc ’srohtuA  ,yduts eht gningised ni detapicitrap ,snoitaeniled eniretu eht tuo deirrac BM
 deirrac CTD .tpircsunam eht detfard dna tnemngila ecneuqes eht tuo deirrac ,sisylana lacitsitats demrofrep
eniled tegrat tuo ta BFC .snoi  etapicitrap tpircsunam eht gnisiver ,yduts eht fo ngised eht ni d  srohtua llA .
.tpircsunam lanif eht devorppa dna daer  
 
stnemegdelwonkcA  
eW  ekil dluow  su depleh ohw seugaelloc ruo lla knaht ot  ;yduts siht tcudnoc ot   ,)TTR( .L rednalluG
rehpargoidar( S gnahzaP ,)TTR( S nossbocaJ ,)TTR( T praZ ,)TTR( K .S nesredeP  )  K .V purennyL dna
.)rehpargoidar(  .yduts siht rof troppus s’atkelE egdelwonkca ot ekil osla dluow eW  
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secnerefeR  
 .1   fo esruoc eht gnirud noitom dna noisserger xivreC .la te ,M ruophelaS ,A nargnihJ ,MB eldaeB
 ;9002 .]tenretnI[ syhP loiB locnO taidaR J tnI .recnac lacivrec rof noitaidaromehc maeb lanretxe
532:)1(37 – .14  
 .2  ,a M rediaH ,R llewinniD ,P nahC   .la te retnI -  ni tnemevom nagro dna romut lanoitcarfartni dna
citamenic a :yparehtoidar gniogrednu recnac lacivrec htiw stneitap - tniop IRM - fo -  tnI .yduts tseretni
8002 .syhP loiB locnO taidaR J  ; 7051:)5(07 – .51  
 .3  retnI .FC snerheB ,AJ nesneJ ,M rekaB - rav rotarepo eerht gnisu noitisop eniretu gninifed ni ytilibai -
 .)SUI( muisopmyS scinosartlU lanoitanretnI EEEI 3102 .gnigami dnuosartlu lanoisnemid
3102 ; 848 – .15  
 .4  C  ,L imahuoS ,G aduonehS ,BLF yru dnuosartlU .la te -  rof yparehtoidar dediug egami desab
 :recnac etatsorp ssorc fo nosirapmoc -  noitazilacol yliad rof sdohtem ytiladomartni dna ytiladom
syhP loiB locnO taidaR J tnI .yparehtoidar maeb lanretxe gnirud 6002 . 2651:)5(66; –6 .7  
 .5  hcsruP ,M awakniP - egamI .la te ,B ruopdasA ,M eeL - recnac etatsorp rof yparehtoidar dediug  .
dnuosartlu fo noitatnemelpmI - retni fo sisylana eht rof noitazilacol etatsorp desab -  noitcarfartni dna
loknO rehtnelhartS .noitom nagro 8002 . 976:)21(481; – .58  
 .6  nemeolB ,S reeM red naV - D3 ytiladomartni fo tnemssessa lacitirC .la te ,J snamreH ,E pruG nav  
707170:04;3102 .syhP deM .srekram laicudif ot derapmoc TRGI etatsorp rof gnigami dnuosartlu –  1
– 707170 – .11  
 .7   ,V J euqsebeL ,PHM snamstimS ,X nangitrA .la te   rof ecnadiug egami dnuosartlu enilnO
oitisiuqca egami fo tcapmi :recnac etatsorp fo yparehtoidar  taidaR J tnI .tnemecalpsid etatsorp no n
4002 .syhP loiB locnO 595:)2(95; – .106  
 .8   etatsorp ni rorre fo ecruos a sa erusserp eborp dnuosartlU .M atagoF ,J uyR ,PJ nahaGcM
:)3(06;4002 .syhP loiB locnO taidaR J tnI .yparehtoidar maeb lanretxe rof noitazilacol 887 – .39  
 .9   ,JS kriksuB ,JS nibgnuhC ,FC ogareS .la te   rof noitazilacol dnuosartlu htiw ecneirepxe laitinI
syhP loiB locnO taidaR J tnI .yparehtoidar maeb lanretxe rof stneitap recnac etatsorp gninoitisop  .
2002 0311:)5(35; –3 .8  
 .01  reigraF - selserP ,M norioV   etatsorp no ytilibairav erusserp eborp fo tcapmI .la te ,P reimmoP ,B
dnuosartlu rof noitazilacol - egami desab - 231:)1(111;4102 .locnO rehtoidaR .yparehtoidar dediug – .7  
 .11  relhuJ ,M rekaB - iretu no erusserp eborp dnuosartlu fo tcapmI .FC snerheB ,T purttøN  lanoitisop en
385:)6(01;4102 .htlaeH snemoW .stneitap recnac cigolocenyg ni tnemecalpsid –5 .09  
 .21  ni gninimreteD .M rekaB ret -  gnirud gnigami dnuosartlu D3 gnisu suretu eht fo noitom lanoitcarf
ar  .recnac lacivrec rof yparehtoid osartlU :gnigamI lacideM eipS  .hpargomoT dna gnigamI cin
;4102 .0409 eipS  
 .31   nacsotuA ytiralC eht htiw tnemeganam noitom etatsorp lanoitcarfartnI .T oclaF ,M eniahcaL
27:)1(1;3102 .tnI syhP deM .metsys – .08  
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 .41  i SURT D3 ni noitatnemges etatsorp tsaF .la te ,I vokscayG ,B uihC ,M gniD  no desab segam
.9014:)11(43;7002 .syhP deM .ledom evissergerotua na gnisu tniartsnoc ytiunitnoc  
 .51   ,Y gnaW ,C nehC ,M gniD  .la te lanidrac eht gnisu segami SU D3 ni noitatnemges etatsorP - enilps -
.ruotnoc cimanyd etercsid desab   eipS fo sgnideecorP -  eht  lacitpO rof yteicoS lanoitanretnI
3002 .gnireenignE ; 96 –  .67  
 .61  ymasladnoK ,S kyD naV -  ,M redienhcS ,S navasekannehC .la te   fo stnemerusaem fo nosirapmoC
 ot gnigami dnuosartlu lanimodbasnart dna ecnanoser citengam yb deniatbo xivrec dna suretu eht
yfitnedi  syhP loiB locnO taidaR J tnI .recnac xivrec htiw stneitap ni tegrat yparehtyhcarb eht  .
4102 068:)4(88; – .5  
 .71  snarT .la te ,J sadimawS ,N annahK ,U yttehstnahaM -  citengam dna )SU( dnuosartlu lanimodba
artni lamrofnoc rof noitalerroc )IRM( gnigami ecnanoser  fo amonicrac ni yparehtyhcarb yrativac
031:)1(201;2102 .locnO rehtoidaR .xivrec eniretu eht – .4  
81  .   ,A civokraM ,G nahC ,AJ yolloM .S.U fo ecnarussa ytilauQ .la te -  maeb lanretxe dediug
 .451 puorG ksaT MPAA fo tropeR :recnac etatsorp rof yparehtoidar hP deM sy 758:)2(83;1102 . - 17  .  
91  .   detupmoc egatlovagem yb gnigami cirtemuloV .la te ,M uaetahcuD ,B slegnE ,C nelloC
 J tnI .recnac lacivrec rof yparehtoidar gnirud noitom nagro lanretni fo tnemssessa rof yhpargomot
syhP loiB locnO taidaR 0102 . 0951:)5(77; – .5  
02 .   xivreC rof semuloV tegraT lacinilC fo noitaenileD ni ytilibairaV .la te ,W llamS ,K miL ,WA selyF
ytisnetnI recnaC - 9002 .locnO taidaR J tnI .yparehtoidaR civleP detaludom ; :)3(57,).lppuS( 38 –  .4   
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.1 ELBAT   dna retni naeM artni - revresbo  eerht eht rof MOC eniretu ni secnereffid   gnisu ,snoitcerid
C- A dna SU - .seborp SU   
 retnI - revresbo a 
naeM  ]mm[  DS1 ±  
 artnI - revresbo  
naeM  ]mm[  DS1 ±  
snoitceriD  C- SU  eborp  A- SU  eborp  C- SU  eborp  A- SU  eborp  
S/)+(I b 3.6 ± 2.3  9.3 ± 8.1  - 1.6 ± 9.0  -  ± 3.1 2.3  
R/)+(L  5.5 ± 9.0  6.3 ± 0.0  8.5 ± 2.0  - 8.3 ± 1.2  
P/)+(A  - 6.6 ± 4.0  6.3 ± 4.0  - 5.3 ± 7.0  5.3 ± 8.0  
a retnI -  :revresbo id eht artnI ;srevresbo owt neewteb secnereff - :revresbo   eht teb secnereffid  owt neew
 snoitaeniled .revresbo emas eht yb  
b  :S/I roirefnI - tfeL :R/L ;roirepuS - roiretnA :P/A ;thgiR - .roiretsoP  
 
 
.2 ELBAT  F-  fo tset retni rof DS eht - revresbo   dna retni sa llew sa secnereffid MOC eniretu artni -
revresbo   lla ni secnatsid MOC naedilcuE  eht  si tset ehT .snoitcerid lanogohtro eerht
 rof enod .snacs tseb eht dna snacs lla  
 
 snacs llA  
)63 = n(  
 snacs tseB a 
)91 = n(  
 
snoitceriD  
  fo oitaR
secnairav  
IC %59 b 
rewoL/reppU  
p  fo oitaR
secnairav  
IC %59  
rewoL/reppU  
p 
S/)+(I  16.2  )33.5 ot 33.1(  600.0  61.1  )10.3 ot 54.0(  1757.0  
R/)+(L  83.2   ot 12.1( )76.4  210.0  48.1  )77.4 ot 17.0(  7602.0  
P/)+(A  92.3  )54.6 ot 86.1(  100.0  38.2  )53.7 ot 90.1(  1330.0  
 naedilcuE
( retni - revresbo ) 
09.4  )16.9 ot 05.2(  600000.0     
 naedilcuE
( artni - revresbo ) 
38.1  )95.3 ot 39.0(  770.0     
a  ehT :snacs tseB SU  htob derutpac si suretu elohw eht erehw snacs  A eht htiw - C eht dna SU -  SU
eborp . 
b .lavretnI ecnedifnoC :IC  
 
01  
 
erugiF  1 dnuosartlU .  )SU(  segami   gnisu C- SU   dna A- SU  )A( .seborp  ami dnuosartlu 1 reetnuloV  fo eg
eht gnisu suretu dna reddalb  A- SU   .eborp  )B(  gnisu tub reetnulov emas ehT C- SU   erehw ,eborp  egami
 dna noitrotsid evresbo eb nac ytilauq egami rewol  .d  )C(  2 reetnuloV eht gnisu  A- SU   eht erehw ,eborp
 .derutpac si suretu elohw )D(  eht gnisu tub reetnulov emas ehT  C- SU  retu eht fo flah ylno erehw ,eborp  su
.degami si  
 
11  
 
2 erugiF  fo )sreksihw( egnar dna ,)xob( selitnecrep ht57 dna ht52 ,)enil latnoziroh( naideM .
 eniretu neewteb secnatsid naedilcuE ertneC  ( ssaM fo MOC )  dna ,2 SBO dna 1 SBO yb detaeniled
 revresbo emas eht  eciwt  .)1 SBO( A( B , ) reffid ecnatsiD 2 SBO sunim 1 SBO( secne rof )  eht  C- SU   dna
A- SU  a gnisu seborp snacs 63 ll   .ylevitcepser ,snacs 91 tseb dna C( D ,  owt( secnereffid ecnatsiD )
 ))1 SBO( revresbo emas eht yb snoitaeniled eht rof  C- SU   dna A- SU   lla gnisu seborp snacs 63   91 tseb dna
 .ylevitcepser ,snacs  
 
21  
 
3 erugiF  tnednepedni owt dna )D ot A( 2 SBO dna 1 SBO yb detaeniled emulov eniretu gnirapmoC .
 gnisu )H ot E( 1 SBO yb snoitaeniled C- SU   dna A- SU   thgir ;snacs 63 lla ,shparg tfeL .seborp
snacs 91 tseb ,shparg noissergeR .   %59 rof )senil dehsad( lavretni detciderp dna )senil dilos(  ecnedifnoc
( lavretni IC ) .detacidni era  
 
31  
 
4 erugiF  no 2 SBO dna 1 SBO yb htgnel eniretu mumixam eht fo nosirapmoC . C- SU   dna A- SU  
 ni snacs roirefnI - tfeL ;)S/I( roirepuS -  ;)R/L( thgiR roiretnA - )P/A( roiretsoP -  .snoitcerid  noissergeR
%59 rof )senil dehsad( lavretni detciderp dna )enil dilos( tif enil  ( lavretni ecnedifnoc IC ) .detacidni era   
 
41  
 
 latnemelppuS A( .metsys )SU( dnuosartlu ytiralC .1 erugiF C ) - A dna SU -  .seborp SU )B(   ehT
.elosnoc dnuosartlu  C(  ) ytiralC ehT  noitatskrow  . )D(   dna )E(   lanimodbasnart reetnuloV SU   yb snacs
C fo snaem - A dna SU -  .ylevitcepser ,seborp SU )F(  gniliec dna tinu elibom ytiralC ehT -  RI detnuom
.moor tnemtaert eht ni aremac  
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Abstract
Purpose/Objective: In prostate radiotherapy, it is essential that the prostate po-
sition is within the planned volume during the treatment delivery. The aim of this
study is to investigate whether intrafractional motion of the prostate is of clinical
consequence, using a novel 4D autoscan ultrasound probe.
Methods and Materials: Ten prostate patients were ultrasound (US) scanned at the
time of CT imaging and once a week during their course of radiotherapy treatment
in an ethics-approved study, using the transperineal Clarity autoscan system (Clar-
ity, Elekta Inc., Stockholm, Sweden). At each US scanning session (fraction) the
prostate was monitored for 2 to 2.5 minutes, a typical beam-on time to deliver a
RapidArc radiotherapy fraction. The patients were instructed to remain motionless
in supine position throughout the US scans. They were also requested to comply
with a bladder-filling protocol. In total, 51 monitoring curves were acquired. Data of
the prostate motion in three orthogonal directions were analyzed. Finally, the BMI
value was calculated to investigate correlation between BMI and the extent of prostate
displacement.
Results: The patients were cooperative, despite extra time for applying the TPUS
scan. The mean (±1SD) of the maximal intrafractional displacements were [mm];
I(+)/S: (0.2 ± 0.9); L(+)/R: (-0.2 ± 0.8); and A(+)/P: (- 0.2 ± 1.1), respectively.
The largest displacement was 2.8 mm in the posterior direction. The percentage of
fractions with displacements larger than 2.0 mm was 4 %, 2 %, and 10 % in the
IS, LR, and AP directions, respectively. The mean of the maximal intrafractional
Euclidean distance (3D vector) was 0.9 ± 0.6 mm. For 12 % of the fractions the
maximal 3D vector displacements were larger than 2.0 mm. At only two fractions
(4 %) displacements larger than 3.0 mm were observed. There was no correlation
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between BMI and the extent of the prostate displacement.
Conclusions: The prostate intrafractional displacement is of no clinically conse-
quence for treatment times in the order of 2 to 2.5 minutes, which is typical for a
RapidArc radiotherapy fraction. However, prostate motion should be considered for
longer treatment times e.g. if applying conventional or IMRT radiotherapy.
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 gninimreteD lanoitcarfartni   etatsorp  gnisu noitom  lanoisnemid ruof  dnuosartlu
metsys  
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kramneD ,velreH ,negahnepoC fo ytisrevinU ,latipsoH velreH ,tinU hcraeseR yparehtoidaR ,ygolocnO fo tnemtrapeD 1  
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TCARTSBA  
 
evitcejbO/esopruP  :  dennalp eht nihtiw si noitisop etatsorp eht taht laitnesse si ti ,yparehtoidar etatsorp nI
emulov   yduts siht fo mia ehT .yreviled tnemtaert eht gnirud si   ot  etagitsevni rehtehw  noitcarfartni la  
noitom  etatsorp eht fo   si  fo lacinilc  neuqesnoc ec ,  gnisu evon a .eborp dnuosartlu nacsotua D4 l  
:slairetaM dna sdohteM   erew stneitap etatsorp neT dnuosartlu  )SU(  dennacs   dna gnigami TC fo emit eht ta
 tnemtaert yparehtoidar fo esruoc rieht gnirud keew a ecno scihte na ni - gnisu ,yduts devorppa  eht  
 .)nedewS ,mlohkcotS ,.cnI atkelE ,®ytiralC( metsys nacsotua ytiralC laenirepsnart  gninnacs SU hcae tA
noitcarf( noisses  ) maeb lacipyt a ,setunim 5.2 ot 2 rof derotinom saw etatsorp eht -  a reviled ot emit no
 yparehtoidar ®crAdipaR stneitap ehT .noitcarf  rew e  niamer ot detcurtsni sselnoitom   noitisop enipus ni
eht tuohguorht  SU   .snacs yehT  osla erew  reddalb a htiw ylpmoc ot detseuqer -  .locotorp gnillif latot nI ,  15
 ataD .deriuqca erew sevruc gnirotinom  eht fo  erew snoitcerid lanogohtro eerht ni noitom etatsorp .dezylana  
 ot detaluclac saw eulav IMB eht ,yllaniF etagitsevni   dna IMB neewteb noitalerroc  eht netxe t  etatsorp fo
  .tnemecalpsid   
:stluseR   gniylppa rof emit artxe etipsed ,evitarepooc erew stneitap ehT  eht  fo )DS1±( naem ehT .nacs SUPT
 eht  lamixam 2.0( :S/)+(I ;]mm[ erew stnemecalpsid lanoitcarfartni  ± ( :R/)+(L ;)9.0 - 2.0  ± ( :P/)+(A dna ;)8.0 -
2.0  ±  fo egatnecrep ehT .noitcerid roiretsop eht ni mm 8.2 saw tnemecalpsid tsegral ehT .ylevitcepser ,)1.1
 htiw snoitcarf aw mm 0.2 naht regral stnemecalpsid 4 s  2 ,%  01 dna ,%   ,snoitcerid PA dna ,RL ,SI eht ni %
 naem ehT .ylevitcepser  lamixam eht fo  lanoitcarfartni  )rotcev D3( ecnatsid naedilcuE saw  9.0  ±  .mm 6.0  roF
 lamixam eht snoitcarf eht fo % 21 tnemecalpsid rotcev D3 s  erew mm 0.2 naht regral owt ylno tA .   snoitcarf
)%4(  stnemecalpsid  mm 0.3 naht regral  erew  devresbo .  erehT on saw  oc  eht dna IMB neewteb noitalerr
tnetxe   .tnemecalpsid etatsorp eht fo  
:snoisulcnoC  T tatsorp eh  e lanoitcarfartni  tnemecalpsid  si   on fo  yllacinilc neuqesnoc ec  ni semit tnemtaert rof  
 2 fo redro eht – setunim 5.2 ,  lacipyt si hcihw  a rof  crAdipaR  yparehtoidar noitcarf  ,revewoH .  noitom etatsorp
 eb dluohs  .g.e semit tnemtaert regnol rof deredisnoc ro lanoitnevnoc gniylppa fi   TRMI yparehtoidar .  
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noitcudortnI  
maeb lanretxe nI   dereviled ylesicerp si esod debircserp eht taht laitnesse si ti ,etatsorp eht fo yparehtoidar
etatsorp eht ot ,  etarucca yliad yb deveihca eb nac sihT .reddalb dna mutcer ot yticixot gnicuder elihw
noitacifirev lanoitisop  egami gnisu etatsorp eht fo - dediug   )TRGI( ypareht noitaidar )2,1(  ecniS .  ni noitairav
noitisop etatsorp  ( yreviled tnemtaert gnirud lanoitcarfartni  )noitom etatsorp  rucco thgim  tegrat eht , yam   eb
 tfihs etatsorp elbissop a ot eud desodrednu )4,3(  dna ,segnahc emulov latcer ,snoitairav gnillif reddalB .
 emos era noitom yrotaripser  eht fo ot dael thgim taht srotcaf  noitcarfartni  noitom etatsorp la 5( – )7   .  
 eht enimreted oT lanoitcarfartni   etatsorp noitom  seuqinhcet gnigami suoirav , neeb evah   ni detagitsevni
hcus ,seiduts tnereffid  X sa - eniC ,gnigami )VM( egatlovagem dna TCBC D3 )Vk( egatlovolik ,gnigami yar -
ni ,IRM - srekram detnalpmi ,TC moor  srednopsnart dna  dnuosartlu dna , 8( – )11 ts eht fo tsoM .  desab era seidu
erp gniriuqca no - tsop dna -  segami tnemtaert )31,21(  .  
suoiraV   era seuqinhcet depoleved  ot  lbane  e laer - gnirotinom dna noitazilacol etatsorp enilno emit ,  hcus
sa :  lacideM ospylaC( srednopsnart citengamortcele detnalpmi gnikcart T ,)AW ,elttaeS ,seigolonhce   dna
srekram laicudif gnikcart  )sMF(  laer gnisu )yparehtyhcarB ni( sdees evitcaoidar detnalpmi ro - X emit -  yar
yltneceR .gnigami ,  a ,)nedewS ,mlohkcotS ,.cnI atkelE ,®ytiralC( nacsotua )SUPT( dnuosartlu laenirepsnart
non - non ,gnizinoi - iladom gnigami evisavni  ,yt neeb sah   depoleved  ot wolla  laer -  gnikcart etatsorp emit )41(  .
V  seiduts suoira  evah  detagitsevni  eht  enimreted ot metsys ospylaC lanoitcarfartni   noitom etatsorp 51( – )91  ,
 ,revewoh t eno ylno si ereht ,egdelwonk ruo o  yduts   nesuahllaB( .la te  metsys SUPT ytiralC eht gnisu ) )02(  .
 nesuahllaB yb yduts eht nI .la te   morf atad  stneitap etatsorp 6  detagitsevni era )02( .  .la te nesuahllaB
edulcnoc s “ taht noitcarfartni  fo noitom  klaw modnar a si etatsorp eht ”  eht morf yawa sevom etatsorp eht dna
 gnirud retnecosi  nI .yreviled tnemtaert tneserp eht   eht enimreted ot dezilitu saw metsys SUPT eht ,yduts
etatsorp eht fo noitom lanoitcarfartni . 
cirtemulov sa hcus ,seuqinhcet yparehtoidar decnavda gnisU   detaludom  cra ro )TAMV( ypareht  
ygolonhceT yparehtoidaR ®crAdipaR tnemtaert eht ,   nac emit yreviled suht ,decuder yltnacifingis eb  
 gniziminim lanoitcarfartni   noitom etatsorp )22,12(  crAdipaR ,noitutitsni ruo nI .  yparehtoidar  a si s  dradnat
 euqinhcet rof  etatsorp gnitaert  recnac  maeb lacipyt a dna ,stneitap -  si noitcarf tnemtaert a rof emit no
    .setunim 5.2 yletamixorppa  
 ehT  mia  si yduts siht fo  ot i  etagitsevn  rehtehw  eht d ,noitom etatsorp lanoitcarfartni gniru   lavretni emit a
 eht ot gnidnopserroc maeb -  no  emit  rof  ,crAdipaR  si mm 0.2 nihtiw si mm 2 .   si hcihw eulav ecnarelot a
 tnavelerri yllacinilc eb ot deviecrep  erusopxE lacideM noitaidaR noitazinoI hsitirB eht ot gnidrocca
  .)0002 REMRI( 0002 snoitalugeR  
 
sdohteM dna slairetaM  
 
stneitaP  
 na htiw ,stneitap recnac etatsorp neT 85 egnar( sraey 86 fo ega egareva -  ni dennacs SU erew ,)sraey 67
moor TC eht   moor tnemtaert eht ni keew a ecno dna  llA .metsys gnirotinom SUPT D4 ytiralC eht gnizilitu
tsop  eitap ymotcetatsorp stneitap ehT .dedulcxe erew stn  fo esod evitalumuc a deviecer  67  Gy  ni 83   ,snoitcarf
noitcarf rep yG 0.2 keew rep snoitcarf 5 ,  ehT .  SUPT  ypareht noitaidar xis yb demrofrep erew snacs
 eht yb devorppa saw yduts ehT .)sTTR( stsigolonhcet hsinaD   yratnulov dna ,eettimmoc lacihte lanoitan
cae rof deniatbo saw tnesnoc demrofni  eht ot gnidrocca tnapicitrap h  noitaicossA lacideM dlroW
)0002/5791( iknisleH fo noitaralceD  niamer ot detcurtsni dna noitisop enipus a ni decalp erew stneitap ehT .
sselnoitom  ew stneitap eht ,ytilauq egami retteb erusne oT .snacs tneuqesbus eht tuohguorht  ot detseuqer er
reddalb etaredom a htiw ylpmoc -  .locotorp gnillif  
 
metsys dnuosartlu ytiralC  
 ytiralC ehT  metsys  tnemtaert eht ni dnoces eht dna moor TC eht ni eno( stinu elibom owt fo stsisnoc
 ehT .revres/noitatskrow a hguorht detcennoc era hcihw ,)moor noitaeniled tegrat rof desu saw noitatskrow  
 dna snoitcurtsnocer egami D3 SU fo sliateD .sevruc gnirotinom etatsorp eht gniveirter dna  eht  fo noisicerp
 yduts suoiverp a ni ylhguoroht denialpxe era metsys eht )32( gniliec a ,trohs nI . -  )RI( derarfni detnuom
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zingocer aremac es  eht SU  RI eht gnitceted yb eborp - xiffa srotcelfer  .meht ot de  rof laitnesse si sihT
.serutcurts lacimotana detcurtsnocer eht fo noitisop lacihpargoeg eht gninimreted  
 TC eht no eborp nacsotua D4 eht morf segami SU detcurtsnocer eht fo noitisopmirepus elbane oT
 emas eht ot detarbilac saw metsys eht ,segami  .smoor tnemtaert dna noitalumis TC eht sa metsys etanidrooc
 eht yb dedivorp motnahp tnemngila detacided a fo snaem yb dehsilpmocca saw erudecorp noitarbilac ehT
.rodnev  
 
moor TC  
nacs TC gninnalp tnemtaert a tnewrednu stneitap llA  A .nacs IRM na yb dewollof  retf  eht TC -  eht nacs
D3 - PT  SU dna noitisiuqca egami gnirud llits niamer ot detcurtsni saw tneitap ehT .deriuqca saw nacs SU
SU eht ,sdrawretfA .gnirotinom -  dna detaeniled saw emulov etatsorp eht hcihw no ,demrofrep saw noisuf TC
lkeew rof ecnerefer a sa desu  .moor tnemtaert eht ni gnigami SU y  
 
eborp nacsotuA  
nacsotua ehT -  a fo stsisnoc eborp SU  )D1( lanoisnemid eno  gnisu ,stnemele 821 fo yarra recudsnart  a
tceted eb nac taht yaw a ni dexif srotcelfer RI htiw dedivorp si eborp ehT .zHM 0.5 fo ycneuqerf lartnec  de
RI detnuom gniliec eht yb - si eborp eht ,yllaitinI .aremac  dexiffa   rednu hcaoc eht revo decalp ,tik SUPT a ot
stneitap eht ’ dna ,seenk  dehsup  neg laer fo elbapac si daeh dezirotom ehT .gninnacs rof tneitap eht ot ylt -  emit
.etatsorp eht fo gninnacs enilno   
 
moor tnemtaert eht ni gnirotinom etatsorP  
 skram ecnerefer yb dediug sresal eht ot mih gningila yb tnemtaert yliad rof deraperp saw tneitap ehT
TC eht morf noitisop putes s’tneitap eht ecudorper ot .e.i ,niks eht no )soottat( -  .moor noitalumis  ot roirP
ert retni eht ,tnemta -  eerht gnizilitu yb segami Vk yliad yb rof detcerroc saw gninoitisop tneitap noitcarf
sMF detnalpmi  .  keew a ecnO  yletaidemmi dna  tes saw metsys gnirotinom SUPT eht yreviled tnemtaert retfa
laer rof pu - etatsorp eht fo gnikcart emit . T  etatsorp( stnemecalpsid etatsorp tnedneped emit eh lanoitcarfartni  
w )noitom ere   .setunim 5.2 ot 2 ni dedrocer  ehT  ni stnemecalpsid etatsorp  eht  snoitcerid lanogohtro eerht
 .sisylana evitcepsorter rof dedrocer erew  
 
sisylana lacitsitatS  
 ,atad etatsorp ehT laer gniwohs - roirefnI eht ni noitisop MOC etatsorp emit - tfeL ,)S/I( roirepuS -  thgiR
roiretnA dna )R/L( -  ,snoitcerid )P/A( roiretsoP  erew detaulave   revresbo eno yb noitatskrow ytiralC eht gnisu
 .)BM( i ,snoitcarf emos roF  gninnigeb eht ta atad gnitautculf ralugerr fo   evruc gnirotinom eht erew   .dedracsid
T  eh mecalpsid etatsorp mumixam  tne w noitcerid hcae ni sa  noitcarf hcae rof dedrocer  . t ,eromrehtruF  eh
 detupmoc saw )rotcev D3( ecnatsid naedilcuE ht dna e w rotcev D3 lamixam as noitcarf hcae rof dedrocer  .
( naem eht ,yllaniF )DS( noitaived dradnats 1 ±  eht rof dna noitcerid hcae ni stnemecalpsid lamixam eht fo )
 .detaluclac erew rotcev D3  eulav IMB ehT  tneitap hcae rof  neewteb noitalerroc etagitsevni ot detaluclac saw
sedutingam  niaga tnemecalpsid eht fo s  margorp lacitsitats eht sisylana lacitsitats dna atad eht roF .IMB eht t
.desu saw )3.51.2 noisrev( R  
 
stluseR  
 llA  eht  stneitap dellorne   rof setunim 01 tuoba fo emit artxe eht etipsed ,evitarepooc erew yduts siht ni
noitcarf hcae  putes nacsotua eht rof dedeen  dna   yna desserpxe stneitap eht fo enoN .gnirotinom etatsorp
laer SUPT eht morf ron ,putes nacsotua eht gnirud trofmocsid - nacs emit gnin . 
 fo sisylana ataD  eht ni detluser snacs SUPT 15  eulav naem s  eht fo )DS1±(  lamixam lanoitcarfartni  
2.0( :S/)+(I ;]mm[ etatsorp eht fo stnemecalpsid  ± ( :R/)+(L ;)9.0 - 2.0  ± ( :P/)+(A dna ;)8.0 - 2.0  ±  ehT .)1.1
 fo egatnecrep ehT .noitcerid roiretsop eht ni mm 8.2 saw tnemecalpsid tsegral snoitcarf   mm 0.2 naht regral
4 saw  2 ,%  01 dna ,%  i %  fo ecnatsid naedilcuE naem ehT .ylevitcepser ,snoitcerid PA dna ,RL ,SI eht n  eht
9.0 saw snacs 15  ±  ehT .mm 6.0  fo egatnecrep  htiw snoitcarf  saw mm 0.2 naht regral tnemecalpsid rotcev D3
21  4( snacs 2 ylno dna ,%   )% stnemecalpsid dewohs  mm 0.3 naht regral  . oN   noitalerroc  dnuof saw  neewteb
IMB -  eulav dna  .tnemecalpsid etatsorp eht fo edutingam eht  
 etatsorp eht fo sevruc gnirotinom ehT wohs   snoitairav ni   tnemecalpsid etatsorp neewteb   tnereffid
 na gnisoohc yb dehsilbatse saw ,sevruc eht rof tniop trats ,tniop orez nommoc A .)1 erugif( snoitcarf
4 
 
noitisop yrartibra -  dna ,detaitini gnikcart etatsorp eht retfa yletaidemmi noitisop a ,evruc/nacs hcae rof eulav
orf eulav taht gnitcartbus neht  .tser eht m  ,snoitcarf emos roF  regral fo ycnednet eht lanoitcarfartni  
 tnemecalpsid  semit noitavresbo degnolorp rof  ehT .devresbo eb nac erugif   osla  setacidni  fo tnetxe eht taht
 etatsorp eht lanoitcarfartni  P/A eht ni lasrepsid tsegral sti sah tnemecalpsid   stnemecalpsid tsael dna ,noitcerid
 .noitcerid R/L eht ni  
A 2 erugiF -  fo stolpxob stneserp C  fo hcae rof noitcarf hcae ta stnemecalpsid lamixam eht  stneitap net eht
.ylevitcepser ,snoitcerid P/A dna ,R/L ,S/I ni  setacidni xob eht edisni dnab latnoziroh ehT   elitrauq dnoces eht
 xob eht fo segde reppu eht dna rewol eht ,)naidem( etacidni  52( tsrif eht ht 57( driht dna ) ht  .selitrauq )
sreksihw eht fo semertxe reppu eht dna rewol eht ,eromrehtruF   ni seulav mumixam dna muminim eht yalpsid
 eht atad elgnis fo ecnesba  .sreiltuo tniop  tolpxob laudividni ehT  stnemecalpsid etatsorp lamixam fo   desab si
4 fo sisylana no -  etatsorp ni snoitairav emos era ereht ,devresbo eb nac sA .tneitap rep snacs SUPT 6
 ehT .snoitcerid tnereffid eht ni dna stneitap eht neewteb stnemecalpsid  llarevo lamixam   etatsorp
 tsom rof mm 0.2 naht ssel eb ot nwohs erew rotcev D3 naedilcuE eht dna snoitcerid eerht lla ni tnemecalpsid
 2 erugif( snoitcarf eht fo D  )  
 
noissucsiD  
I lanoitcarfartn   detagitsevni neeb sah noitom etatsorp ylsuoiverp  erp gnisu - tsop dna - aert  .gnigami tnemt
enO  ni ssenkaew   gniylppa retni si dohtem siht -  ytniatrecnu gnihctam revresbo )42(  gnihctam etipseD .
 si ereht ,sdees fo gnigami latrop gnisu ,ytilibairav  lanoitidda na eht htiw detaicossa rorre   eht fo ssenkciht TC -
ecils ht s  ta  yam  si kcabward rehtonA .tnemecalpsid eht fo noitanimreted eht otni ytniatrecnu rehtruf ecudortni
 dna decalpsid eb nac etatsorp eht taht  neht ver tre   ot  sti noitisop laitini  hcihw ,1 erugif ni devresbo eb nac sa ,
ed eb tonnac o yb detcet elgnis a yln   tohspans erp - tsop dna - tnemtaert  egami  )52(  . laer eroferehT -  emit
 a si gnikcart reporp  dohtem gnirotinom  noitom etatsorp lanoitcarfartni tceted yletarucca ot . alubat 1 elbaT  set
 eht fo stluser eht detroper ylsuoiverp dna yduts tneserp  atad . 
yduts siht nI  SUPT D4 eht  gnirotinom   elba eb ot nwohs saw metsys ot  kcart  etatsorp eht T .  ,srotarepo eh
nacs lanimodbasnart desu yltneuqerf morf ecneirepxe htiw gnin  ,  detroper  ,metsys SUPT eht gnisu taht  saw ti
 reisae ot  riuqca e segami  yfitnedi dna   serutcurts eussit tfos  ot derapmoc nacs lanimodbasnart gnin  a nI .
 ,yduts motnahp suoiverp  ztiwomarbA .la te   ospylaC dna nacsotua SUPT eht neewteb tnemeerga doog dnuof
etatsorp deddebme eht gnikcart ni )AC ,otlA olaP ,smetsyS lacideM nairaV( metsys -  erehps ekil )62(  ehT .
hcihw ,seiduts tnereffid ni detagitsevni neeb sah metsys ospylaC  evah   demrifnoc  si ti taht  etarucca na
 dohtem gnirotinom rof  g etatsorp eht gnikcart .dnal  
 ,yduts tnerruc eht nI maeb lacipyt a ,setunim 5.2 yletamixorppa ot detimil saw gnirotinom etatsorp -  no
 a reviled ot emit  crAdipaR noitcarf  .  gnirud yranoitats ton si etatsorp eht taht devresbo eW  eht  ,emit gnikcart
 dna  ot dnet stnemecalpsid  eht htiw sesaercni  despale  fo sgnidnif eht htiw enil ni si hcihw ,emit gnirotinom
 srepap dehsilbup rehto )02(  nesuahllaB . .la te  eht taht dnuof  tni ra noitcarf la   sdnet etatsorp eht fo noitom  a“ ot
rav eht fo esaercni raenil  .noitcarf eht fo noitarud eht htiw ”ecnai  dnuof ew ,eromrehtruF  eht taht
 snoitcarf tnereffid rof seirav tnemecalpsid  dna stneitap tnereffid rof osla  .  
som rof ,taht deciton ew ,yduts ruo nI  eht ,snoitcarf eht fo t lanoitcarfartni   yltsom saw noitom etatsorp
llams  ot 2 fo doirep a rof ,mm 2 naht re  .setunim 5.2 la te iohC ,ylbarapmoC . )72(  latcersnart gnisu ,
 ,)snoitcarf 633 dna stneitap 21( srekram laicudif detnalpmi eerht kcart ot snacs dnuosartlu devresbo   ylno taht
o %11 rew stnemecalpsid rotcev D3 eht f 4 gnirud mm 2 naht regral e -  ,ylralimiS .gnirotinom fo setunim 5  iL
la te . )4(  , gnizilitu  C a  gnikcart ospyla metsys   eht taht detroper ,)snoitcarf 7621 dna stneitap 53(
 etatsorp eht fo noitom lanoitcarfartni rof yllaicepse ,mm 2 naht ssel yltsom si   fo setunim eerht tsrif eht
VTC a taht dedulcnoc yehT .gnikcart -  eht htiw tegrat eht gnirevoc erusne ot etauqeda si mm 2 fo nigram VTP
alp n esod debircserp den ,  .stneitap eht fo emos rof ytniatrecnu lanoitcarfartni regral etipsed  ,eromrehtruF
la te sagraV . )82( a ni , eniC n - RM I VTC eht detaluclac ,yduts -  te iL ot elbarapmoc ,mm 1.2 eb ot nigram VTP
la .  ,s’ hcihw   dluow f tnuocca .noitom lanoitcarfartni eht ro   si noitom etatsorp eht taht osla dewohs yehT
.gninoitisop tneitap enorp naht enipus ni rellams   ,dnah rehto eht nO la te kneemS . )92(  ,  ospylaC gnisu niaga
metsys  )snoitcarf 675 dna stneitap 51( , derevocsid  rotcev D3 ni noitom etatsorp taht   ni mm 3 naht regral saw
 01 fo noitarud gnirotinom a rof %81 ot desaercni tub ,setunim 5.2 tsrif eht gnirud snoitcarf eht fo %4.1 ylno
la te gnoT ,ylbarapmoC .setunim . )8( gnisu osla ,  tcarf 0668 dna stneitap 632( metsys gnikcart ospylaC  ,)snoi
dewohs  mm 3 naht regral eb nac tfihs etatsorp eht fo %02 ot pu taht  nehw  setunim 21 si emit gnikcart  tuB .
 yeht deniatrecsa  noitom etatsorp eht taht ,setunim eerht tsrif eht rof ,   .stneitap tsom rof )mm 2 <( llams yrev si
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la te notlehS ,ylralimiS . )03(   ,noitom etatsorp noitcarfartni eht detagitsevni  ecno  niaga  metsys ospylaC gnisu
 ,)snoitcarf 2331 dna stneitap 73( taht dnuof dna  eht  llarevo   ssel si tnemecalpsid rotcev D3 eht fo eulav naem
 ,setunim 3 tsrif eht rof mm 3 naht desaercni tub  ni mm 5.6 ot pu ot emit noitarud htiw  htneetruof eht  etunim .   
la te nailepuK ,esiwekiL . )2(  ,  erom ecno  ospylaC gnisu  metsys (  )snoitcarf 055 dna stneitap 71  detceted  taht
 ni gnirotinom setunim 01 gnirud saw tfihs eht snoitcarf eht fo %41   .mm 3 naht regral  gN ,eromrehtruF la te . 
)13( laer fo yduts a ni , -  emit MF   )snoitcarf 862 ,stneitap 01( snoitcarf eht fo %26 ni taht devresbo ,gnikcart
t etatsorp eht fo tnemecalpsid rotcev D3 eh , 3 gnirud -  dna ,mm 1 naht rellams saw gnikcart setunim 4
 ni %08 dna ,%28 ,%59 erew seulav dednopserroc  eht cerid PA dna ,SI ,RL  yehT .ylevitcepser ,snoit
derevocsid   ylno taht 6 M .mm 3 naht regral erew stfihs eht fo %  negnaL ,revoero  te la . )81(  ,  llew sa  gnisu
ospylaC  metsys  )snoitcarf 055 dna stneitap 71( , dettops  aht  elihw mm 3 naht regral si tfihs eht fo %3 ylno t
.setunim 2 tuoba rof etatsorp eht gnikcart   ittemoL ,noitidda nI la te . )23( ulf VM gnisu , ;ypocsoro  er la -  emit
 MF  ,)snoitcarf 331 dna stneitap 11( gnikcart demrifnoc   taht  ni snoitcarf eht fo %4 ylno   tnemecalpsid eht  si
gnikcart elihw mm 2 naht regral  rof   .etunim eno ylno  sayyaM ,tsaL la te . )9( ruof fo yduts nosirapmoc a ni ,  
)snoitcarf 0011 dna stneitap 72( smetsys tnereffid , noitcarfartni fo egatnecrep eht taht dnuof la   nihtiw stfihs
 .snoitcerid P/A dna ,R/L ,S/I eht ni %28 dna ,%49 ,%67 saw mm 5.1±  eht ,yrammus nI  dehsilbup  ecnedive  ni
 yduts siht htiw noitanibmoc seifitsuj   noitressa eht noitcarfartni eht taht la   si etatsorp eht fo noitom
 tsrif eht gnirud tnacifingisni  5.2  suht ,setunim  fo ton  lacinilc ecneuqesnoc   decnavda gniyolpme elihw
TAMV / crAdipaR        .  
ht ,seiduts rehto lla sA tnerruc eht ni srotcaf gnitimil era ere   eht laever ton seod yduts eht ,yltsriF ;yduts
 eht fo edutingam noitcarfartni la  dna stneitap fo rebmun eht ,dnoceS .noitamrofed mrof ro noitator etatsorp  
       .detimil era snoitcarf                
 
noisulcnoC  
 seirav tnemecalpsid etatsorp lanoitcarfartnI  ehT .stneitap tnereffid rof dna snoitcarf neewteb
2 tsrif eht rof tnacifingisni si tnemecalpsid - 5.2  t gnirotinom eht fo setunim despale htiw sesaercni tub ,emi  
kat eb dluohs yreviled tnemtaert TRMI dna lanoitnevnoc gnirud stfihs etatsorp ,yltneuqesnoC .emit  otni ne
 tub ,noitaredisnoc era   decnavda gniyolpme elihw laitneuqesnocni yllacinilc /TAMV  euqinhcet crAdipaR s.  
 
stseretni gnitepmoC  
.stseretni gnitepmoc on evah yeht taht eralced srohtua ehT  
 
snoitubirtnoc ’srohtuA  
 eht tuo deirrac BM noitaeniled etatsorp  ,  ,sisylana lacitsitats demrofrep ,yduts eht gningised ni detapicitrap
 eht fo ngised eht ni detapicitrap BFC .tpircsunam eht detfard dna tnemngila ecneuqes eht tuo deirrac
tpircsunam eht gnisiver ,yduts dna ,  .tpircsunam lanif eht devorppa dna daer  
 
taiverbbA snoi  
lanoisnemid eerhT :D3  
lanoisnemid ruoF :D4  
dnuosartlU :SU  
yhpargomot detupmoC :TC  
snoitaived dradnatS :DS  
I :TRGI egam - ypareht noitaidar dediug  
ypareht noitaidar detaludom ytisnetnI :TRMI  
oliK :Vk - egatlov  
ageM :VM - egatlov  
rekram laicudiF :MF  
 :SUPT dnuosartlu laenirepsnarT  
 :TAMV V ypareht cra detaludom cirtemulo  
 :TTR tsigolonhcet ypareht noitaidaR  
gnigami ecnanoser citengaM :IRM  
 :zHM ztreh ageM  
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roirefnI :S/I - roirepus  
roiretnA :P/A - roiretsop  
tfeL :R/L - thgir  
emulov tegrat lacinilC :VTC  
rat gninnalP :VTP emulov teg  
 
stnemegdelwonkcA  
;yduts siht tcudnoc ot depleh ohw seugaelloc ruo lla knaht ot ekil dluow eW   ,)TTR( .L rednalluG
rehpargoidar( S gnahzaP ,)TTR( S nossbocaJ ,)TTR( T praZ ,)TTR( K .S nesredeP  )  K .V purennyL dna
 dluow eW .)rehpargoidar(  osla ekil   rieht rof dtL atkelE knaht ot  .troppus  
 
secnerefeR  
 .1   fo nosirapmoC .la te ,a P nailepuK ,A gnoW ,DC relluF ,YJ gniT ,MN nedloG ,JT hguorbracS
 noitazilacol etatsorp rekram dees detnalpmi dna dnuosartlu egami rof snoitacilpmI :sdohtem -  dediug
873:)2(56;6002 .syhP loiB locnO taidaR J tnI .yparehtoidar –3  .78  
 .2  egamI .LS skeeM ,.a O nadieZ ,RT ybhguolliW ,MK negnaL ,.a P nailepuK -  rof yparehtoidaR dediuG
S .tegraT gnivoM a gnitaerT :recnaC etatsorP dezilacoL 85:)1(81;8002 .locnO taidaR nime –  .66  
 .3  eerhT .K arumatiK - laer gnirud derusaem etatsorp fo tnemevom lanoitcarfartni lanoisnemid -  emit
romut -  .syhP loiB locnO taidaR J tnI .snoitisop tnemtaert enorp dna enipus ni yparehtoidar gnikcart
7111:)5(35;2002 – 11  .32  
 .4   cirtemisoD .la te ,AP naillepuK ,RT ybhguolliW ,DR retsoF ,AC eknE ,JI yttehC ,SH iL
oitom etatsorp noitcarfartni fo secneuqesnoc syhP loiB locnO taidaR J tnI .n  8002 . ; 108:)3(17 –8  .21  
 .5  uof ni tnemevom etatsorp yrotalitnev fo nosirapmoc A .AL noswaD idaR J tnI .snoitisop tnemtaert r  ta
913:)2(84;0002 .syhP loiB locnO - 323 . 
 .6   noitisop dnalg etatsorp no tnemevom latcer dna noisnetsid latcer fo tceffe eht gnitaulavE .A inahdaP
525:)3(44;9991 .syhP loiB locnO taidaR J tnI .IRM enic gnisu –5  .33  
 .7  reH naV  eerht yb etatsorp eht fo yparehtoidar lamrofnoc gnirud noitom nagro fo noitacifitnauQ .M k
.syhP loiB locnO taidaR J tnI .noitartsiger egami lanoisnemid  1131:)5(33;5991 – 31  .02  
 .8  m etatsorp lanoitcarfartnI .la te ,L nehC ,M niL ,Q uX ,J iL ,X nehC ,X gnoT  lanretxe gnirud noito
laer a yb derotinom yparehtoidar maeb -  .metsys noitazilacol tegrat emit  lacinilc deilppa fo lanruoJ
 .scisyhp lacidem 15:)2(61;5102 –  .16  
 .9   elpitlum fo noitaulavE .la te ,T vehsuruN ,T ucieN ,N neW ,M voktrevtehC ,JI yttehC ,E sayyaM
i egam - egami rof seitiladom desab -  a :amonicrac etatsorp fo )TRGI( ypareht noitaidar dediug
epsorp syhP deM .yduts evitc  .707140:)4(04;3102 .  
 .01  Y ohC ,a M rediaH ,R llewinniD ,P nahC - retnI .la te ,G doowkcoL ,D yarffaJ ,B -  lanoitcarfartni dna
agro dna romut citamenic a :yparehtoidar gniogrednu recnac lacivrec htiw stneitap ni tnemevom n -
tniop IRM - fo - R J tnI .yduts tseretni syhP loiB locnO taida 7051:)5(07;8002 . – .51  
 .11  g etatsorP .la te ,BM eprahS ,A yttehS ,M kreH naV ,HJ nesdreweiS ,a D yarffaJ ,JM nazelihG  dnal
enic htiw dessessa noitom - enic( gnigami ecnanoser citengam -  .syhP loiB locnO taidaR J tnI .)IRM
604:)2(26;5002 – .71  
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 .21   .la te ,A lathcsreH ,R newO ,A nospmohT ,C xoF ,J samohT ,T norK noitcarfartnI   etatsorp
erp morf detamitse yparehtoidar ni tnemecalpsid - tsop dna -  htiw stneitap fo gnigami tnemtaert
191:)2(59;yaM 0102 .locnO rehtoidaR .srekram laicudif detnalpmi – 91  .7  
 .31  erp morf noitom noitcarfartni etatsorp tuoba secnerefnI .Q uW ,J nosmadA -  dna  tnemtaerttsop
062:)1(57;9002 .syhP loiB locnO taidaR J tnI .gnigami cirtemulov –  .7  
 .41   .metsys nacsotuA ytiralC eht htiw tnemeganam noitom etatsorp lanoitcarfartnI .T oclaF ,M eniahcaL
27:)1(1;3102 .tnI syhP deM –  .08  
 .51  uM ,LJ deeR ,MW reltuB ,N renttiB  .la te ,EK renllaW ,SB okruK ,CB yarr  gnikcart citengamortcelE
 J tnI .noitisop enorp eht ni dezilibommi yllanretxe stneitap ni tnemecalpsid etatsorp noitcarfartni fo
094:)2(77;0102 .syhP loiB locnO taidaR – 94 .5  
 .61  ,M ejtnelF ,C nnamreH ,K reiaB ,J trebliW  laer fo ycaruccA .M regrebnekcuG -  gnikcart hcuoc emit
3 gnirud -  dna ,ypareht noitaidar detaludom ytisnetni ,ypareht noitaidar lamrofnoc lanoisnemid
732:)1(58;3102 .syhP loiB locnO taidaR J tnI .recnac etatsorp rof ypareht cra detaludom cirtemulov –
2  .24  
 .71   ycneuqerf gnigami fo pihsnoitaleR .P aiX ,R rakludneT ,K snahpetS ,A illengaM ,M nahK ,W sitruC
laer no desab sisylana :noitom etatsorp noitcarfartni rof tnuocca ot nigram gninnalp dna -  emit
007:)3(58;3102 .syhP loiB locnO taidaR J tnI .atad gnirotinom – 07 6  .  
 .81   .la te ,L eniveL ,A mahgninnuC ,A manahtnaS ,LS skeeM ,RT ybhguolliW ,MK negnaL
laer no snoitavresbO -  locnO taidaR J tnI .gnikcart citengamortcele gnisu noitom dnalg etatsorp emit
4801:)4(17;8002 .syhP loiB – 01  .09  
 .91  tatsorp fo snoitavresbO .SJ iL  ebmfI .ypareht noitaidar maeb lanretxe gnirud noitom lanoitcarfartni e
994:)1(52;9002 .corP –  .205  
 .02  N nnamegeH ,M iL ,H nesuahllaB -  .C akleB ,U tdniwsnaG ,S noitcarfartnI   a si etatsorp eht fo noitom
945:)2(06;5102 .loiB deM syhP .klaw modnar –5 .36  
 .12  iL  M niL ,SJ - C aM ,ME ztiwroH ,KM iksuonuoyyuB ,H -  lanoitcarfartni etatsorp fo noitcudeR .M
1294:)41(85;3102 .loiB deM syhP .emit tnemtaert eht gninetrohs morf noitom – 94 .23  
 .22  yaD .MJB nemjieH ,L iccorcnI ,PLM xkriD ,V najaR ,JCH reoB ed ,FT agnatuM - ot -  yad
 fo gnigami VM dna Vk elpitlum yb dessessa noitom noitcarfartni etatsorp fo ytilibicudorper
004:)1(38;2102 .syhP loiB locnO taidaR J tnI .tnemtaert gnirud srekram detnalpmi – 04 .7  
 .32  nemeolB ,S reeM red naV - uG ,D snamlevueH ,R nekcnoV ,J snamreH ,E pruG nav  .la te ,C slebb
 laicudif ot derapmoc TRGI etatsorp rof gnigami dnuosartlu D3 ytiladomartni fo tnemssessa lacitirC
707170:)3102(04;3102 .syhP deM .srekram –  1 – 707170 –  .11  
 .42  av revresboretnI .la te ,A yhtraCcM ,J sggiB ,L streboR ,T tloH ,R newO ,T nageeD  fo ytilibair
 taidaR gnigamI deM J .ypareht noitaidar etatsorp rof srekram laicudif ot gningila stsipareht noitaidar
915:)4(75;3102 .locnO –5 32 .  
 .52  lanretxe gnirud etatsorp eht fo noitom noitcarfartnI .JTNA ettoK -  fo sisylana :ypareht noitaidar maeb
 724 )2(96;7002 .syhP loiB locnO taidaR J tnI .srekram laicudif detnalpmi htiw stneitap 914 : - 524  .  
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 .62  laeR evisavninoN .la te ,M eniahcaL ,R skoorB ,X uW ,R koolF ,E trassoB ,CM ztiwomarbA -  emit
 tnI .hcaorppA dnuosartlU laenirepsnarT a gnisU gnikcarT etatsorP 331S:)3(48;2102 .locnO taidaR J . 
 .72  D kawK ,Y iohC - H eeL ,W - W ruH ,S - W ohC ,J -  no amene latcer fo tceffE .la te ,TG gnuS ,Y
egami gnirud tnemevom etatsorp noitcarfartni -  .locnO taidaR gnigamI deM J .yparehtoidar dediug
632:)2(95;5102 –2  .24  
 .82  S ,C sagraV eniC .la te ,Q mgneZ ,A koohclaF ,D otacilednI ,CW isH ,IA otia -  ecnanoser citengam
 dna htiw enorp ro enipus stneitap recnac etatsorp rof noitom noitcarfartni fo tnemssessa gnigami
 a tuohtiw .locnO nilC J mA .noollab latcer  11:)1(33;0102 –1  .6  
 .92  JR kneemS  latcerodne nA .la te ,TJNE niL nav ,AP nailepuK ,PA hahS ,MK negnaL ,WJR ewuoL ,
 .syhP loiB locnO taidaR J tnI .yparehtoidar gnirud noitom etatsorp noitcarfartni secuder noollab
166:)2(38;2102 – 66  .9  
 .03  naJ ,.a V retsaM ,Y uiL ,H nehC ,JP issoR ,J notlehS  .BA i  noitcarfartni etatsorp no snoitavresbO
 taidaR tcarP .ypareht cra detaludom cirtemulov gnisu emit tnemtaert decuder fo tceffe eht dna noitom
342:)4(1;1102 ;ygolocnO noitaidaR rof yteicoS naciremA .locnO –2 .05  
 .13  suiledelF ,RP nesluoP ,TJ htooB ,AJ gN   noitcarfartni egatlovoliK .la te ,T edaE ,SE mroW ,W
 loiB locnO taidaR J tnI .stluser lacinilc tsrif :ypareht cra detaludom ytisnetni etatsorp rof gnirotinom
556e:)5(48;2102 .syhP –6  .16  
 .23   .M ittemoL noitcarfartnI  I .ypocsoroulf VM gnisu noitom etatsorp  .syhP loiB locnO taidaR J tn
 .)2(36;5002  
 .33  KK gnaW -  yfitnauq ot yduts A .la te ,H niL ,R nnamreuehcS ,PJ saratsalP ,C elliveD ,N alawipaV ,H
 J tnI .tnemeganam noitom noitcarfartni etatsorp rof noollab latcerodne yliad fo ssenevitceffe eht
B locnO taidaR 5501:)3(38;2102 .syhP loi –  .36  
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 .1 elbaT  yduts tneserp eht fo nosirapmoc a ;rotcev D3 dna snoitcerid eerht ni noitom etatsorp noitcarfartnI
 .smetsys tnereffid gnisu atad dehsilbup ylsuoiverp htiw  
  
stfihs etatsorp xam fo naeM  
]mm[ )DS1±(  
 
 
 ,rotagitsevnI
raey  
 N
)snoitcarf(  
metsyS  ]nim[ emiT   S/)+(I  R/)+(L  P/)+(A   rotcev D3 %
tfihs  
D3 -
rotcev  
]mm[  
 ,.la te ittemoL
5002 32 
)331( 11   :ypocsoroulf VM
laer -  MF emit
gnikcart  
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